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INTRODUCTION 
Over the past twenty years researchers have made great 
strides in advancing our understanding of the biology of 
cancer. Despite our better understanding of such things as 
tumorigenesis, DNA repair, and drug resistance, the clinical 
treatment of cancer has not greatly improved in the past ten 
years. This outcome is due largely to the unpredictable 
difficulties encountered in the translation of laboratory 
science to the clinical arena. A poignant example is drug 
resistance. Extensive scientific advances have been made in 
this field with regards to defining the many mechanisms by 
which a tumor cell can become resistant to chemotherapeutic 
agents. However, the emergence of tumor cells with a drug 
resistant phenotype is still the major obstacle encountered 
in the clinical treatment of cancers. 
The discovery of oncogenes and the elucidation of their 
role in cellular proliferation and tumorigenesis 
revolutionized the field of cancer research. The long 
standing tenet that cancer is a disease 
deregulated cellular proliferation was 
resulting 
developed 
from 
when 
activated oncogenes were shown to exist in tumor cells. As 
a result, the majority of cancer research has been focused on 
gaining a better understanding of the mechanisms responsible 
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for cellular proliferation and its regulation in both normal 
and neoplastic cells. One of the first oncogenes to be 
characterized was c-myc. That c-myc has a role in cellular 
proliferation, differentiation, immortalization, 
transformation, and apoptosis is undisputed. However, the 
precise mechanism(s) by which c-myc mediates these cellular 
functions has remained enigmatic despite almost one and a 
half decades of research. 
The second revolution to occur in cancer research was 
the discovery of tumor suppressor genes. These genes were 
shown to act as a brake on cellular proliferation and were 
antagonistic to the function of oncogenes. The removal of 
these brakes was sufficient to deregulate the growth of 
cells, therefore, these two classes of genes appeared to 
regulate cellular proliferation by either pushing down on the 
accelerator and overriding the brake, or by releasing the 
brake. As might be expected, the combination of accelerating 
and releasing the brake synergized the effect on cellular 
proliferation. This concept has been supported by many 
studies which have demonstrated the transforming properties 
of cells possessing an activated oncogene along with a 
deleted or mutated tumor suppressor gene. 
The most studied tumor suppressor gene to date is the 
p53 gene. p53 is a complex gene in that along with its role 
as a tumor suppressor, some of its mutated forms possess 
oncogenic, gain of function, activity. p53 is the most 
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frequently mutated (or deleted) cancer gene known to date. 
Mutations of the p53 gene have been shown to occur in 
approximately 60% of all human tumors and thus its role in 
tumorigenesis is well supported. Recent findings have added 
to our current understanding of how p53 functions to prevent 
the formation of tumors. p53 is thought to maintain genomic 
stability via its involvement in the Gl, G2, and mitotic 
spindle checkpoints and has been shown to induce apoptosis in 
certain cell types following DNA damage or activation of 
certain oncogenes. Thus, p53 suppresses the formation of 
tumors by preventing the genetic changes that could occur in 
cells which are allowed to replicate with a damaged genome 
and more importantly, by inducing apoptosis in those cells 
that are damaged beyond repair or harbor genetic alterations 
that are incompatible with its presence. 
The third revolution in cancer research, ironically, is 
the result of work done before the discovery of oncogenes 
themselves. In the early 1970's, the role of apoptotic cell 
death in the kinetics of tissue and tumor growth had been 
elucidated along with its role in the elimination of tumor 
cells treated with antineoplastic agents. However, these 
seminal findings were largely overlooked until recently. The 
current focus of research on apoptosis as it relates to 
cancer chemotherapy and tumorigenesis has finally begun to 
bring these early studies to fruition, and as a result has 
led to further revisions in the central theory of 
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oncogenesis. 
cancer can no longer be looked upon as a disease 
resulting solely from the deregulation of proliferation. 
Tumor growth is the balance between cellular proliferation 
and cellular death, and can be regulated by changes in either 
component. Therefore, an increase in cellular proliferation 
coupled with the inhibition of cell death would be 
synergistic with respect to tumor growth. The inhibition of 
apoptotic cell death would not, in and of itself, be 
sufficient to transform a cell since proliferation would 
still be under tight control and therefore, no real growth 
advantage would be imparted to the cell: it simply would not 
die. However, the prolonged survival of a cell that was 
programmed to die at a certain point in its life span would 
predispose it to further genetic changes (activation of 
oncogenes) that could impart a growth advantage to the cell. 
This would lead to the emergence of a tumor with a fast rate 
of growth and poor clinical prognosis, both due in part to 
the inhibition of apoptosis. 
The existence of such a "death repressor" was 
demonstrated by the discovery of bcl-2 which is the proto-
typical member of a new family of oncogenes that regulate 
cell survival. The precise mechanism by which bcl-2 inhibits 
apoptosis is currently unknown, although it involves 
dimerization with the bax protein. Both in vitro and in vivo 
studies have verified the co-transforming effects of the bcl-
5 
2 and c-myc proteins, thus supporting the hypothesis that 
alterations in components of the apoptotic cell death 
machinery can participate in the transformation of cells. 
More importantly, the ectopic overexpression of bcl-2 in 
tumor cell lines has been shown to increase the resistance of 
many cell types to the majority of chemotherapeutic agents 
used in the treatment of human cancers. 
The next breakthrough in cancer research will possibly 
be in how cancer is treated. The concept that tumorigenesis 
is the result of multiple, step-wise, genetic changes is 
widely accepted and there is compelling evidence supporting 
the notion that the combinations of these genetic alterations 
leading to the transformed state may be as variable as the 
types of tumors encountered. Essentially, each type of 
cancer is a different disease and needs to be treated as 
such. 
The importance of apoptotic death as a mechanism for 
tumor regression following chemotherapeutic agent exposure is 
gaining acceptance. Studies have shown that in many cell 
types, most, if not all, anti-cancer drugs kill tumor cells 
by inducing apoptotic cell death. Many oncogenes are known 
to have dual roles as initiators of cell proliferation and 
regulators (negative or positive) of apoptosis; c-myc, ras, 
c-raf, c-abl and rel are just some examples. These genes 
along with p53, bcl-2 and others have all been shown to be 
capable of directly or indirectly regulating the induction of 
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apoptosis in tumor cells following exposure to anti-
neoplastic agents. More importantly, the activation of 
certain oncogenes or loss of tumor suppressor genes can 
render tumor cells inherently more resistant to a wide 
variety of chemotherapeutic agents as a result of the 
inhibition of apoptosis. 
The emerging concept is that different tumor cells have 
different thresholds for the induction of apoptosis in 
response to anti-neoplastic agents and that these thresholds 
may be regulated or altered as a result of the genetic 
changes possessed by the cell. This concept may help to 
explain the inherent resistance of many tumors to multiple 
classes of chemotherapeutic agents when classical modes of 
resistance are insufficient to explain this phenomenon. 
Therapeutic modulation of genes involved in the regulation of 
apoptosis may be a potential mechanism for overcoming drug 
resistance. Therefore, further understanding of the 
regulation of apoptosis in human tumor cells in response to 
anti-neoplastic drugs will be essential for the advancement 
of the clinical treatment of human cancers. 
The studies presented in this dissertation attempted to 
establish a relationship between the expression of oncogenes 
and tumor suppressor genes and cell death induced by the 
bifunctional alkylating agent, nitrogen mustard, in human 
colon carcinoma cell lines. The genes investigated in these 
studies included c-myc and other members of the myc 
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transcription factor network, bcl-2, and p53. Initial 
studies investigated the role of the proliferative functions 
of c-myc in HN2-mediated cytotoxicity and were designed to 
test the following hypothesis: bifunctional alkylating 
agents, such as nitrogen mustard, inhibit the clonogenicity 
of human tumor cells by down-regulating the expression of 
critical cellular oncogenes, such as c-myc. The remaining 
studies in this dissertation investigated the involvement of 
the apoptotic functions of c-myc in the regulation of cell 
death induced by HN2. The initial hypothesis was tested: 
human tumor cell lines which overexpress c-myc will undergo 
an enhanced apoptotic cell death following exposure to 
chemotherapeutic agents that cause DNA damage. The remaining 
studies attempted to determine how the c-myc enhancement of 
apoptosis was being regulated in a subset of human colon 
carcinoma cell lines following exposure to nitrogen mustard. 
These investigations provide evidence that gene products 
involved in the regulation of apoptosis can be modulated by 
exposure to HN2 . These results are consistent with a 
stimulus-response type of model in which the cellular 
response to a drug stimulus determines the fate of the cell. 
These studies also show that drug-induced apoptosis can occur 
in human tumor cells in a wild-type p53-independent manner, 
and describe a novel mechanism by which c-myc-enhanced 
apoptosis may be regulated in human tumor cells exposed to 
HN2. 
Nitrogen Mustard 
CHAPTER 1 
BACKGROUND 
The nitrogen mustards are the most important class of 
clinically used alkylating agents (1,2). The parent 
compound, bis (2-chloroethyl) methylamine (mechlorethamine, 
nitrogen mustard, HN2) was the first clinically effective, 
non-hormonal anti-cancer agent (3). The current use of HN2 
is limited to Hodgkin's and non-Hodgkin's lymphomas because 
the newer mustard analogs, such as melphalan, chlorambucil, 
cyclophosphamide, and ifosfamide have a higher therapeutic 
index, can be administered both orally and intravenously, and 
cover a wider spectrum of both soft and solid tumors. 
Nitrogen mustard is actively transported across the 
plasma membrane of cells via the low affinity choline 
transporter (4). Once inside the cell, HN2 binds covalently 
to cellular macromolecules, including DNA, RNA, protein, 
amino acids, and nucleotides via two 
electrophilic, aziridinium intermediates 
bifunctionality of the nitrogen mustards 
highly reactive, 
( 2 , 5 , 6 ) . The 
results in the 
crosslinking of cellular macromolecules, and the anti-tumor 
and cytotoxic activities of these compounds have been shown 
8 
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to require both alkylating moieties (7). Brookes and Lawley 
( 8, 9) suggested that nitrogen mustard could form DNA-DNA 
intrastrand and interstrand crosslinks, and that these 
lesions were responsible for the anti-tumor and cytotoxic 
effects of this compound. Many sites on DNA are targets for 
alkylation by HN2, however, the N-7 position of guanine is 
the most electronegative and therefore, the major site of 
alkylation (8,10-14). Initial studies showed that crosslinks 
could be formed on the guanines of DNA (8,15,16) and DNA-DNA 
intrastrand, DNA-DNA interstrand, and DNA-protein crosslinks 
were shown to exist in tumor cells treated with therapeutic 
doses of nitrogen mustard (17-19). 
Despite the presence of various types of crosslinking 
lesions, the cytotoxic potential of HN2 is strongly 
correlated with the formation of DNA-DNA interstrand 
crosslinks (15,20). Assuming that the DNA-DNA interstrand 
crosslink is the cytotoxic lesion, the inhibition of DNA 
synthesis has been postulated to be the most likely mechanism 
by which HN2 produces its cytotoxic effects (1,21,22). In 
this regard, the evidence favors a mechanism involving the 
inactivation of the DNA template by crosslink damage rather 
than the inhibition or inactivation of DNA polymerase or 
other enzymes involved in DNA synthesis (23-27). 
Another possible mechanism by which DNA-DNA interstrand 
crosslinks may exert a cytotoxic effect is the inhibition of 
gene transcription. Interstrand crosslinks formed by 
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nitrogen mustards occur in a sequence specific manner, where 
runs of guanines are the favored sites of alkylation (12,13). 
Mattes et al. (12) suggested that GC rich areas of the genome 
would make good targets for alkylation and subsequently 
showed that GC rich regions in the H-ras promotor are 
preferentially alkylated by a variety of chemotherapeutic 
agents. Other studies have shown that nitrogen mustard 
inhibits transcription in vitro (28-30), and taken together, 
these studies suggest that nitrogen mustards may 
preferentially inhibit the transcription of GC rich genes, 
such as oncogenes, which could contribute to their anti-tumor 
effects. To this end, studies from this laboratory have 
shown that c-myc mRNA expression is down-regulated in a human 
tumor cell line following exposure to various nitrogen 
mustards (31). However, no evidence exists to suggest that 
DNA-DNA crosslinks directly inhibit the transcription of 
human genes in vivo, therefore, the down-regulation of c-myc 
mRNA may not have been a direct consequence of drug-induced 
lesions in the c-myc gene. In support of this possibility, 
other targets for HN2-induced damage have been shown and 
include the Na+/K+ ATPase (32), and the plasma membrane of 
cells (33) Also, many studies have shown that the mechanism 
by which HN2 exerts its cytotoxic effects must involve 
lesions other than the DNA-DNA interstrand cross link ( 34-3 9) . 
Despite almost fifty years of research, the exact mechanism 
by which the nitrogen mustards exert their cytotoxic effects 
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on human tumor cells remains unknown. 
APoptosis 
cell death is an important, evolutionarily conserved, 
physiological process which is required for the development 
and maintenance of most, if not all, multicellular organisms 
(40). Every somatic cell in a multicellular organism 
contains the genetic blueprint for the death machinery and is 
thought to be capable of implementing it. The inappropriate 
execution or inhibition of cell death can be deleterious for 
the organism and can result in a diseased state (41-45) 
The term "apoptosis" (from the Greek: refers to the 
"dropping off" of leaves from a tree) was first used by Kerr 
et al. (46) in 1972 to describe a type of cell death that was 
morphologically distinct from necrosis. Apoptosis is a 
descriptive term that 
death induced by a 
is applied to a common type of cell 
variety of physiological and non-
physiological stimuli under numerous types of circumstances 
(47 and references within) . Although thought to be mediated 
by a genetic program (40,46,48-52), apoptosis is not 
specifically associated with the element of time and should 
not be confused with "programmed cell death", a functional 
term describing the developmental process of cell elimination 
that is associated with a genetically programmed "cellular 
clock" (47,53). Therefore, it must be noted that not all 
programmed cell deaths occur by apoptosis ( 54, 55) , and 
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certainly, not all apoptotic cell deaths are programmed with 
respect to the time of their occurrence (53,56-62). 
Apoptosis is involved in the removal of cells from both 
healthy and diseased tissues (46) and the role of this type 
of cell death is well documented in embryonic development 
(41,63-69), organogenesis (70-73), tissue and organ 
homeostasis (46,74-78), development and maintenance of the 
immune system (79-81,42 and references within), 
carcinogenesis (42,82-85) and cancer chemotherapy (86-91), 
AIDS (43,92,93), autoimmune diseases (44), neurodegenerative 
diseases (45,94,95) and viral infections (42,96). 
Apoptosis and necrosis are the two morphologically and 
biochemically distinct types of cell death recognized by 
pathologists. Necrotic cell death usually results from 
severe environmental trauma, such as hypoxia or hypothermia, 
which directly damages the plasma membrane or interferes with 
the production of ATP, resulting in the impairment of ion 
homeostasis across the cell membrane. Consequently, the cell 
loses the ability to osmoregulate and swells due to the 
influx of water. Although reversible at this stage, the 
continued increase in the levels of cytosolic calcium disrupt 
the cytoskeleton and activate membrane-bound phospholipases 
and proteases. The lack of ATP forces a switch to anaerobic 
glycolysis, and leads to a decrease in both intracellular pH 
and macromolecular synthesis. Finally, the swollen cell 
ruptures and dies, releasing its contents into the 
extracellular compartment. 
13 
Necrosis is a passive, energy-
independent death which elicits an inflammatory response and 
results in the synchronous death of neighboring cells 
(48,97). In contrast to necrosis, apoptosis is an 
asynchronous, energy-dependent process requiring cellular 
participation in the sense that a molecular death pathway 
must be activated after death-inducing stimuli are 
encountered by the cell. The most important aspect of 
apoptotic cell death is that single cells can be removed from 
tissues without provocation of an inflammatory response and 
damage to neighboring cells (48,97). 
Morphology of Apoptosis 
The morphological changes which occur in apoptotic 
cells have been extensively characterized and reviewed 
(46, 69, 98, 99). Apoptotic cells lose contact with neighboring 
cells as a result of cellular shrinkage and loss of 
specialized cell surface elements such as microvilli and 
desmosomes. Surface changes occur rapidly and are followed 
by the fragmentation of the cell into a series of membrane-
bound, condensed apoptotic bodies. Most of the organelles, 
including mitochondria, remain intact and functional. 
However, the endoplasmic reticulum dilates and fuses with the 
cell surface resulting in the characteristic membrane 
blebbing of apoptotic cells (100). The most striking and 
morphologically characteristic changes in apoptosis occur in 
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the nucleus. During the early stages of apoptosis, chromatin 
is fragmented and condenses in the region immediately 
underlying the nuclear membrane, forming dense, coarse, 
osmiophilic aggregates, next to which nuclear pores are 
seldom visible. The nucleus shrinks substantially and 
chromatin caps are visible at multiple sites around the 
nuclear periphery. The nucleolus disintegrates and 
eventually the nuclear membrane becomes discontinuous with 
chromatin found amongst the cytoplasmic constituents of the 
cell. As previously mentioned, the cell then fragments into 
apoptotic bodies which contain a variety of organelles and/or 
condensed chromatin. During this process, surface markers 
are expressed which target the apoptotic bodies for 
phagocytic engulfment by macrophages and neighboring cells, 
thus ensuring the efficient removal of potentially harmful 
debris. 
Biochemistry of Apoptosis 
The biochemical hallmark of apoptosis is the non-random 
fragmentation of chromatin into oligonucleosomal DNA 
"ladders" (internucleosomal integers of 180-200 bp) (101). 
The appearance of DNA ladders corresponds with the activation 
of an endogenous endonuclease that specifically cleaves DNA 
in the linker region of nucleosomes and is thought to be an 
early event in the apoptotic process (101,102). The presence 
of this specific pattern of DNA fragmentation has been 
documented in a number of cell types using a variety of 
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apoptotic stimuli (47 and references within) . 
Despite extensive efforts by many laboratories, the 
putative apoptotic endonuclease has not been cloned (101). 
Indeed, current evidence suggests the existence of more than 
one endonuclease (53) One prospective apoptotic 
endonuclease is a Ca2+/Mg2+-dependent endonuclease that was 
isolated from thymocytes and has been characterized as an 
anionic protein with a molecular weight greater than 110 kDa. 
This endonuclease has a double strand cleavage preference for 
DNA and a pH optimum of 7.5; and its regulation has been 
extensively reviewed ( 103) . Another candidate for the 
apoptotic endonuclease is DNase I I which is a Ca2+ /Mg2+ -
independent endonuclease that functions optimally in an 
acidic environment (pH 6.5-7.0) (104,105). These 
endonucleases have been shown to be either constitutively 
expressed, or induced, depending upon the system used in the 
study (103). 
Recent studies have shown that apoptosis can occur in 
some cell types without the presence of oligonucleosomal DNA 
ladders (106,107). Further investigation revealed that 
specific changes in the integrity of higher order chromatin 
occurred in apoptotic cells before, concomitantly with, or 
even in the absence of internucleosomal DNA cleavage (107-
111) . Chromatin changes were manifested as discrete DNA 
fragments of 300 kbp "rosettes" and 30-50 kbp "chromatin 
loops" suggesting the cleavage of looped domains of DNA at 
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the attachment points of the nuclear matrix. Studies using 
murine thymocytes (112) and isolated rat liver nuclei (113) 
suggested that internucleosomal cleavage and higher order DNA 
fragmentation were independent events. The original concept 
that internucleosomal DNA fragmentation was responsible for 
the changes in nuclear morphology is now suspect. The fact 
that higher order chromatin changes occurred before the 
appearance of DNA ladders and, more importantly, that these 
changes occurred in the absence of DNA ladders, provides 
convincing evidence that the changes in higher order 
chromatin, and not the internucleosomal fragmentation of DNA, 
were responsible for the condensation of chromatin associated 
with apoptotic cells (107,114). The 50 kbp chromatin loops 
are thought to serve as the substrates for endogenous 
endonucleases that cleave the DNA at internucleosomal sites. 
Therefore, those cells that undergo apoptosis without the 
formation of DNA ladders either do not express the proper 
endonuclease or it simply is not activated. These and other 
studies suggest that the apoptotic endonuclease is a 
dispensable component of the apoptotic machinery (107,115). 
The role of both divalent cations and protein synthesis 
is another well studied, albeit poorly understood, area in 
apoptosis research. The role of ca2+ ions in the induction 
of apoptosis is well documented in some systems (116-118). 
The sustained increase in intracellular free ca2 + has been 
shown to occur prior to the induction of apoptosis by a 
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variety of stimuli (119-121). In these systems, preventing 
the increase in intracellular Ca2+ inhibits the onset of 
apoptosis, while treatment with a calcium ionophore, such as 
A23187, induces apoptosis, suggesting that the influx of Ca2 + 
may be a trigger for the induction of apoptosis (53,119). 
The potential targets for Ca2 + in an apoptotic cell are many 
and may include the endogenous endonuclease, 
transglutaminase, cytoskeletal components, and a variety of 
calmodulin-dependent protein kinases and proteases 
( 53, 85, 122) . However, ca2 + is not an absolute requirement in 
all apoptotic systems (105,122-126) and further studies need 
to address the possibility that Ca2 + influx is a common 
consequence, rather than a trigger for apoptosis. The 
existence of both Ca2+ /Mg2 + -dependent and -independent 
endonucleases may explain why the role of calcium in the 
apoptotic process can vary between cell types. The 
possibility that calcium may not be a trigger for the 
induction of apoptosis should not take away from the 
importance of this ion as a possible common effector for many 
of the various morphological and biochemical changes 
associated with an apoptotic cell (53,85,122). 
The requirement for de novo protein synthesis is another 
complex issue in the regulation of apoptosis. Studies in 
thymocytes showed a requirement for de novo protein synthesis 
in the induction of apoptosis since protein synthesis 
inhibitors were capable of preventing apoptosis (117, 127-
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12 9). However, many studies have since shown that de novo 
RNA/protein synthesis is not a universal requirement and 
indeed, in many cell systems, inhibitors of RNA and protein 
synthesis actually induce apoptosis (60, 96, 97, 130, 131). This 
topic has been reviewed elsewhere (132). The bottom line 
seems to be that apoptosis can occur in either a protein 
synthesis-dependent or protein synthesis-independent manner 
depending upon the cell type and the apoptotic stimulus 
employed in the study. 
The activation of tissue transglutaminase is yet another 
frequent but dispensable feature of apoptosis (53,133,134). 
Tissue transglutaminase is a calcium-dependent enzyme that 
catalyzes the crosslinking of appropriate protein substrates 
forming a protein net that may prevent the leakage of 
cellular constituents during apoptosis and aid in the 
formation of apoptotic bodies (53,85). The role of 
transglutaminases in apoptosis has been reviewed elsewhere 
(135) . 
Recent studies demonstrating the solubilization of 
nuclear matrix proteins in apoptotic cells have provided 
evidence suggesting a role for nuclear matrix changes in the 
induction of chromatin degradation and the morphological 
changes associated with the nucleus of apoptotic cells. The 
role of nuclear matrix proteins in apoptosis has been 
recently reviewed (136) . 
The final stage of apoptosis is the removal of the 
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cellular debris which is neatly packaged into apoptotic 
bodies. The apoptotic bodies are either sloughed off into 
the lumen of tissues or, more commonly, phagocytized by 
macrophages and neighboring cells. The recognition of the 
apoptotic bodies by these phagocytic cells is an important 
step in apoptosis and involves changes in the plasma membrane 
that facilitate their recognition and removal. These cell 
surface changes are cell type-dependent and have been 
reviewed elsewhere (137) . 
The Role of Apoptosis in Oncogenesis and Cancer Chemotherapy 
Cell populations in normal adult tissues are in constant 
flux responding to autocrine, paracrine, and endocrine 
signals that regulate their size and function. Tissue size 
is kept relatively constant by maintaining a balance between 
cell proliferation and cell death, which occurs almost 
exclusively by apoptosis (46,77,78,138-140) Any disruption 
in the maintenance of this balance results in either tissue 
hyperplasia or atrophy and may have a negative impact upon 
the organism (40). Cells within many tissues are thought to 
be under social control and require factors that are supplied 
by other cells to proliferate and/or survive (85,141,142). 
These growth factors and survival factors are responsible for 
maintaining tissue homeostasis by regulating both cellular 
proliferation and cell death (142). 
Carcinogenesis is a multi-step process in which cells 
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acquire genetic lesions that alter the expression and/or 
function of a specific subset of cellular proteins (143-146) . 
These genetic lesions are manifested as gene amplifications, 
chromosomal translocations, deletion mutations, point 
mutations, and viral insertions, and impart a growth 
advantage to the cell by freeing it from the constraints of 
social control. The mechanisms and genes that are involved 
in the oncogenesis of human tumors are many and have been 
extensively reviewed (147-152). 
The uncontrolled growth of cells has long been 
attributed to the deregulation of genes involved in cellular 
proliferation and differentiation (147,149,151). These genes 
fall into one of two categories: oncogenes or tumor 
suppressor genes. However, recent studies have reestablished 
the importance of apoptotic cell death in the maintenance of 
cell populations. Genetic alterations that inhibit apoptosis 
or increase the threshold for its induction result in tissue 
hyperplasia in a similar manner that would occur from an 
increase in cellular proliferation. Cells in which the 
inhibition of apoptosis has enhanced their survival, however, 
are not necessarily tumorigenic since the regulation of their 
proliferation is still under social control and therefore, 
they possess no real growth advantage ( 153) Likewise, a 
cell that proliferates in a deregulated fashion is not 
necessarily highly tumorigenic since these cells may show 
normal or enhanced rates of apoptosis which could prevent 
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tumor formation (154) . 
The recent discoveries of genes that are involved in the 
regulation of apoptosis have provided great impetus in 
suggesting a role for apoptosis in oncogenesis (reviewed in 
42, 82, 85, 86, 155) . These genes fall into two classes: 1) 
inducers of apoptosis whose expression can directly induce 
cell death or increase the susceptibility of cells to death 
inducing stimuli; and 2) repressors of cell death whose 
expression can prevent or delay the onset of apoptosis. The 
irony of these discoveries was that the majority of these 
genes had been previously characterized and were well studied 
because they were the same genes known to be involved in the 
transformation of normal cells, i.e. oncogenes and tumor 
suppressor genes. The fact that these genes are now known to 
be involved in the regulation of both cell proliferation and 
cell death further supports a role for apoptosis in both the 
prevention and development of an oncogenic state. In the 
following sections the major apoptosis regulatory genes will 
be individually discussed in detail and evidence will be 
presented which suggests that mutations affecting genes that 
are either inducers or repressors of apoptosis, coupled with 
a second mutation which enhances cellular proliferation, may 
be a common occurrence during the development of malignancy. 
The goal of cancer chemotherapy is a simple one, 
maximize the ablation of cancerous cells while minimizing 
damage to normal tissues. In the past, the philosophy for 
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chemotherapy has been "more is better". Current clinical 
regimens try to maximize the tolerable dose of drug in an 
attempt to inflict the greatest amount of damage upon cells 
with the goal of overwhelming the cancer cell, thus causing 
its demise. The drugs used to fight cancer are by no means 
selective for tumor cells and it should come as no great 
surprise that their dosage is limited by the various toxic 
side effects on normal tissues. Actually it is hard to 
imagine how a drug which is present at such a high dose can 
be selective at all since the range of doses at which the 
drug could show selectivity has been greatly surpassed. 
The current resurgence of apoptosis research has had a 
great impact on the cancer field 
evidence has shown that low 
(86-90) . Increasing 
concentrations of 
chemotherapeutic agents from drug classes with disparate 
modes of action induce apoptosis in the majority of tumor 
cells tested (156, 157, and 85, 86 and references within) . 
Studies have shown that the type of cell death utilized 
(apoptosis or necrosis) is largely dictated by the level of 
cellular injury rather than the type of agent used to cause 
such injury, and that the concentration of drug or duration 
of exposure required to reach this crossover point is 
radically different between tumor cell types (158-160). 
These findings have forced a reevaluation of the current 
philosophy of chemotherapeutic intervention in the treatment 
of cancer. 
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The cytotoxic effect of chemotherapy has long been 
thought to be due to the direct effect of the various agents 
on their specific biochemical targets (90,156,161), thus the 
more damage inflicted upon the target, the greater the chance 
for cell death. Ironically, the drug/target interactions for 
the majority of anti-neoplastic agents have been extensively 
studied, and yet the rationale for how and why such 
interactions should bring about the death of sensitive cells 
remains speculative to say the least (156). However, the 
fact that apoptosis is the common mechanism of cell death in 
nearly all tumor cells, regardless of the drug/target 
interaction employed, suggests that the drug/target 
interaction has an indirect role in cytotoxicity, with the 
final outcome being determined by the cellular response to a 
drug-induced change in homeostasis (90,156,161). The 
cellular response to drug exposure does not appear to be 
based solely upon the quality or quantity of change or damage 
induced by the drug (90) . This simple pharmacological 
principle of stimulus-response coupling may go a long way in 
providing a possible explanation of what has been termed 
11 inherent 11 drug resistance. Tumors that respond well to 
therapy are generally capable of readily engaging the 
apoptotic pathway of cell death, while those tumors which are 
resistant either do not receive the stimulus (classical drug 
resistance) or more importantly, do not respond to it, i.e. 
they have uncoupled the response from the stimulus (90). The 
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fact that different types of tumor cells have different 
thresholds for implementing the apoptotic pathway in response 
to the same drug further supports the concept that the 
cellular response to drug perturbations is an important 
determinant in the outcome of drug exposure (90,160,162) 
The discovery that apoptosis can be regulated by 
oncogenes and tumor suppressor genes has taken on even 
greater importance given the role of apoptosis in the 
mediation of cancer chemotherapy. Many studies have shown 
that the apoptotic threshold in tumor cells is directly 
modulated by many of the oncogenes and tumor suppressor genes 
that regulate the apoptotic process (reviewed in 85,87,155). 
Therefore, the inherent drug resistance encountered in many 
tumors may very well be the result of the oncogenic process 
itself given the role of apoptosis in both chemotherapy and 
carcinogenesis (85,88). In support of this concept, the cell 
death repressor, bcl-2, has been shown to cooperate with c-
myc in the oncogenesis of tumors (153,163) and its 
overexpression in many different tumor cell types imparts 
resistance to a wide spectrum of anti-neoplastic agents 
(164, 165). Likewise, activating mutations of H-ras and 
translocation of the c-abl oncogenes have been shown to play 
a role in cellular transformation (166-168) and these lesions 
also increase the resistance of cells to chemotherapeutic 
agents by inhibiting the induction of apoptosis (154,169). 
Finally, the deletion or mutation of the tumor suppressor, 
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ps3 , has been shown to participate in the progression of 
tumor development (170,171), and cells lacking p53 or 
possessing a mutant form have been shown to be more resistant 
to many types of anti-cancer drugs as a result of the 
inhibition of apoptosis (172-175). The specific roles of 
apoptosis-regulating oncogenes and tumor suppressor genes in 
the modulation of neoplastic cell responses to 
chemotherapeutic interventions will be discussed on an 
individual basis in detail in the following section. 
Genes Involved in the Regulation of Apoptosis 
Repressors of Apoptosis 
bcl-2 
The B-cell lymphoma/leukemia-2 (bcl-2) oncogene was 
first identified at the t(l4;18) (q32;q21) breakpoint (176-
178) and constitutes the most common chromosomal 
translocation in human lymphoid malignancies, occurring in 
approximately 85% of follicular and 20% of diffuse B-cell 
lymphomas (179,180). The t (14; 18) (q32 ;q21) translocation 
occurs when the bcl-2 gene is moved from its normal 
chromosomal location at 18q21 into juxtaposition with the 
powerful enhancer elements in the immunoglobin heavy-chain 
(IgH) locus at 14q32 and results in the aberrant 
overexpression of bcl-2 mRNA and protein (181). These 
findings suggested that bcl-2 possessed oncogenic potential. 
Vaux et al. initially demonstrated that bcl-2 could prolong 
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the survival of factor-dependent pre-B-cells following the 
removal of interleukin 3, without any concomitant cell 
proliferation, suggesting that bcl-2 was blocking the normal 
apoptotic response of these cells following factor withdrawal 
(182). The cell death repressor activity of bcl-2 was 
formally demonstrated by Hackenbery et al. (183) and further 
supported by other studies (184,185), including antisense 
studies which showed that reductions in bcl-2 protein levels 
were insufficient by themselves to cause cell death, but 
accelerated cell death following survival factor removal 
(186) . The lack of a proliferative effect by bcl-2 cast 
doubt on its oncogenic potential, however, some studies 
suggested that bcl-2 could cooperate with a proliferation-
inducing oncogene to transform cells (182,187). 
The subtlety of bcl-2's oncogenic activity was 
demonstrated in transgenic mice that were engineered to 
express a bcl-2-immunoglobin minigene that mimicked the 
t ( 14; 18) translocation. These mice initially displayed a 
polyclonal follicular lymphoproliferation and accumulation of 
B cells due to increased survival (188), but over time 
developed diffuse large cell immunoblastic lymphomas, half of 
which possessed deregulating c-myc translocations (189) . 
These results showed that bcl-2 possessed oncogenic potential 
by prolonging the survival of cells that would normally be 
eliminated by apoptosis, allowing for the accumulation of 
secondary genetic lesions that could promote the 
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proliferation of these cells. The oncogenic cooperativity 
between bcl-2 and c-myc has been further demonstrated both in 
y_itro (190, 191) and in vivo by crossing bcl-2 and c-myc 
transgenic mice which produced progeny that rapidly developed 
leukemias (163,192). These findings reclassified bcl-2 into 
a new category of oncogenes: the death repressor genes. 
bcl-2 is a large, three exon gene containing a 225 kb 
intron 2 that divides the protein coding exons 2 and 3 from 
the untranslated exon 1 (193) . The major promotor, Pl, is GC 
rich and contains multiple SPl sites, while the minimally 
used P2 promotor has a classic TATA- and CAAT-box and an SV40 
decamer/Ig octamer motif (194,195). Recently, a putative, 
p53-dependent negative response element has been identified 
in the bcl-2 promotor (196). The mRNA for bcl-2 is 
approximately 6 kb, contains a large 3'-untranslated region, 
and encodes a 239 amino acid, 26 kDa protein (194) 
Bcl-2 is an integral 
inhibit cell deaths that 
membrane oncoprotein that can 
are induced by a variety of 
physiological and non-physiological stimuli ( 85, 197, 198) . 
These findings have led to the concept that bcl-2 represses 
apoptosis by blocking a final, common pathway in the cell 
death process. That bcl-2 can prevent or delay apoptosis in 
almost any cellular context is well accepted. However, some 
pertinent physiological exceptions do exist; namely, 
complement-mediated lysis, apoptosis induced by cytotoxic T-
cells (199), withdrawal of some cytokines (200), and positive 
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and negative thymic selection (197,201,202). Bcl-2 is 
restricted to tissues in which apoptosis molds developing 
structures or accounts for the turnover of cell populations; 
these tissues include thymus, bone marrow, breast, thyroid, 
prostate, pancreas, GI tract, skin, and nervous system tissue 
(203). The physiological role of bcl-2 in these tissues is 
thought to be related to maintaining the progenitor and long-
lived cells in these lineages (203). A number of these 
tissues that express bcl-2 also have a high incidence of 
cancer, with skin, colon, breast, prostate, and pancreas 
ranking first, third, fourth, fifth, and ninth, respectively 
in disease sites (204), suggesting that changes in bcl-2 
expression in these tissues may contribute to their 
oncogenesis. 
Despite the resources and effort invested in bcl-2 
research, the biochemical mechanism(s) by which this protein 
represses cell death is unknown. The amino acid sequence of 
the bcl-2 protein, as predicted from its cDNA, reveals no 
sequence motifs that would suggest a specific biochemical 
function for this protein. However, studies on the 
intracellular localization of bcl-2 might begin to shed some 
light upon this mechanism or at least help determine where to 
concentrate future efforts. The bcl-2 protein has been shown 
by confocal, laser scanning, and electron microscopy to be 
localized to the nuclear envelope, parts of the endoplasmic 
reticulum, and outer mitochondrial membrane (205-207) . These 
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findings are consistent with the fact that bcl-2 is 
posttranslationally anchored to cellular membranes by a 
single, COOH-terminal stretch of 19 hydrophobic amino acids 
flanked on both sides by positively charged residues 
(208, 209). Indeed, the insertion of bcl-2 into membranes 
orients the protein towards the cytosol and has been shown to 
be important for its death repress or activities 
(208,210,211). 
Recent studies have suggested an antioxidant role for 
bcl-2 (212,213). The main source of reactive oxygen species 
in the cell is the mitochondria, with potential production by 
the endoplasmic reticulum, and nuclear envelope, the main 
sites of bcl-2 distribution. However, inhibition of 
apoptosis by bcl-2 has been shown to occur in the absence of 
a functional electron transport chain ( 2 05) and in the 
absence of a nucleus (214,215) suggesting that the death 
repressing activity of bcl-2 does not have an absolute 
requirement for these organelles. The endoplasmic reticulum 
is a major storage site for intracellular Ca2+, a divalent 
cation with an important role in apoptosis, and implicated as 
a potential trigger of the process in some cell types. Bcl-2 
has been shown to inhibit cell death triggered by Ca2+ 
ionophores without preventing an increase in intracellular 
C 2+ . a , suggesting that bcl-2 blocks a downstream event in this 
process (216). Other studies have shown that bcl-2 can 
prevent apoptosis by inhibiting the efflux of ca2 + through 
the endoplastic reticulum membrane (217). 
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Although a bcl-
2;caz+ association makes an attractive hypothesis, especially 
given the importance of Ca2+ in many apoptotic processes, it 
must be remembered that many of these processes, such as the 
activation of ca 2 + - dependent endonucleases, 
transglutaminases, and protein kinases, have been shown to be 
dispensable for apoptosis and its inhibition by bcl-2 in some 
systems (53, 107, 122) . Such a hypothesis implies that the 
activation of the initial trigger of apoptosis, or a proximal 
upstream event, requires an increase or redistribution of 
intracellular Ca2+ that is inhibited by bcl-2. The 
identification of the initial trigger(s) of apoptosis, Caz+_ 
dependent or otherwise, has eluded researchers to date. 
Recent studies have shown that bcl-2 can associate with 
other proteins and these protein-protein interactions may 
help elucidate the mechanism (s) by which cell death is 
inhibited by bcl-2. The discovery of the 21 kDa, bcl-2-
associated factor (bax) was a major boost for death repressor 
research (218) . These studies showed that bcl-2 was capable 
of interacting with a protein partner (bax) through two 
highly conserved bcl-2 homology domains, BHl and BH2, which 
would serve to define the bcl-2 family of proteins (218,219). 
More importantly, these studies showed that the 
overexpression of bax in the presence of a death-inducing 
stimulus abrogated the death repressing actions of bcl-2, 
leading to the 11 rheostat concept 11 where the ratio between 
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bcl-2 and bax determines whether a cell is susceptible to 
apoptosis following a death stimulus, with high levels of 
bcl-2 favoring survival and high levels of bax favoring cell 
death (218,220). Bcl-2 homodimers are not capable of 
repressing death and in fact, bcl-2 was shown to require 
dimerization with bax to propagate cell survival ( 219) . 
These results suggested two possibilities, the first being 
that the bcl-2/bax heterodimer was the functional death 
repressing complex. In this case, the heterodimer levels 
would be determined by the relative levels of both bcl-2 and 
bax proteins, and when bax protein levels were greater than 
bcl-2 protein levels, bax homodimers would dominate over bcl-
2/bax heterodimers and cell death would result. When bcl-2 
levels were greater, bcl-2/bax heterodimers would predominate 
and death would be repressed. The other possibility is that 
the bax/bax homodimer is a death-inducing complex and bcl-2 
promotes survival by heterodimerizing with bax, thus, 
antagonizing the formation of the bax/bax homodimer. The 
recent development of a bax knockout mouse unfortunately did 
not provide a decisive resolution to this question since the 
loss of bax resulted in hyperplasia or hypoplasia, depending 
on the cellular context (221) . 
The discovery of bax prompted the search for other bcl-2 
interacting proteins and family members and has uncovered 
several novel proteins. Another bcl-2 family member which is 
capable of interacting with bcl-2 is bad, a 22 kDa protein 
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which binds to both bcl-2 and bcl-xL (a novel gene belonging 
to the bcl-2 family of death repressors) and abrogates the 
death repressor activity of bcl-xL but not that of bcl-2 
(222). Other non-bcl-2 family member proteins have also been 
shown to interact with bcl-2 and include bag-1, an anti-death 
gene that promotes the survival activity of bcl-2 under some 
circumstances where bcl-2 alone has no death repressor 
activity (223). Both p23 ras-related protein (R-ras) and 
raf-1, an oncogene, have been shown to interact with bcl-2, 
linking this protein with important signal transduction 
pathways (224,225). 
The remaining bcl-2 family members, bcl-x, mcl-1, and Al 
do not specifically interact with bcl-2 but are functional 
homologs in that they can repress death and heterodimerize 
with bax (226-230). The most studied of these genes to date 
is bcl-x which exists in both a short (xs) and long (xL) form 
as a result of alternative splicing (226) . Bcl-xL exhibits 
death repressing activity that is virtually interchangeable 
with bcl-2 and has been shown to be expressed in embryonic 
and postnatal neural tissues where it functions to prevent 
neuronal cell death (231) . Bcl-x has also been shown to be 
involved in the survival of double-positive thymocytes (232). 
The short form, bcl-xs, lacks the conserved BHl and BH2 
domains and does not dimerize with bax, yet still interacts 
with bcl-xL and bcl-2 (226,230). When bcl-xs was 
overexpressed in the presence of bcl-2 the survival function 
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of bcl-2 was abrogated and cell death was promoted (226) . 
This observation suggests a function similar to bad in that 
bcl-Xs may prevent the formation of bcl-2/bax heterodimers by 
antagonizing bax-bcl-2 interactions. The multiplicity of 
these bcl-2 family interactions suggests that the regulation 
of cell death by these proteins may be dependent upon their 
relative expression in specific cell types and the regulation 
of their subsequent interactions. Other posttranslational 
modifications to these protein family members may also be 
important for their interaction and/or functional regulation. 
In support of this concept, studies have shown that the 
phosphorylation of bcl-2 on serine residues inactivates its 
death repressor activity (233). 
The Role of bcl-2 in Chemotherapy 
As described in the previous sections, there is now much 
evidence supporting the involvement of bcl-2 overexpression 
in the development of human malignancies. The frequent 
occurrence of genetic lesions that inhibit the cell death 
pathway in human tumors underscores their importance in 
oncogenesis, however, the impact of these types of lesions 
may go beyond the development of tumors. Many types of tumor 
cells that overexpress bcl-2 have been shown to be more 
resistant to a variety of death stimuli, including a large 
majority of the anti-neoplastic agents used in the treatment 
of human malignancies (164,165,234-238). The sensitivity of 
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tumor cells to chemotherapeutic agents can be restored by the 
targeted depletion of bcl-2 via antisense technology 
(239,240) More importantly, bcl-2 protected cells from 
chemotherapeutic agents by suppressing the tendency of 
damaged cells to induce apoptosis, and this effect was not 
mediated by alterations in drug efflux, metabolism, or levels 
of DNA damage (241-243). These results show that the direct 
suppression of apoptosis represents a discrete mechanism of 
anti-neoplastic agent resistance. Other components of the 
death repressor pathway are being discovered and their roles 
in drug resistance are also being revealed (244-246) . The 
involvement of cell death repressors in the outcome of 
chemotherapeutic intervention will no doubt be an important 
area of future research in oncology. The importance of death 
repressors in the clinical outcome of cancer chemotherapy is 
still a matter of debate. However, many new studies have 
shown that these proteins are expressed in clinical tumor 
specimens, suggesting a role in oncogenesis (247,248). 
ras, abl, and raf-1 
The GTP-binding protein Harvey ras (H-ras) is frequently 
overexpressed in primary human neoplasms. The overexpression 
of wild-type H-ras in rodent fibroblasts led to an elevation 
in both the mitotic and apoptotic indices. The 
overexpression of a mutant H-ras also resulted in an elevated 
mitotic index, however, the apoptotic index remained the same 
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S or lower than in the parental cells resulting in a tumor a I 
phenotype which was far more aggressive in its growth 
characteristics than tumors expressing a wild-type H-ras 
(154). 
The role of the c-abl translocation, t{9;22) I 
{Philadelphia chromosome) in chronic myeloid leukemia {CML) 
has been well characterized { 166) . Recent studies have shown 
that v-abl can delay cytokine withdrawal-induced apoptosis of 
a mast cell line without inducing proliferation {249). Other 
studies have shown that the resistance of a CML cell line to 
several normally lethal stimuli can be overcome by 
downregulating the expression of bcr-abl mRNA with antisense 
oligodeoxynucleotides {ODNs) . These studies suggested that 
the death resistant phenotype of CML cells was due to 
enhanced cell survival resulting from the suppression of 
apoptosis {169) . 
Raf-1 is a serine/threonine protein kinase that is 
important in mitogenic signal transduction pathways. Recent 
reports suggested that raf-1 can synergize with v-myc in the 
abrogation of IL-3-dependence in myeloid 32D cells by 
suppressing apoptosis {250), and that raf-1 may suppress 
apoptosis by promoting the function of bcl-2 {225,251). 
Inducers of Apoptosis 
The p53 tumor suppressor protein was initially 
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classified as a tumor antigen that could interact with the 
large T antigen of Simian Virus 40 (SV-40) (252). p53 was 
reclassified as an oncogene when studies showed that the 
transfection of some isolated cDNA clones could immortalize 
cells in culture and transform them in cooperation with 
another oncogene, such as ras (253,254). The true nature of 
p53 as a tumor suppressor was revealed when researchers 
discovered that the majority of the cDNA clones used in these 
studies were not representative of wild type p53, but 
contained missense mutations. Subsequent studies showed that 
the wild type p53 protein was not capable of transforming 
cells in culture, and more importantly, was able to prevent 
the transformation of cells by other oncogenes (255,256). 
These findings helped to reclassify p53 from an oncogene to 
a tumor suppressor gene or anti-oncogene. However, the 
mutant forms of p53 were still thought to possess gain of 
function oncogenic activity. These initial studies provided 
the foundation for future p53 research by hinting at the 
complex nature of this protein and how its loss/gain of 
function could be involved in oncogenesis. 
p53 is the most frequently mutated cancer gene studied 
to date, with mutations occurring in approximately 60% of 
human tumors (257) . Missense mutations are the most common, 
but nonsense mutations and allelic deletions also occur. The 
p53 gene has been localized to the short arm of chromosome 17 
(p13.1) and is comprised of 11 exons, the first of which is 
non-coding (258). 
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The 2.5 kb p53 mRNA encodes for a 393 
amino acid nuclear phosphoprotein that is present in normal 
dividing cells at low levels. 
The wild-type p53 protein is a 53 kDa protein that 
functions as a sequence-specific transcriptional activator, 
the activity of which is essential for its tumor suppressor 
functions (259) . The protein is composed of four functional 
domains and includes a transcriptional activation domain in 
the acidic NH-terminus (260,261): a DNA-binding domain 
(residues 102-290) that binds to two copies of the consensus 
sequence, 5'-PuPuPuC(A/T) (A/T)GPyPyPy-3', which can be 
separated by as many as 13 bp of random sequence (262,263); 
an oligomerization domain (residues 319-360) responsible for 
the formation of p53 tetramers (264); and a basic, COOH-
terminus with putative negative-regulatory functions (265) . 
The COOH-terminal end also contains three putative nuclear 
localization signals (NLS) . The predominant nuclear 
localization signal (NLS) is located adjacent to serine 315, 
which is an in vitro and in vivo substrate for p34c<1c2 kinase 
(cdkl). It has been postulated that phosphorylation at Ser 
315 may alter the cellular localization and/or function of 
p53 (266). 
The wild-type and mutant forms of the p53 protein 
possess conformational and functional differences that are 
responsible for their tumor suppressive or oncogenic 
activities, and have been extensively reviewed (267, 268). 
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The wild-type p53 protein has a very short half-life (less 
than 30 min) (269), can suppress the growth of tumors in 
yitro (270,271) and in vivo (272), and prevent the 
transformation of primary fibroblasts by cooperating 
oncogenes (256). Evidence suggests that the suppressor 
function of wild-type p53 requires the transactivation of 
target genes (259). The wild-type protein can form complexes 
with several viral oncoproteins, including SV40 large T 
antigen, adenovirus ElB, HPV16 E6, and others, which either 
functionally inactivate or enhance the degradation of the p53 
protein. Normal p53 has also been shown to complex with the 
TATA-box binding protein (TBP), the DNA replication factor 
RPA, SP-1, WT-1 and CCAAT binding factors, single stranded 
DNA, DNA helicases, and the MDM2 oncoprotein (273 and 
references within) . MDM2 expression is upregulated by wild-
type p53 and the protein product of this gene has been shown 
to bind to and inactivate wild-type p53, suggesting a 
potential feedback mechanism for p53 regulation (274) . Wild-
type p53 is capable of suppressing transcription from 
promotors containing a TATA element via its interactions with 
TBP (275) . Wild-type p53 protein displays a different 
conformation than most of the mutant forms since the wild-
type protein is not recognized by the commercially available 
PAb 240 monoclonal antibody which is specific for many of the 
mutant forms of p53 (276). Some studies have shown that 
wild-type protein can exist in 2 cellular pools, one with a 
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wild-type conformation and one in which wild-type proteins 
adopt a mutant conformation (277) . One hypothesis suggests 
that the wild-type p53 protein is conformationally flexible 
and alters its function as either a growth suppressor (wild-
type conformation) or growth promotor (mutant conformation) 
as needed (278) . The relevance of such a theory is unknown 
but the engineering of p53-/- knockout mice that developed 
normally did not support a role for wild-type p53 as a growth 
promotor (279). 
Mutant p53 protein exists in many subtle forms which 
result mainly from missense point mutations. The majority of 
these point mutations have been mapped by analysis of p53 
cDNAs obtained from a large number of tumor specimens. Not 
surprisingly, these point mutations occurred almost 
exclusively within the DNA binding domain (257,280). Of the 
four known hotspots for point mutations, two are directly 
involved in contacting DNA, one in the minor grove and the 
other in the major grove. The third mutated residue bridges 
the two loops which contain these two residues, aligning them 
so they can make proper contact with the DNA (281) . Missense 
mutations are often associated with a conformational change 
in the mutant protein (282) . Conformational changes and 
substitution of important amino acid residues in the DNA 
binding domain help to explain why the majority of mutant 
proteins tested can no longer bind to DNA and transactivate 
genes (283-286) These characteristics are most likely 
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responsible for the inability of mutant p53 to suppress the 
growth of tumor cells, and transformation of primary 
fibroblasts (256,270). The half-lives of mutant p53 proteins 
vary depending upon the mutation involved, but are several 
hours in length (287 t 288) • The post translational 
stabilization of mutant proteins results in their 
0 verexpression. 
Wild-type p53 is often non-functional when in the 
presence of overexpressed mutant p53 proteins (as is the case 
in most tumors which contain both alleles) . Some mutant 
forms of p53 have been shown to exert a trans-dominant 
negative effect on the wild-type protein, negating its 
functional properties (253, 255) . The loss of wild-type 
function can result from changes in conformation and it has 
been shown that mutant protein can force wild-type p53 into 
a mutant conformation (289) . Also, the presence of mutant 
proteins in a p53 tetramer inhibits the DNA binding and 
transactivation activities of these heterogeneous oligomers 
(285, 286). Studies have shown that mutant proteins do not 
necessarily aid in transformation by just interfering with 
the growth suppressing properties of wild-type p53. Many of 
the mutant proteins have been shown to possess gain of 
function oncogenic activity in the absence of a trans-
dominant mechanism and this may explain why p53 mutations are 
so strongly selected for in tumor cells, and wild-type p53 so 
strongly selected against (290). In support of possible gain 
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of function activities, studies have shown that mutant p53, 
but not wild-type, can upregulate the expression of the MDRl 
drug resistance gene, and synergize with protein kinase C to 
induce the expression of vascular endothelial growth factor 
(291,292). 
Nonsense mutations result in a truncated protein that is 
devoid of function because it can no longer oligomerize with 
other p53 molecules (268) . Deletions result in the loss of 
functional p53 alleles from the genome. The loss of a single 
allele is not detrimental in the presence of a wild type 
allele since tumor suppressors act in a dominant/recessive 
fashion. The loss of both wild type p53 alleles, although 
not detrimental to the development of the organism, 
predisposes it to the rapid onset of tumors (279) The most 
common scenario for the loss of p53's suppressor functions 
occurs when one allele sustains a somatic missense mutation. 
The mutant protein may possess gain of function oncogenic 
activity and/or exert a trans-dominant negative effect on the 
wild-type protein. The presence of both a wild-type and 
mutant p53 allele is usually selected against, resulting in 
the eventual loss of the remaining wild-type allele (280). 
The fact that p53 can suppress the formation of tumors 
is well accepted, however, the specific pathway(s) by which 
this occurs is unknown. Other functions for p53 were thought 
to include the suppression and/or promotion of ce.llular 
proliferation during growth and development. The normal 
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development of homozygous p53 - /- knockout mice suggested that 
pS3 was not important for the regulation of normal cell 
proliferation, differentiation, or arrest. However, greater 
than 70% of the knockout mice developed sporadic tumors by 
six months of age which suggested that the normal function of 
p53 was solely involved in the suppression of tumor formation 
(279). 
One specific pathway by which p53 may suppress tumor 
formation is through its regulation of cell cycle checkpoints 
following damage to genomic DNA. One of the hallmarks of 
tumor cells is their preponderance of genomic aberrations 
which include translocations, gene amplifications, 
chromosomal deletions, inversions and insertions, aneuploidy 
and polyploidy. These aberrations contribute to oncogenesis 
and are thought to occur when DNA synthesis and mitosis are 
allowed to proceed in the presence of a damaged genome (293). 
Normal cells arrest at various cell cycle checkpoints which 
allows for the repair of genomic DNA before DNA synthesis or 
mitosis can occur, ensuring that genomic fidelity is 
maintained between cell generations (reviewed in 294) . 
The role of p53 in the regulation of the Gl checkpoint 
following DNA damage has been well characterized (295,296, 
reviewed in 273,297). Ionizing and UV radiation, and most 
DNA damaging chemotherapeutic agents directly or indirectly 
cause single and/or double strand DNA breaks, resulting in 
the Gl arrest of normal cells. The trigger for this arrest 
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appears to be the presence of DNA strand breaks which are 
recognized by the COOR-terminus of p53, leading to the 
stabilization and accumulation of p53 protein in the nucleus, 
and activation of its sequence-specific DNA binding (296, 298-
300). The increase in p53 levels leads to the 
transactivation of the GADD45 (growth arrest DNA-damage) and 
p21 WAFllCIPl genes, among others. Expression of the GADD45 gene 
following irradiation is p53-dependent and capable of 
arresting cells in Gl by an unknown mechanism (301, 302). 
other types of DNA damage can increase GADD45 expression by 
p53-independent mechanisms (301,303). GADD45 has been shown 
to bind the proliferation cell nuclear antigen (PCNA) , a 
regulatory subunit of DNA polymerase o and E, and induce DNA 
excision repair, linking Gl arrest to the repair of genomic 
DNA (304) . 
The more probable pathway for the p53 -mediated Gl arrest 
involves the induction of the p21WAFllCIPl gene (305,306). p21 
is a cyclin dependent kinase (cdk) inhibitor with multiple 
functions. p21 binds to and inhibits the kinase activity of 
cyclin/cdk complexes which are required for cell cycle 
progression and also binds to and inhibits PCNA (307,308). 
The consequences of p21 activation are straightforward: 
blocking PCNA inhibits DNA replication while the inhibition 
of specific cyclin/cdk complexes arrests the cell cycle in 
Gl. Unlike GADD45, p21 is also induced by p53-independent 
pathways during the normal cellular growth response, however, 
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the response to genotoxic stress requires induction via a 
p53-dependent pathway (309). 
The recent development of a p21-/- knockout mouse has 
provided direct evidence that p21 is a significant mediator 
of DNA damage-induced Gl arrest. However, the Gl checkpoint 
was only partially impaired in response to T-irradiation 
suggesting that another p53-dependent mechanism existed that 
could also induce Gl arrest following DNA damage (310). p21 
was not required for the p53-regulated mitotic spindle 
checkpoint or p53-dependent apoptosis (310). Unlike p53-/-
mice, which developed tumors within 6 months of age, p21 
deficient mice, which were greater than 7 months old, had not 
yet developed tumors (310). This finding is quite surprising 
but consistent with the fact that mutations of p21 are not 
commonly found in human tumors (311) . These results, 
although preliminary, strongly suggested that the regulation 
of the Gl checkpoint was not the primary mechanism by which 
p53 suppressed tumor formation (310) . The role of p53 in 
other cell cycle checkpoints, namely the mitotic spindle 
checkpoint and possibly the G2 checkpoint, was still 
maintained in the cells of these mice and may be involved in 
tumor suppression ( 312) . However, evidence from many studies 
has directly implicated p53-mediated apoptosis in the 
suppression of tumor growth and transformation by oncogenes 
and in the removal of severely DNA-damaged cells 
(173,272,313-315). Taken together, these results strongly 
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suggested that apoptosis was the primary mechanism by which 
p53 suppressed tumor formation. 
Yonish-Rouach and colleagues provided the first evidence 
that p53 was a regulator of apoptosis when they showed that 
the ectopic overexpression of wild-type p53 directly induced 
apoptosis in the non-p53-expressing murine Ml myeloid 
leukemic cell line (172). This study utilized a p53 
temperature-sensitive mutant to show that the overexpression 
of wild-type p53 was sufficient to induce apoptosis, which 
was inhibited by interleukin 6, and that apoptosis did not 
occur when the mutant form of p53 was overexpressed (172). 
Thymocytes readily undergo apoptosis when exposed to DNA-
damaging agents, glucocorticoids, and calcium ionophores 
(116,117) Thymocytes from p53-/- knockout mice underwent 
apoptosis in response to glucocorticoids and calcium 
ionophores in a similar fashion as cells from p53+/+ mice, 
but were resistant to apoptosis initiated by DNA-damaging 
agents (173,316). Thymocytes from heterozygous p53-/+ mice 
showed a response to DNA-damaging agents that was 
intermediate between p53-\- and p53+\+ thymocytes (173,316). 
Similar findings have been demonstrated in bone marrow-
deri ved myeloid progenitor cells and embryonic fibroblasts 
from p53-deficient mice (175,317). These studies and others 
have shown that p53-dependent and p53-independent mechanisms 
for the induction of apoptosis exist (reviewed in 318) and 
suggested that the apoptotic pathway induced by DNA damage is 
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pS3-dependent (173,316). These results suggested that p53 
maY function by arresting cells in Gl to allow time for DNA 
repair, but if the damage is too extreme the cells are 
triggered to die via apoptosis ( 85) . In support of this 
concept, p53 has been shown to induce the genetic programs of 
Gl arrest and apoptosis in the same cell type (319) . 
However, the role of p53 in DNA damage-induced apoptosis may 
be more complex than previously thought since DNA damage-
induced apoptosis has been shown to occur in cycling T 
lymphoma cells and mitogenically activated T lymphocytes in 
a p53-independent manner (320). 
The mechanism and pathways involved in p53 -mediated 
apoptosis are still a mystery. However, recent studies have 
started to reveal some of the many possible players, and 
undoubtedly, the complete story will be complex. The 
inability of mutant p53 to activate transcription and induce 
apoptosis suggested that one possible mechanism by which 
wild-type p53 induced apoptosis was via the transactivation 
of downstream effector genes. In support of this concept, 
p53 has been shown to be a direct transcriptional activator 
of the human bax gene (321) and regulated the induction of 
apoptosis in Ml leukemic cells by inducing the expression of 
bax and concomitantly suppressing the expression of bcl-2 
through a p53 negative response element (196,322,323). 
However, other studies have shown that p53-dependent 
apoptosis can occur in the absence of transcriptional 
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activation of p53-target genes and suggested that the 
regulation of apoptosis by p53 occurred via the suppression 
of genes necessary for survival or a non-transcriptional 
function of p53 (324). Clearly the pathways involved in the 
mediation of p53-dependent apoptosis are cell type and 
species-dependent. 
Other possible effectors of p53-dependent apoptosis are 
the retinoblastoma gene product (Rb) and the transcription 
factor E2F-1 (325,326). Some studies have suggested that p53 
mediated the c-myc enhancement of apoptosis and mutant p53 
has been shown to abrogate this process (327,328). c-myc can 
transactivate p53 expression but the increase in p53 observed 
during c-myc-enhanced apoptosis resulted from the 
posttranslational stabilization of the p53 protein (327, 329). 
The alteration in subcellular trafficking and subsequent 
modulation of p53 function has also been implicated as a 
mechanism by which p53 regulates apoptosis and both c-myc and 
bcl-2 are involved in this process (330). Both p53-dependent 
and independent pathways have been shown to be inhibited by 
bcl-2 (320 I 331) o 
The Role of p53 in Chemotherapy 
The role of p53 in carcinogenesis is well established. 
However, recent evidence has suggested that the status of p53 
may also influence the therapeutic response of tumors exposed 
to anti-neoplastic agents or radiation. In a situation 
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analogous to bcl-2, p53 mutations that affected the apoptotic 
functions of the wild-type protein seemed to confer a 
radiation/chemotherapeutic agent-resistant phenotype to some 
tumor cells. In vitro and in vivo mouse studies have shown 
that the presence of wild-type p53 in tumor cells resulted in 
favorable responses to chemotherapeutic modalities via drug-
induced apoptosis, while the presence of a mutant form of p53 
rendered these cells inherently more resistant to the same 
agents (175,332). Similar results have been obtained in some 
human systems (333,334). However, studies in human systems 
have also shown that p53 status did not influence the outcome 
of anti-cancer agent exposure, and that drug-induced 
apoptosis could occur via p53-independent mechanisms (335-
338). The role of p53 in the efficacy of cancer chemotherapy 
is certainly complex. The existence of p53-dependent and 
independent pathways for drug-induced apoptosis suggested 
that the involvement of p53 in tumor cell responses to anti-
cancer therapy was cell type and species-specific (339,340). 
Indeed, what seemed to be important in determining the role 
of p53 in drug-induced apoptosis was the cellular context in 
which p53 was expressed (341) . Unfortunately, the cellular 
context of tumor cells is essentially unique for each tumor 
type, rendering p53 status useless as a prognostic indicator 
for tumor response. 
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The c-myc proto-oncogene was originally identified as 
the cellular homolog of the MC29, avian myelocytomatosis 
retroviral v-myc oncogene (342). The role of c-myc in 
cellular proliferation, differentiation, and transformation 
has been well characterized and extensively reviewed 
(343, 344) . c-myc is essential for the proliferation of 
quiescent cells and its expression has been shown to be 
sufficient, but not necessary, for the transition of cells 
from GO into Gl (345,346). c-Myc has been shown to promote 
the Gl-S phase transition via the direct induction of cyclin 
Dl which can regulate Gl progression and the Gl-S phase 
transition (347) . Other evidence has suggested a role for c-
rnyc in the S-G2 transition (348). The deregulated expression 
of c-myc is sufficient for the immortalization of cells in 
culture (349) and is capable of transforming cells in 
cooperation with another oncogene, such as ras or bcl-2 
(191, 350). Deregulated overexpression of c-myc protein 
occurs in almost all tumors (except those that overexpress N-
rnyc or L-myc) and has been strongly implicated in the 
development and progression of malignancies (344,351). 
c-Myc belongs to the myc family of highly related 
oncogenes which includes two other bona fide members, N-myc 
and L-myc. The myc genes are highly conserved throughout 
vertebrate evolution and have been isolated in fish (352), 
amphibians (353), birds (342), and mammals (354). The myc 
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genes are differentially expressed in mammalian development, 
with N-myc and L-myc exhibiting a very restricted pattern of 
tissue and developmental stage specificity (355). c-Myc 
expression during development is rather generalized and c-myc 
is the major myc gene expressed in normal adult tissues 
(355) . 
The c-myc gene has been localized to chromosome 8q24 and 
consists of three exons spanning approximately 6 kb, the 
first of which is essentially noncoding (356, 357) . The 
regulation of c-myc expression in both normal and neoplastic 
cells is extremely complex and has been extensively reviewed 
(358) . c-Myc transcripts can be generated from any of four 
separate promotors, P0 , P1 , P2 , or P3 • The two major 
promotors, P1' and P2 , are located in exon 1 and account for 
10-25% and 75-90% of the total c-myc steady-state mRNA, 
respectively (359,360). The transcription of c-myc mRNA can 
be regulated at the level of both transcription initiation 
and elongation (reviewed in 361). The two major c-myc 
transcripts are approximately 2. 4 and 2. 2 kb in size and 
originate from the P1 and P2 promotors, respectively 
(359, 360) . The half-life of c-myc mRNA is extremely short 
(10 min to 1 h) (362). The modulation of mRNA stability is 
another mechanism utilized in the regulation of c-myc 
expression and is often superimposed on transcriptional 
controls. The rapid degradation of c-myc mRNA occurs in two 
steps, the first of which is the translation-dependent 
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shortening of the poly(A) tail that is inhibitable by 
cycloheximide. The last step is the rapid degradation of the 
body of the mRNA which is translation-independent (363,364). 
The major c-myc protein (Myc 2) is a 439 amino acid, 
nuclear phosphoprotein with a molecular weight of 
approximately 64 kDa which is translated from an AUG start 
codon located at the 5' end of exon two (365). A less common 
c-myc species (Myc 1) is the 67 kDa, 453 amino acid protein 
which is translated from a cryptic CUG initiation codon 
located at the 3' end of exon 1 (366). The half-life of c-
myc proteins is approximately 15-30 minutes (365) . The 
regulation of c-myc translation has also been suggested as a 
mechanism for the control of c-myc expression, however, this 
remains controversial (365,367). The c-myc protein has been 
shown to be involved in the negative autoregulation of c-myc 
expression in normal cells and some tumor cells. The c-myc 
protein is capable of inhibiting the transcriptional 
initiation from endogenous c-myc promotors in a dose-
dependent fashion and requires the presence of trans-acting 
factors (368) . This negative autoregulation is lost in many 
tumor cells and may explain how c-myc is overexpressed in 
tumor cells in which the more common mechanisms of 
deregulated c-myc expression are absent (369) . 
The expression of c-myc in normal cells is tightly 
regulated at almost every step in the gene expression 
pathway. Despite this rigorous network of checkpoints, c-myc 
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protein is overexpressed in almost all tumor cells and, as 
might be expected, the mechanisms by which this 
overexpression is achieved are quite varied. The most 
obvious mechanisms are translocations, gene amplification, 
and proviral insertions. Translocations of c-myc are a 
common occurrence in many Burkitt's lymphomas and B-ALL in 
which the c-myc gene is translocated and placed under 
transcriptional control of one of the immunoglobulin loci on 
chromosomes 2, 14, or 22 (reviewed in 358,370). Gene 
amplifications are also common and can serve as a prognostic 
indicator for a number of tumors (358,370). Proviral 
insertions are associated with the activation of the c-myc 
locus in a number of B- and T-lymphoid tumors (358,370). All 
of these mechanisms serve to increase the expression of the 
normal c-myc protein and contribute to the oncogenic 
progression of tumors. Other oncoproteins have also been 
shown to contribute to the transcriptional regulation of c-
myc and include v-abl, p53, fos/jun, adenovirus Ela, v-erb B, 
v-raf, and c-myb (371 and references within) Since cancer 
is a multi-step process, the oncogenic activation or 
overexpression of any of these various oncoproteins could 
certainly account for some of the unknown mechanisms by which 
c-myc expression is deregulated in tumor cells. 
c-myc contains several structural protein motifs which 
are important for its functions. Consistent with its role as 
a transcriptional activator, the NH-terminal 143 amino acids 
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of the myc protein are able to transactivate genes (372). 
Three independent transactivation domains (TADs) can be found 
within the NH-terminus at residues 1-41, 41-103, and 103-143 
(J72). A non-specific DNA binding domain can be found 
between residues 265-318 (373). Two nuclear localization 
signals (NLS) reside within the myc protein. The first NLS 
spans residues 320-328 (designated Ml) and is sufficient to 
provide complete nuclear localization (374). The M2 domain 
(residues 364-374) induces only partial localization and 
probably does so coincidentally along with its other putative 
functions (374) . The last domain is the COOH-terminal basic 
region, helix-loop-helix, leucine zipper motif (bHLH-LZ) 
which is characteristic of many known transcription factors 
(bHLH or bLZ) . The basic region (355-367) defines a specific 
DNA binding domain and is immediately NH-terminal to the two 
protein dimerization motifs, the HLH (368-410) and LZ (411-
439) (375) . The HLH-LZ motifs mediate specific 
protein/protein interactions with an obligate partner and 
align the basic regions of the dimerized proteins to define 
a sequence-specific DNA binding domain. 
The c-myc protein is posttranslationally modified by 
both phosphorylation and glycosylation. The in vivo 
phosphorylation sites within the c-myc protein include Thr58 , 
Ser62 , and Ser71 (376-378), all of which reside within the TAD, 
and two sequences in the COOH-terminus of myc, one in the 
acidic region (240-262) and one between residues 342-357 
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(379 ). Thr58 and Ser62 are phosphorylated in vitro by glycogen 
synthase kinase-3, MAP kinase, and p34cdc2 kinase (376-378), 
and their phosphorylation appears to be both mitogen and cell 
cycle regulated (378) . In vivo phosphorylation of Thr58 and 
ser62 residues can alter c-myc function. Ser62 phosphorylation 
has been shown to increase the serum-induced transactivating 
properties (380,381) and transforming activity (376,377) of 
c-myc, while phosphorylation of Thr58 can inhibit focus 
formation (377). The COOR-terminal phosphorylation sites are 
both in vitro substrates for casein kinase II (CK II), 
although no known in vivo functions have been observed for 
these two sites (379) . Another recently demonstrated 
post translational modification of the c-myc protein is the 0-
linked N-acetylglucosamine (0-GlcNAc) glycosylation of Thr58 
within the TAD which may regulate the transactivating 
activity of the c-myc protein (382,383). 
The c-myc protein has been extensively studied and many 
of the domains responsible for its various functions have 
been mapped by deletion and mutation analysis. Studies have 
demonstrated that the amino-terminal 143 amino acids and the 
carboxy-terminal 89 amino acids are necessary for 
transformation by c-myc, with an absolute requirement for 
residues 106-143 (384,385). These areas correspond to the 
TAD and bHLH-LZ domains, areas responsible for activating the 
transcription of other genes and mediating protein 
dimerization and subsequent sequence-specific DNA binding, 
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respectively, suggesting that c-myc cooperates in the 
transformation of cells via its ability to induce the 
expression of transforming gene products. Alterations in the 
middle portion of the c-myc protein, namely the acidic 
region, may decrease transformation efficiency but do not 
abolish transforming activity (384) . The areas necessary for 
the autosuppression functions of myc (386) and the inhibition 
of cellular differentiation (387) appear to be almost 
identical to those areas responsible for transformation. 
c-Myc has been shown to be both an activator and 
repressor of transcription (388-390) . The dimerization of c-
myc with its recently described, obligate protein partner, 
max, is central to many of myc's functions, including gene 
transactivation, and will be described in subsequent 
sections. Independent of max, the amino-terminal portion of 
c-myc has been shown to interact in vivo with TBP (391,392) 
and the retinoblastoma-related protein, pl07 (393,394), and 
in vitro with the retinoblastoma gene product (Rb) (395). 
The interaction between c-myc and TBP may facilitate c-myc-
mediated transactivation or the inhibition of TFIIA-dependent 
pre-initiation complexes (372,396). pl07-c-myc complexes are 
capable of suppressing myc-mediated transcriptional 
activation (393, 394). Evidence has recently shown that c-myc 
can also directly repress initiator element-dependent 
transcription via its physical interaction with either Yin 
Yang 1 or TFII-I (396,397). The interaction between c-myc 
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and these transcription factors requires the presence of the 
bHLH-LZ of the c-myc protein (396, 397) . Therefore, it 
appears likely that not all of the biological activities of 
c-myc are dependent upon its interaction with max or its 
ability to activate transcription. 
Many genes have been identified as targets of c-myc-
mediated activation or repression. Those genes which are 
repressed by c-myc include MHC class I (398), collagen 
(390,399), neu (400), LFA-la (401), cyclin Dl (402,403), 
c/EBPa (389), and c-myc itself (368). The transcriptional 
repression of these genes is either direct via inhibition of 
initiator element-dependent transcription (389) or via 
indirect mechanisms where c-myc influences the binding 
activity or abundance of other binding factors (399) . Genes 
that are transacti vated by c-myc include ornithine 
decarboxylase (ODC) (404), a-prothymosin (405), ECA39 (406), 
eIF4E and eIF2a (407), cyclins A, E, and Dl (347,402,408), 
hsp70 (409), lactate dehydrogenase (LDH) (410), p53 (329), 
dihydrofolate reductase (DHFR) (411), and carbamoyl-phosphate 
synthase (glutamine-hydrolyzing)/aspartate carbamoyl-
transferase/dihydroorotase (cad) (412). The c-myc-mediated 
activation of eIF4E, eIF2a, hsp70, cyclin A and cyclin E 
appears to be indirect since no c-myc binding sites have been 
located in the regulatory sequences of the these genes. Of 
the remaining genes, ODC, cad, p53, a-prothymosin, and ECA39 
all appear to be transactivated via the consensus, c-myc E-
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bOX binding sequence (CACGTG) (329,404-406,412). The DHFR, 
LDH, and cyclin Dl genes all contain E-box motifs in their 
regulatory regions, but direct transcriptional activation of 
these genes via these myc binding sites remains to be 
demonstrated (347,410,411). 
MYC Transcription Factor Network 
The c-myc protein does not form homodimers in vivo, 
therefore the transactivation of genes via the binding to a 
core DNA consensus sequence (CACGTG) requires interaction 
with an obligate protein partner (413) . The discovery of max 
(414), an obligate partner for c-myc, was a major stepping 
stone in myc research and led to the establishment of a myc 
transcription factor network of proteins, which was found to 
include two other max binding proteins, mad (415) and mxil 
(416). 
Max is a 151 amino acid nuclear phosphoprotein that 
contains a bHLH-LZ motif (residues 15-99) and an NLS 
(residues 140-147) (414). Two major forms of max protein, 
p21 and p22, are found in relatively equal amounts in most 
cells and result from the alternative splicing of a single 
max gene which adds a 9 amino acid insert NH-terminal of the 
basic region (414). Max proteins are capable of forming 
homodimers and heterodimers with c-myc, L-myc, N-myc (414), 
mad (415), and mxil (416) . Of the four known members of the 
myc transcription factor network, only c-myc contains a TAD 
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and is capable of transcriptional activation in concert with 
max (417, 418). Max mRNA and proteins are constitutively 
expressed at relatively high levels in growing, resting, or 
differentiating cells and are very stable, with half-lives of 
greater than 3 h and 18 h, respectively (419-423) . 
Recently, two novel bHLH-LZ proteins, mad and mxil, have 
been isolated on the basis of their interaction with max 
(415,416). Mad and mxil are both 220 amino acid proteins and 
contain bHLH-LZ motifs between residues 58-150 and 32-112, 
respectively (415,416). Both proteins contain a potential 
bipartite NLS and are 43% identical suggesting that they are 
evolutionarily related (415) . The mad protein has been shown 
to be a 35 kDa, nuclear phosphoprotein with a half-life of 
15-30 minutes (422). Mad migrates on SDS-PAGE as a doublet 
and the faster migrating species is thought to be a precursor 
of the slower migrating species (422) . 
Mad and mxil do not form homodimers, nor do they 
heterodimerize with each other or any of the myc proteins 
(415,416) When dimerized with max, however, mad and mxil 
are able to bind the CACGTG E-box motif and antagonize 
transcriptional activation by competing with c-myc/max dimers 
for the occupation of these sites (415,416). The affinity of 
mad and c-myc for max binding is equal, suggesting that the 
relative levels of these two proteins may act to regulate the 
levels of each dimer type, and thus the transactivating 
status of this network (415) . This concept has been 
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demonstrated in differentiating hematopoietic cells in which 
the levels of c-myc decreased while the levels of mad (or 
mxil in some cases) increased with a concomitant decline in 
c-myc/max dimers and increase in mad/max dimers (421,422). 
The emerging model of this network suggests that max is the 
central component because of its constitutive expression and 
ability to interact with all of the other members. 
Transcription from E-box containing genes would be predicted 
to occur when c-myc/max dimers predominate while 
transcription would be predicted to be repressed when 
max/max, mad/max, or mxil/max dimers predominate. 
The functional theme of the myc transcription factor 
network is the ability of dimerized partners to bind the 
consensus core hexanucleotide DNA sequence, CACGTG, known as 
an E-box motif (414,424). As previously discussed, not all 
of the functions of c-myc appear to require dimerization with 
max, however, those functions that do require an interaction 
with max are thought to be mediated by the transactivation of 
E-box containing genes. Important functions of c-myc that 
have been shown to require dimerization with max include cell 
cycle progression, transformation, and growth factor 
withdrawal-induced apoptosis (425,426) As mentioned before, 
one mechanism by which this system may be modulated is the 
independent regulation of max binding partners which 
determines the relative levels of the various dimers, c-
myc/max, max/max, mad/max, and mxil/max. However, another 
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level of modulation in this network may occur via the 
phosphorylation of partner proteins which may alter the 
functional state of the various dimers. 
Phosphorylation of both c-myc and max is capable of 
altering the transactivating and DNA binding activities of 
these proteins, respectively (380,381,427). The 
phosphorylation of c-myc does not alter its DNA binding 
ability when dimerized with max (427) . Homodimers and 
heterodimers of p21 max, p22 max, and c-myc all have subtly 
different binding specificities in vivo that are regulated by 
both phosphorylation status and the flanking sequences of the 
core E-box motif (424,428,429). Heterodimers of c-myc/p21 
max and c-myc/p22 max were shown to transcriptionally 
activate core E-box motifs equally well, however, if the core 
was flanked 5' by a T and 3' by an A, the activity of c-
rnyc/p21 max dimers was repressed by greater than 30 fold 
while the activity of c-myc/p22 max dimers was only repressed 
by 4-5 fold (429). Other studies have shown that 
phosphorylation of max at Ser11 (an in vitro substrate for 
casein kinase II) inhibits the binding of max homodimers to 
core E-box sequences (427). More importantly, studies have 
shown that CKII phosphorylation of Ser2 and Ser11 of p21 and 
P22 max enhanced the off rate for DNA binding of max 
hornodimers and c-myc/max heterodimers, with the heterodimers 
of c-myc/p21 max being more unstable than c-myc/p22 max 
heterodimers (428) . The phosphorylation of max increased the 
61 
on rate for DNA binding of c-myc/p22 max heterodimers but not 
c-myc/p21 max dimers (428) . These data suggested that 
phosphorylation did not alter the affinity for DNA binding of 
c-myc/p22 max heterodimers but reduced the affinity of c-
myc/p21 max heterodimers for DNA binding (428) . Therefore, 
the DNA binding kinetics of c-myc/max dimers depends upon the 
form of max and its phosphorylation status and is consistent 
with the possibility that dimers of c-myc/p21 max and c-
myc/p22 max may transactivate different subsets of target 
genes based upon E-box flanking sequences, phosphorylation 
status, and ratios of heterodimers containing p21 and p22 max 
(430). 
c-myc-Induced Apoptosis 
The involvement of c-myc in the induction of apoptosis 
was first demonstrated in factor-dependent 32D. 3 myeloid 
progenitor cells when Cleveland and colleagues showed that 
the enforced expression of c-myc accelerated apoptotic cell 
death following IL-3 withdrawal (431). Evan et al. 
subsequently showed that the activation of a c-myc/ER 
chimeric protein could induce apoptosis in Ratl fibroblasts 
or primary rat embryonic fibroblasts when cell cycle 
progression was blocked by various methods including serum-
deprivation, isoleucine deprivation, thymidine block, or 
cycloheximide (432) . c-Myc was shown to induce apoptosis in 
a dose-dependent manner which was cell cycle phase-
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independent (432,433). Thus, it seems that the inappropriate 
expression of c-myc is capable of inducing apoptosis and this 
appears to be a general function of c-myc. The regions of c-
myc required for its apoptotic functions are the same as 
those necessary for cotransformation, autosuppression, and 
inhibition of differentiation (432), and an absolute 
requirement for dimerization with max has been shown (426). 
These results suggested that c-myc-induced apoptosis is 
mediated by the transactivation of E-box containing genes. 
The deregulated expression of c-myc can induce apoptosis 
under growth limiting conditions, a scenario which is common 
to many tumors. Indeed, many studies have shown that 
deregulated c-myc expression increased the apoptotic index of 
tumors in vivo suggesting a role for myc-induced apoptosis in 
oncogenesis (154,434). The fact that c-myc overexpression 
accelerates proliferation and increases the rate of apoptosis 
helps to explain why c-myc is not tumorigenic by itself. 
Many studies have shown that c-myc is only tumorigenic in 
cooperation with other oncogenes such as bcl-2, ras, raf, and 
abl, and all of these oncogenes are able to suppress the 
induction of apoptosis by c-myc (153,154,166,169,250,251). 
Thus, while the deregulation of c-myc is a common, and 
apparently important step in oncogenesis, mutations within 
the myc gene or secondary genetic lesions which function to 
abrogate the ability of c-myc to induce apoptosis appear to 
be required for the oncogenic progression to a more 
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aggressive tumor phenotype (154). This leads to the 
question: does c-myc-induced apoptosis have a function under 
normal physiological conditions where c-myc expression is 
tightly regulated? The answer appears to be yes. A direct 
role for c-myc in apoptosis has been demonstrated for 
activation-induced apoptosis in T-cell hybridomas, a model 
system for the negative selection of thymocytes (435, 
reviewed in 436) . Similar findings have also been found in 
the TNF-a-induced death of HeLa cells (437) . 
The fact that c-myc expression is involved in both 
cellular proliferation and death seems rather ironic. 
However, upon further consideration it seems appropriate that 
such a potentially "dangerous" gene product would have a 
fail-safe mechanism guarding its expression. From the 
standpoint of a metazoan organism, the uncontrolled 
proliferation of just one cell is a potentially life 
threatening situation. Therefore, the emergence of such a 
risky gene would not be expected to occur unless a mechanism 
to keep its expression in check was co-evolved. This appears 
to be the case with c-myc. Two models have been proposed to 
explain this phenomenon. The first is the "conflict" model 
(431,432). This model predicts that the expression of c-myc 
results in cellular proliferation only and when the cellular 
environment becomes growth restrictive, apoptosis is induced 
as a result of the "conflict" between growth stimulatory 
signals (presence of myc) and growth inhibitory signals 
(factor withdrawal, 
etc.). In essence, 
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DNA damage-induced cell cycle block, 
the cell becomes a victim of two 
diametrically opposed cellular signals and dies in what has 
been described as a "mitotic catastrophe". Evidence exists 
to support this type of model (432,433). 
The second model is the "dual signal" model which 
predicts that apoptosis 
expression (438). Thus, 
double-edged sword in 
is a normal outcome of c-myc 
the expression of c-myc is like a 
that it activates the cellular 
proliferation pathway and also implements the components of 
the apoptotic program. Whether a cell will proliferate or 
die is then regulated by the presence of cell-specific 
survival factors such as interleukins, IGF-1 or PDGF, which 
directly suppress the apoptotic pathway (431,433). Evidence 
also exists to strongly support this type of model (439 and 
references within) . The fact that both models have data to 
support them may be reconciled by the circumstances under 
which they were tested. The dual signal model seems more 
applicable to the normal physiological conditions of cell 
growth and regulation where c-myc expression is still under 
tight control, whereas the conflict model may be more 
appropriate for cells that express c-myc in a deregulated 
fashion, such as tumor cells. Tumor cells generally 
overexpress c-myc in an unregulated fashion and are less 
dependent upon growth factors, therefore, treatment of some 
tumor cells with a cytostatic agent would seem to create a 
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situation in which a cellular conflict is created. 
Many studies have shown that c-myc-mediated apoptosis is 
important, however, c-myc is an enhancer of apoptosis and 
therefore, it is not an obligate component of all apoptotic 
pathways (431,435). When c-myc is involved in the regulation 
of apoptosis, it is thought to exert its functions via the 
transactivation of target genes (426). Several potential 
target genes for myc-induced apoptosis include cyclin A, p53, 
and ODC. Overexpression of cyclin A is sufficient for the 
induction of apoptosis and its induction has been linked to 
c-myc expression, although the mechanism for this induction 
is not clear (408) . p53 is a direct inducer of apoptosis 
(172) and its expression can be regulated by c-myc via an E-
box motif (329). Indeed, studies have shown that myc-
enhanced apoptosis is mediated by p53 (327,440), however, p53 
levels were induced by a posttranslational mechanism showing 
that p53 was not a direct target of c-myc (327) . More 
importantly, other studies have shown that c-myc-enhanced 
apoptosis can occur in the absence of p53 or without inducing 
its expression, suggesting that the involvement of p53 in c-
myc-enhanced apoptosis is cell type- and species-specific 
(441-443). The strongest candidate for a mediator of c-myc-
induced apoptosis is the ornithine decarboxylase gene (ODC) 
(444). ODC is a direct transcriptional target of myc/max 
dimers and is required for cell cycle progression (404). The 
enforced expression of ODC is capable of inducing apoptosis. 
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However, ODC was not as effective as c-myc, suggesting that 
oDC was only a partial mediator of c-myc-induced apoptosis in 
this system (444). Finally, the promotor of the human bax 
gene has recently been shown to contain four E-box motifs 
suggesting that c-myc may be able to directly regulate the 
expression of the bax gene, a known regulator of apoptotic 
cell death (321) . 
CHAPTER 2 
MATERIALS AND METHODS 
g_ell Culture and Drug Treatments 
The HT-29 and BE human colon carcinoma cell lines, and 
the IMR-90 normal human fibroblast cell line were cultured in 
Eagle's minimum essential medium (HyClone Laboratories, 
Logan, UT) supplemented with 10% BCS (HyClone Laboratories), 
1 mM L-glutamine (JRH Biosciences, Lenexa, KS), 1 mM sodium 
pyruvate (JRH Biosciences) , 20 mM HEPES (JRH Biosciences), lX 
non-essential amino acids (JRH Biosciences), lX 
biotin/vitamin Bu (lOOOX is 0.1 mg/ml d-biotin, 1.36 mg/ml 
vitamin Bu) (Sigma, St. Louis, MO), and 50 µg/ml gentamycin 
(JRH Biosciences) at 37°C, in closed flasks. 
The human colon carcinoma cell line Colo320HSR was 
cultured in RPMI 1630 (JRH Biosciences) supplemented with 15% 
heat inactivated (56°C for 1 h) BCS (HyClone Laboratories), 
2 mM L-glutamine, 50 U/ml of penicillin, and 50 µg/ml of 
streptomycin (JRH Biosciences) at 37°C in closed flasks. 
The human cervical carcinoma cell line, HeLa, was 
cultured in Dulbecco' s modified Eagle's essential media 
(Sigma) supplemented with 10% BCS (HyClone Laboratories), and 
50 µg/ml of gentamycin at 37°C in a humidified atmosphere 
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consisting of 92% air/8% C02 • 
The human promyelocytic leukemic cell line, HL-60, and 
the human Epstein Barr virus-infected B-cell line, LM-EBV, 
were cultured in RPMI 1640 (JRH Biosciences) supplemented 
with 10% BCS, 2 mM L-glutamine, 50 U/ml of penicillin and 50 
µg/ml of streptomycin at 37°C in a humidified atmosphere 
consisting of 92% air/8% C02 • 
All cell lines were subcultured every 4-5 days and 
maintained as exponentially growing cultures. Cell counts 
for subculturing and experiments were determined by counting 
cells either on a Coulter Counter, Model ZBI (Coulter 
Electronics, Inc., Hialeah, FL) or a bright-line 
hemacytometer (Reichert Scientific Instruments, Buffalo, NY). 
Nitrogen mustard (Sigma) was dissolved in sterile 
filtered 0.1 N HCl and stored as a 10 mM stock solution at 
Actinomycin D (Act D; Boehringer Mannheim, 
Indianapolis, IN) was dissolved in 100% ethanol and a 1 mg/ml 
stock solution was wrapped in aluminum foil and stored at -
20°C. Exponentially growing cells (2.5 X 105 cells/ml for 
Colo320HSR and 6-8 X 106 cells per T-75 flask for HT-29 and 
BE cell lines) were exposed to HN2 for 1 h at 37°C. Cells 
were then washed free of drug, refed with fresh medium, and 
cultured at 37°C until lysed at various time points. Cells 
treated with Act D were continuously exposed to drug until 
lysed at various time points. 
~romolecular Isolation 
Total RNA Isolation 
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Total cellular RNA was isolated essentially by the 
method of Chirgwin et al. (445). Briefly, 2-10 X 106 cells 
were washed 2X in ice cold lX Dulbecco's phosphate buffered 
saline (pH 7.4) (Gibco BRL, Gaithersburg, MD), and lysed in 
1 .a ml of RNA lysis buffer (4 M guanidium isothiocyanate 
(Gibco BRL), 20 mM sodium acetate, 10 mM DTT, and 0.5% N-
lauroyl sarcosine (w/v) (Sigma)) Chromosomal DNA was 
sheared by repeated passage of the lysate through a 20 gauge 
syringe needle. At this stage RNA samples could be frozen 
and stored at -70°C. RNA was recovered as follows: 1.8 ml of 
lysate was layered on top of a 400 µl 5.7 M CsCl, 100 mM EDTA 
cushion in an 11 X 34 mm Ultra-Clear centrifuge tube (Beckman 
Instruments, Inc., Palo Alto, CA) and centrifuged at 49,000 
rpm for 2.5 h at 20°C in a Beckman TL-100 ultra-centrifuge 
using a TLS-55 rotor. 
Following sedimentation, the supernatant was aspirated 
and the tubes were inverted for 10-15 min to drain the excess 
liquid. The RNA pellet on the bottom of the tube was 
resuspended in DEPC-treated (Sigma) distilled/de-ionized 
water for 15 min and transferred to an autoclaved 1. 5 ml 
microfuge tube. RNA was precipitated 2X with 1/10 volume of 
3 M sodium acetate (DEPC-treated) and 2. 5 volumes of 95% 
ethanol for at least 30 min at -70°C. RNA was pelleted by 
microcentrif ugation (12,000 X g at 4°C), air dried, 
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resuspended in DEPC-treated distilled/de-ionized water, 
quantitated by A2~, and stored at -70°C. 
Genomic DNA Isolation 
Genomic DNA was isolated as follows: 10-20 X 106 cells 
were washed 2X in ice cold PBS (pH 7. 4) and lysed in a 
solution (3 X 106 cells/ml) consisting of 50 mM NaHC03/Na2C03 , 
1 mM EDTA, 0.5% N-lauroyl sarcosine (w/v), and 300 µg/ml 
proteinase K (pH 10. 4) . The cell lysate was incubated at 
37oc for 3-6 h with occasional gentle mixing. The lysate was 
deproteinized by extraction with an equal volume of 
phenol:chloroform:isoamyl alcohol (PCI) (25:24:1) 2X and once 
with chloroform: isoamyl alcohol (24: 1). The lysate was 
gently mixed with the organic phase until an emulsion was 
formed (5 min). The phases were separated by centrifugation 
in a Beckman J6-M centrifuge at 2370 rpm (1600 X g) for 5 min 
at 22°C. After the last extraction, the aqueous phase was 
transferred to a 25 ml Erlenmeyer flask and the DNA 
precipitated with 0.2 volumes of 11 M ammonium acetate and 
2.5 volumes of 95% ethanol. The DNA was spooled out with a 
glass rod, washed by dipping into 70% ethanol, transferred to 
a 1. 5 ml microcentrifuge tube, resuspended in 400 µl of 
milli-Q water, and treated with RNase A (10 µg/ml) for 30 min 
at 37°C. 
Following RNase digestion, the DNA solution was 
extracted 2X with an equal volume of PCI and once with 
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chloroform:isoamyl alcohol. Emulsions were formed by gentle 
mi:x:ing and phases were separated by centrifugation in a 
Beckman Microfuge 11 at 500 X g for 5 min using a fixed angle 
rotor. The DNA was recovered by precipitation with 1/10 
volume of 3 M sodium acetate and 2.5 volumes of 95% ethanol 
(<? 30 min at -70°C) I pelleted by microcentrifugation (12,000 
x g at 4°C) , washed in 70% ethanol, and resuspended in 400-
800 µl of TE (10 mM Tris, 1 mM EDTA, pH 8) . 
The DNA was digested to completion with a restriction 
enzyme of choice (5 U/µg DNA for 1-3 h) at 37°C, PCI 
extracted, ethanol precipitated, washed with 70% ethanol 
(37°C for 30 min), resuspended in milli-Q water, quantitated 
by A2ro, and stored at -70°C. 
Protein Isolation 
Whole cell protein isolation for western blot 
(immunoblot) analysis was performed as follows: cells were 
counted and a specified number of cells was washed 2X in ice 
cold PBS (pH 7.4). The cell pellet was broken up and then 
lysed by the addition of an appropriate volume of sample 
buffer (100 mM DTT, 2% SDS, 80 mM Tris (pH 6.8), 15% 
glycerol, and 0.1% bromophenol blue) which gave a 
concentration of 2 X 104 cells/ µl of lysate. The sample 
lysates were boiled for 10 min and then passed repeatedly 
through a 20 gauge syringe needle to shear chromosomal DNA 
and reduce the viscosity of the lysate. Samples were then 
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stored at -70°C until analysis. Prior to electrophoresis, 
samples were boiled for 10 min to solubilize any precipitated 
proteins . 
.Q.._uantitation of Macromolecules 
Quantitation of DNA and RNA was performed by UV 
spectrophotometry. Absorbance readings were taken on 1 µl 
aliquots of nucleic acids (1 ml total volume) at 325 nm 
(background absorbance) , 280 nm (protein detection) , and 260 
nm (nucleic acid detection). An A2® of 1.0 corresponds to 50 
µg/ml of double stranded DNA, 37 µg/ml of single stranded 
DNA, and 40 µg/ml of RNA. The purity of nucleic acid samples 
was determined by A2®/A280 ratios where pure preparations of 
DNA and RNA have Az®/A280 ratios of 1. 8 and 2. 0, respectively. 
UV absorbance readings were taken on either an LKB Ultrospec 
4050 (LKB Biochrom Ltd., Cambridge, England) or a GeneQuant 
RNA/DNA Calculator (Pharmacia LKB Biochrom Ltd., Cambridge, 
England) using 1 ml quartz cuvettes with a 1 cm path length 
(Hellma) 
Protein quantitation was performed by the method of 
Bradford (446) using a Bio-Rad Protein Assay kit (Bio-Rad 
Laboratories, Hercules, CA). Briefly, 1 µl of cell lysate 
was added to 999 µl of dye reagent mix (1 part dye reagent 
concentrate and 4 parts milli-Q water) in a disposable Ultra-
VU 2.9 ml cuvette (Baxter Scientific Products, McGaw Park, 
IL) and mixed by inversion. Samples were allowed to sit for 
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2 min and then readings were recorded. Protein 
concentrations were determined from a standard curve 
generated with known concentrations of BSA ranging from 0.5-
10. o µg/ml. 
§.._outhern Blot Analysis 
DNA samples containing 1/6 volume of sample loading dye 
(30% glycerol, 0.25% bromophenol blue) were electrophoresed 
on o.5-0.8% neutral agarose gels (Seakem GTG, FMC, Rockland, 
ME) containing 0.5 µg/ml of ethidium bromide at 1-1.5 V/cm 
for 16-24 h in lX TBE (90 mM Tris base, 90 mM boric acid, 2 
mM EDTA (pH 8.0)). Following electrophoresis, to facilitate 
the transfer of high molecular weight DNA, the gels were 
soaked in 0. 25 N HCl for 15 min to depurinate the DNA 
(bromophenol blue dye turns yellow when acid treatment is 
complete). Gels were then soaked in 0.5 N NaOH, 1.5 M NaCl 
for 30 min to cleave the depurinated sites on the DNA 
(tracking dye turns blue when alkali treatment is complete) . 
Finally, gels were soaked in 500 mM Tris, 3 M NaCl for 45 min 
to equilibrate the gels for transfer. 
The DNA was transferred to a nylon membrane 
(GeneScreenPlus, New England Nuclear, Boston, MA) by 
capillary blotting with lOX SSC (lX SSC is 150 mM NaCl, 15 mM 
trisodium citrate, pH 7.0) for 18-24 h. Following transfer, 
the nylon membrane was sequentially soaked in 0.4 N NaOH (45 
sec) and 200 mM Tris, 2X SSC (2 min). The membrane was then 
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UV cross-linked (Stratalinker UV Crosslinker, Stratagene, 
Lajolla, CA), air dried and stored in a sealed plastic 
hybridization bag (Oncor, Gaithersburg, MD). 
slot Blot Analysis 
DNA (1 µg or 5 µg) was added to 50 µl of TE (pH 8.0). 
DNA was denatured by incubating with NaOH (final 
concentration 0.25 N) at 65°C for 1 h. Samples were chilled 
on ice, diluted with 1 volume of 0.125 N NaOH, 0.125X SSC, 
and loaded onto a slot blot apparatus (Hybri-Slot Manifold, 
Gibco BRL) containing a presoaked (400 mM Tris (pH 7.5) for 
at least 30 min) nylon membrane (GeneScreenPlus) and two 
pieces of Whatman 3MM chromatography paper (Whatman 
International Ltd., Maidstone, England). Samples were 
allowed to sit in the apparatus for 30 min, after which time 
vacuum was applied for 30-60 sec. The membrane was removed, 
UV cross-linked and air dried. Filters were hybridized with 
a GAPDH probe to assess loading, stripped, and rehybridized 
with a c-myc probe. 
Northern Blot Analysis 
Total RNA was denatured in 50% DMSO, 1 M glyoxal 
(deionized with Bio-Rad RG 501-X8 mixed bed resin), 10 mM 
NaH2P04/Na2HP04 (pH 6. 8), at 50°C for 1 h. Samples (21 µl 
total volume) were chilled on ice for 5 min and then mixed 
with 1/6 volume of Type IV loading dye (6X is 40% sucrose, 
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0 _25 % bromophenol blue). RNA was electrophoresed through 1% 
agarose gels at 100 V for 4-5 h in a recirculating 10 mM 
NaH
2
P04/Na2HP04 (pH 6. 8) electrophoresis buff er. 
Following electrophoresis, RNA was transferred to a 
nylon membrane (GeneScreenPlus) by capillary blotting with 
lOX SSC for 18-24 h. The glyoxal reaction was reversed and 
membranes neutralized by sequential soaking in 0.05 N NaOH 
for 15 sec, and 200 mM Tris (pH 7.5), lX SSC for 35 sec. 
Membranes were UV cross-linked, air dried, and stored in 
sealed hybridization bags. The integrity of RNA on membranes 
was verified by the visualization of 18S and 28S ribosomal 
RNA bands with a UV light source. These ribosomal bands were 
marked with pencil and later used to determine the size of 
specific RNA hybridization signals (18S and 28S ribosomal RNA 
bands run at a size of= 1.9 and 4.8 kb, respectively). 
Membrane Hybridization 
Prehybridization of all nylon membranes was done in 50% 
formamide (deionized with Bio-Rad RG 501-X8 mixed bed resin), 
10% dextran sulfate, 5X SSPE (lX SSPE is 150 mM NaCl, 10 mM 
NaH2P04/Na2HP04 , 1 mM EDTA, pH 7. 4) , 1% SDS, lX Denhardt' s solution 
(0.02% ficoll 400, 0.02% polyvinylpyrrolidone, 0.02% BSA Pentax 
Fraction V) , and 250 µg/ml of denatured salmon sperm DNA at 
42°C for 6-24 h in a shaking water bath. Hybridization with 
a denatured a 32P dCTP-labeled probe (boiled for 5 min and snap 
cooled on ice for 5 min) was performed in the same 
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prehybridization solution at 42°C for at least 24 h. 
Following hybridization, membranes were washed in 500 ml 
of 2X SSPE, 0.5% SDS at room temperature for 15-30 min with 
agitation, followed by a 6 min wash in 7 L of O.lX SSPE, 0.1% 
SDS at 60°C in a Disk Wisk apparatus (Schleicher and Schuell, 
Inc., Keene, NH). After blotting with Whatman 3MM chromatography 
paper, the damp membranes were sealed in plastic hybridization 
bags for autoradiographic analysis. The membranes were exposed 
to X-ray film (X-OMAT AR, Eastman Kodak Co., Rochester, NY or 
Fuji RX, Fuji Photo Film Co. Ltd., Japan) at -70°C with an 
intensifying screen (Lightning Plus, E.I. du Pont de Nemours 
and Company, Inc., Wilmington, DE). Films were developed in 
a Kodak m35A X-OMAT autoprocessor. 
Membrane Stripping and Reprobing 
Membranes were stripped of probe by boiling in a solution 
of TE (pH 7.5), 1% SDS for 30-60 min with constant stirring. 
The complete removal of probe was verified by autoradiography 
and reprobing of the membrane was performed as previously 
described. 
Sl Nuclease Protection Assay 
RNA (8 µl total volume) was added to a reaction mix (100 
µl total volume) consisting of 80% formamide (deionized) , lX 
81 hybridization buffer (lOX 81 hybridization buffer is 4 M 
NaCl, 400 mM PIPES (pH 6.8), 20 mM EDTA (pH 8.0)), excess 5' 
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32p end-labeled probe, and 100 µg/ml of tRNA in a sterile 1. 5 
ml microfuge tube. Samples were heated at 68°C for 15 min to 
loosen DNA/RNA complexes, and transferred to a 53 ° C water bath 
for at least 12 h. After hybridization of probe to target RNA 
sequences, each tube was removed from the water bath and 300 
µl of ice cold Sl digestion buffer (66 mM sodium acetate, 300 
rnM NaCl, 4 mM ZnS04 ) and 1 µl of Sl nuclease (400 U/µl) were 
added to each sample, which was mixed and placed on ice. Sl 
nuclease digestion was performed at 37°C for 1 h. 
Sl digestion was stopped by extraction of the sample lX 
with an equal volume of PCI. Phases were separated by 
microcentrifugation for 10 min and then the aqueous phase was 
transferred to a sterile microfuge tube. RNA was precipitated 
for at least 30 min at -70°C by the addition of 1 ml of 95% 
ethanol, pelleted by centrifugation at 12,000 X g at 4°C, air 
dried, and resuspended in 5 µl of DEPC treated milli-Q water. 
Samples were denatured in 15 µl of formamide dye ( 90% formamide, 
0.5X TBE, 0.1% bromophenol blue, 0.1% xylene cyanol) at 95°C 
for 5 min, chilled on ice, loaded onto a O. 75 mm thick, 
urea/polyacrylamide gel (4%) and electrophoresed at 25 mA/gel 
in lX TBE (chilled to 4°C) until the bromophenol blue dye front 
ran off the gel. Gels were then fixed in 10% acetic acid for 
15 min, rinsed with milli-Q water for 15 min, placed on Whatman 
3MM paper and dried on a Drygel Jr. model SE 540 (Hoefer 
Scientific Instruments, San Francisco, CA) for 1 hat 80°C with 
vacuum, wrapped in plastic wrap and autoradiographed. 
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probe excess was determined by running a 1:100 dilution 
of undigested probe on each gel and comparing the intensity 
of this band to the intensity of the bands generated by the 
protected fragment. 
protected fragments were sized by comparison to end labeled 
DNA size markers which were run on each gel. The DNA size markers 
were generated by Hinf I restriction endonuclease digestion of 
pBR322 plasmid (Promega, Madison, WI) and resulted in size markers 
of 1632, 506, 517, 396, 344, 220, 221, and 154 nucleotides. 
DNA Probes 
DNA probes used in hybridization studies included the 
following: the 420 bp PstI exon 2 fragment of the human c-myc 
gene which was derived from the genomic c-myc, pHSR-1, (American 
Type Culture Collection, Rockville, MD) and subcloned into a 
pGEM-3Z vector (Promega) ; a PCR generated, 215 bp fragment of 
the Histone H3 .3 gene; a 400 bp (-116 to -516) 5' flanking region 
fragment of the human GAPDH gene which was generously provided 
by Dr. Maria Alexander-Bridges (Harvard Medical School, Boston, 
MA); a PCR generated, 447 bp exon 1/2 fragment of the human 
bcl-2 cDNA; and a PCR generated, 790 bp fragment of the human 
p53 cDNA spanning exons 3-7. 
The c-myc probe used in Sl nuclease protection assays was 
derived from a pGEM-3Z -8 plasmid vector containing the 420 
bp PstI fragment of exon 2 of the human c-myc gene and resulted 
in the protection of a 186 bp Sl nuclease resistant fragment. 
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The c-myc, histone H3. 3, and GAPDH probes have been 
previously characterized and used extensively in our laboratory. 
The bcl-2 and p53 cDNA probes were designed using OLIGO 5.0 
primer Analysis Software (National Biosciences, Inc., Plymouth, 
MN) and the identity of the PCR generated fragments was verified 
by restriction endonuclease analysis. 
cDNA Synthesis and PCR 
First strand cDNA synthesis was performed as follows: 1 
µg of total RNA (8 µl volume) was denatured for 6 min at 65°C, 
snap chilled on ice, and added to a reaction mix (20 µl total 
volume) containing 500 µMeach of dGTP, dATP, dTTP, and dCTP, 
lX reverse transcription buffer (Gibco BRL) ( 5X reverse 
transcription buffer is 250 mM Tris (pH 8.3), 375 mM KCl, and 
15 mM MgC12 ) , 10 mM DTT, 10 µg/ml oligo (dT) 12_18 (Gibco BRL) , 
and 20 U of RNasin (Promega) . The reaction was started by the 
addition of 400 U of Moloney murine leukemia virus reverse 
transcriptase (Gibco BRL) and performed at 37°C for 1.5 h. 
After reverse transcription was complete, the reaction was 
terminated by heating at 95°C for 5 min and then chilled on 
ice. Reactions were now ready for PCR amplification of primer 
specific cDNA fragments. 
All PCR reactions were set up in 0.5 ml GeneAmp reaction 
tubes (Perkin Elmer Cetus, Norwalk, CT) and performed on a Perkin 
Elmer Cetus DNA Thermal Cycler. The template for PCR 
amplification (reverse transcription reaction or DNA) was added 
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to a reaction mix (100 µl total volume) consisting of the 
following: lX PCR buffer (lOX PCR buffer is 15 mM MgC12 , 500 
mM KCl, and 100 mM Tris (pH 8.3)), 200 µMeach of d.ATP, dCTP, 
dGTP, and dTTP, 200 nM of each primer, and 2 U of AmpliTaq 
DNA polymerase (Perkin Elmer Cetus) . Reactions were overlaid 
with 75 µl of mineral oil (Sigma) and subjected to PCR. 
The primer pair used for histone 3.3 amplification was 
as follows: upper primer = 5'CCACTGAACTTCTGATTCGC 3', lower 
primer = 5' GCGTGCTAGCTGGATGTCTT 3' . Reactions were heated to 
960C for 5 min and then subjected to 30 cycles of PCR 
amplification using the following conditions for primer 
denaturation, annealing, and extension: 30 sec at 95°C, 30 sec 
at 55°C, and 45 sec at 72°C, respectively. After PCR, the 
reactions were heated for 5 min at 72°C to complete the extension 
of primers and then the mineral oil was removed by extracting 
the reaction with 2 volumes of chloroform:isoamyl alcohol. 
PCR products were recovered by PC! extraction and ethanol 
precipitation, and then agarose gel purified. 
The primer pair used to amplify the 447 bp fragment of 
the bcl-2 cDNA consisted of the following upper and lower primers: 
5'GGTGAACTGGGGGAGGATTGT 3' and 5'GTGTCTGTCTGTGTGTGTGAT 3', 
respectively. Thirty cycles of PCR amplification were performed 
as previously described except that the bcl-2 primers were 
denatured for 1 min at 94°C, annealed for 1 min at 55°C, and 
extended for 1 min at 72°C. 
The 26-mers 5'CGTCCCAAGCAATGGATGATTTGATG 3 I and 
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S'AGCTCGTGGTGAGGCTCCCCTTTCTT 3' were used to amplify the 790 
bp fragment of the human p53 cDNA using the following PCR 
conditions for 30 cycles: denature for 1 min at 95°C, anneal 
for 1 min at 62°C, and extend for 1 min 45 sec at 72°C. 
32p Labeling of DNA Probes 
DNA probes for hybridization studies were labeled to high 
specific activity using the random primer protocol of Feinberg 
and Vogelstein (447) with a Prime-a-Gene labeling system 
(Promega). Briefly, 25 ng of denatured DNA template (boiled 
for 5 min and snap cooled on ice) were added to a reaction mixture 
containing lX labeling buffer (5X labeling buffer is 250 mM 
Tris (pH 8.0), 25 mM MgC12 , 10 mM DTT, 1 M HEPES (pH 6.6), and 
26 A2~ U/ml random hexadeoxyribonucleotides), 20 mM each of 
unlabeled dATP, dTTP, and dGTP, 50 µCi of a 32P-labeled dCTP (3000 
Ci/mmole, Amersham, Arlington Heights, IL), 400 µg/ml nuclease 
free BSA, and 5 U of the Klenow fragment of DNA polymerase I. 
The reaction was allowed to proceed for at least 2 h (usually 
overnight) at room temperature. 
Unincorporated nucleotides were removed by size exclusion 
chromatography on a Sephadex G-50 spin column (Boehringer 
Mannheim) . Probes were denatured prior to being added to 
hybridization bags by boiling for 5 min and then snap cooling 
on ice. 
The c-myc probe for 81 nuclease protection assays was 
5' end labeled with T4 polynucleotide kinase. Briefly, the 
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pGEM-3Z -8 vector (10 µg) containing the PstI exon 2 fragment 
of the human c-myc gene was digested with BstE II (1 U/µg of 
DNA, Gibco BRL) in 100 µl (total volume) of restriction 
endonuclease REact 2 buffer (lX is 50 mM Tris (8. 0), 10 mM MgC12 , 
and 50 mM NaCl) for 1 hat 37°C. BstE II linearizes the plasmid 
by cutting the DNA at one site within the c-myc insert leaving 
a 5 1 overhang and results in a 186 bp, RNA hybridizable probe. 
Following digestion with BstE II, 5' phosphates were removed 
with bacterial alkaline phosphatase (100-200 U, 65°C for 1 h) 
(Gibco BRL) . The sample was then treated with proteinase K 
(2. 8 mg/ml) in lX proteinase K buffer (6X buffer is 60 mM Tris 
(pH 7.8), 30 mM EDTA, and 3% SDS) for 1 hat 45°C, extracted 
2X with an equal volume (180 µl) of PCI, precipitated with 1/10 
volume of sodium acetate, 2.5 volumes of 95% ethanol at -70°C 
for at least 1 h and microcentrifuged for 30 min at 4°C. The 
pellet was air dried, reconstituted in 100 µl of TE (pH 8.0) 
and purified on a Sephadex G-50 spin column. 
The probe was then 5' end-labeled as follows: 9 µg of 
linearized plasmid DNA was added to a reaction (100 µl total 
volume) containing lX kinase buffer (lOX kinase buffer is 700 
mM Tris (pH 7. 6), 100 mM MgC12 , and 50 mM DTT), 10 µCi of T 32P-
labeled dATP (6000 Ci/mmole, Amersham), and 5-10 U of T4 
polynucleotide kinase (Promega) . DNA was labeled for 30 min 
at 37°C and then the reaction was stopped by the addition of 
EDTA (to 10 mM) • The labeled DNA was extracted lX with an equal 
volume of PCI, ethanol precipitated (-70°C for at least 1 h), 
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pelleted, resuspended in TE (pH 8. 0), purified over a Sephadex 
G-SO column and stored at -70°C. 
_Qµantitation of Hybridization Studies 
Autoradiographs of northern blots were quantitated on an 
LKB Ultrascan XL laser densitometer. Sl gels, Southern and 
slot blots were quantitated on a Betagen Betascope 603 Blot 
Analyzer. 
western Blot Analysis 
Proteins (less than 100 µg/lane) were fractionated by 
discontinuous SDS-PAGE (10 or 12.5% separating gel, 5% stacking 
gel) in a Tris/glycine electrophoresis buffer (25 mM Tris, 192 
mM glycine, 0.1% SDS) at 15 mA/gel for 5-6 h. Proteins were 
transferred to nitrocellulose (S&S NC, 0.2 µm, Schleicher and 
Schuell) in a buffer consisting of 25 mM Tris (pH 8.3), 192 
mM glycine, 1.3 mM SDS, and 20% methanol, for 1-2 hat 100 mA 
using a Hoefer Semiphor semi-dry transfer unit (Model TE-70) . 
The nitrocellulose membrane was blocked overnight at 4°C in 
blocking buffer (10 mM Tris (pH 8.0), 150 mM NaCl, 0.2% Tween 
20 (Sigma), 0.2% Nonidet P-40, 0.02% SDS, 0.02% NaN3 , and 5% 
Carnation nonfat dry milk (Nestle Food Company, Glendale, CA)). 
After blocking, the membrane was incubated with a primary 
Ab (in block buffer) for 1 hat room temperature with agitation 
and then washed (10 min at room temperature with agitation) 
3X in TBST (10 mM Tris (pH 8.0), 150 mM NaCl, 0.2% Tween 20, 
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0 . 2% Nonidet P-40, 0. 02% SDS) . The membrane was then secondarily 
incubated with a horseradish peroxidase-linked whole Ab (either 
a sheep anti-mouse Ig or a donkey anti-rabbit Ig (Amersham), 
diluted 1:5000 in TBST) for 1 hat room temperature and again 
washed 3X with TBST. Specific proteins were detected by enhanced 
chemiluminescence (Amersham) and visualized on X-ray film (X-OMAT 
AR or Fuji RX) with exposure times ranging from 2 sec to 45 
min. 
Western blots were often stripped of a specific primary 
Ab and reprobed with a different Ab. Immunoblots were stripped 
by immersing the membrane in stripping buffer (100 mM 2-
mercaptoethanol, 2% SDS, and 62. 5 mM Tris (pH 6. 7)) for 30 min 
at 50°C with occasional agitation. The membrane was washed 
2X in a large volume of TBST for 10 min, blocked for 1 h at 
room temperature and then immunoblotted as previously described 
using a different primary Ab. 
The molecular weight of a specific protein was determined 
by comparison to low range molecular weight standards (Bio-Rad) 
which were co-electrophoresed with cell lysates. After protein 
transfer, the portion of nitrocellulose containing the molecular 
weight markers was removed and stained with amido black (naphthol 
blue black, Sigma) (0.1% amido black, 10% methanol, 2% acetic 
acid) for 5-10 min and then destained in 50% methanol, 7% acetic 
acid for 30 min. The log10 of the molecular weight of the 
standards was plotted as a function of their Rr values (distance 
of protein migration/distance of tracking dye migration) and 
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used to calculate the molecular weight of an unknown protein. 
Electrophoretic transfer of proteins was verified by the 
staining of post-transferred gels. Briefly, gels were stained 
with coomassie Brilliant Blue R (Sigma) (0.25% Coomassie BB 
in 50% methanol, 10% acetic acid) for 20-30 min at room 
temperature with agitation and then de stained in 2 0% methanol, 
7% acetic acid overnight at room temperature. 
Immunoprecipitation 
Specific proteins were immunoprecipitated using either 
a denaturing lysis buffer (25 mM Tris (pH 8.0), 50 mM NaCl, 
o. 5% Nonidet P-40, O. 5% sodium deoxycholate, O .1% SDS, and 0 .1% 
NaN3 ) or a moderately denaturing lysis buffer (20 mM Tris (pH 
8.0), 150 mMNaCl, 0.5% Nonidet P-40, 0.5% sodiumdeoxycholate, 
and O. 1% NaN3 ) • Coimmunoprecipitation of proteins was done 
using a non-denaturing lysis buffer (20 mM Tris (pH 8.0), 150 
rnM NaCl, 0.2% Nonidet P-40, and 0.1% NaN3). 
All steps in the immunoprecipitation protocol were done 
either at 4 ° C or on ice to reduce endogenous protease activity. 
Briefly, a specified number of cells (up to 50 X 106 ) was washed 
2X in ice cold PBS (pH 7.4). The cells were lysed in 1 ml of 
ice cold IP lysis buff er containing 1 mM phenylmethylsulfonyl 
fluoride (Sigma) , which had been added to the lysis buffer just 
prior to use, vortexed, and placed on ice for 1 h. The viscosity 
of the lysate was reduced by repeated passage through a 20 gauge 
syringe needle and then genomic DNA and cellular debris were 
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cleared from the lysate by microcentrifugation for 30 min at 
16,000 x g. 
The supernate was transferred to a new microfuge tube and 
precleared with 25 µl of a 1: 1 slurry of GammaBind G Sepharose 
(Pharmacia LKB Biotechnology, Uppsala, Sweden) :TSA (10 mM Tris 
(pH 8.0), 140 mM NaCl, and 0.25% NaN3 ) for 1 h with agitation. 
The sepharose was pelleted (16, 000 X g for 3 min) and the lysate 
again transferred to a new microfuge tube. The primary immune 
complex was formed by incubation of the lysate with a specific 
Ab for 1 h with agitation, after which time 25 µl of GammaBind 
G Sepharose:TSA (1:1) was added to the lysate and a precipitable, 
secondary immune complex allowed to form for 1 h with agitation. 
Immune complexes were precipitated by microcentrifugation 
at 16, 000 X g for 3 min, and then washed 3X in 1 ml of ice cold 
wash buffer (wash buffer = lysis buffer) . Following the final 
wash, immune complexes were reduced by adding 40 µl of western 
sample buffer to the sepharose pellet. The samples were boiled 
for 10 min and stored at -70°C until analyzed by SDS-PAGE and 
western blotting as previously described. 
Antibodies 
All of the antibodies used in these studies were commercially 
available. Concentrated antibody stocks ( 1 µg/ µl) were stored 
at -20°C until diluted in PBS (pH 7. 4) + O .1% NaN3 to a working 
stock ( 0 .1 µg/ µl) which was then stored at 4 °C for up to 1 year. 
The p53 antibodies Ab-3 and Ab-6 were obtained from Oncogene 
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science, Inc. (Uniondale, NY). Ab-3 (clone PAb 240) is a mouse 
monoclonal antibody ( IgG1) raised against a human epitope 
(residues 212-217) and is specific for the mutant form of 
mammalian p53. This antibody will also recognize denatured 
wild type p53 protein when the exposed epitope is identical 
to the mutant epitope. Ab-6 (clone D0-1) is also a mouse 
monoclonal antibody ( IgG2a) which was raised against a human 
NH-terminal epitope and recognizes both mutant and wild type 
p53 protein. The Ab-6 antibody was used as the primary Ab in 
p53 related western blot studies at a working concentration 
of 2 µg/ml. The concentration of Ab-6 and Ab-3 used in 
immunoprecipitation studies was 0 .1 µg/ml and 1. 5 µg/ml, 
respectively. 
The mouse anti-human bcl-2 monoclonal antibody (clone 124, 
IgG1) was raised against an NH-terminal epitope (residues 51-54) 
and recognized the 26 kDa human bcl-2 protein. This antibody 
was obtained from Cambridge Research Biochemicals (Wilmington, 
DE) and used in immunoblot studies at a working concentration 
of 5 µg/ml. 
Two c-myc antibodies were used in these studies and were 
obtained from Cambridge Research Biochemicals. The mouse 
monoclonal antibody (IgG1 , clone 6E10) was raised against an 
epitope spanning amino acid residues 171-188 of human c-myc 
and recognized only the human c-myc protein. The rabbit 
polyclonal antibody (IgG) was raised against the NH-terminal 
residues [44-55] + Cys of human c-myc and recognized all of 
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the human myc proteins (pan myc) . The rabbit polyclonal Ab 
was used as the primary Ab in western blot studies at a 
concentration of 5 µg/ml. A cocktail of the monoclonal and 
polyclonal Abs (1 µg/ml of each) was used in immunoprecipitation 
studies of c-myc. 
The anti-mad and anti-max rabbit polyclonal antibodies 
were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, 
CA) . The anti-mad Ab was raised against a COOH-terminal epitope 
spanning residues 203-221 and recognized the human mad protein. 
This antibody was used in western blot studies at a concentration 
of 4 µg/ml. The anti-max Ab was raised against a COOH-terminal 
epitope that spanned from residues 135-151 of the p21 form of 
the human max protein and recognized both the p21 and p22 human 
max proteins. The max antibody was used at a concentration 
of 1 µg/ml in western blot studies and 0.5 µg/ml for 
coimmunoprecipitation analysis of c-myc and max proteins. 
All antibodies used in the studies presented in this 
dissertation were titrated to maximize the signal to noise ratio. 
The apparent molecular weight of specific antigens was determined, 
and the specificity of antigenic bands was verified prior to 
the use of any antibody in an experiment. Specificity controls 
for each Ab varied as follows: for anti-c-myc, a classical serum 
stimulation, cellular differentiation experiment was performed 
in HL-60, IMR-90, and HeLa cells; for anti-p53 Ab, the HL-60 
(p53 -/-) cell line was used as a negative control, while IMR-90 
and HeLa cells (p53 wt/wt) were used as positive controls. 
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.Also, isotype controls were used (MOPC21/IgG1 and UPC10/IgG2a). 
For anti-bcl-2 Ab, the MOPC21 isotype control was utilized along 
with a positive control cell line, LM-EBV. The specificity 
of the anti-max and anti-mad Abs was demonstrated by antigen 
block experiments with the respective peptide antigens. 
APoptotic DNA Isolation and Analysis 
Low molecular weight DNA for nucleosome laddering gels 
was isolated as follows: approximately 10x106 cells were washed 
2x in ice cold PBS (pH 7.4) and lysed in 1 ml of lysis buffer 
(10 mM EDTA (pH 8.0), 50 mM Tris (pH 8.0), and 0.5% N-lauroyl 
sarcosine, w/v), treated with RNase A (250 µg/ml) for 1 h at 
37°C and with proteinase K (500 µg/ml) for 2 h at 50°C. The 
lysates were microcentrifuged (13,000 X g) for 30 min at 4°C. 
High molecular weight DNA was removed and the supernates were 
extracted 2X with PCI, once with chloroform:isoamyl alcohol, 
and ethanol precipitated with 1/10 volume of 3 M sodium acetate, 
2. 5 volumes of 95% ethanol, overnight. Samples were pelleted, 
washed in 70% ethanol, air dried, resuspended in TE (pH 8.0), 
quantitated by A200 , and stored at 4°C. One fifth the volume 
of loading dye (5X loading dye is 10 mM EDTA (pH 8.0), 0.25% 
bromophenol blue and 50% glycerol) was added to each 10 µg sample, 
which was heated at 65°C for 10 min, loaded onto a 2% agarose 
mini-gel (Seakem GTG) containing 0.5 µg/ml ethidium bromide, 
and electrophoresed at 6 V/cm until the tracking dye ran off 
the bottom of the gel (2-3 h). The gel was photographed using 
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a Fotodyne UV-440 transilluminator system (Fotodyne Inc., New 
Berlin, WI) with Polaroid Type 57 film (Polaroid Corporation, 
Cambridge, MA) . 
~rminal Deoxynucleotidyl Transferase Assay (TOTA) 
Apoptosis-induced DNA fragmentation was assessed in situ 
by means of the TDTA. Following drug treatments, approximately 
1ox106 cells were washed lX in ice cold PBS (pH 7. 4) and fixed 
in 2 ml of ice cold 1% formaldehyde (Mallinckrodt) in PBS for 
15 min on ice. Cells were then washed 3X in cold PBS, resuspended 
in 70% ethanol and stored at -20°C overnight. The cells were 
rehydrated in PBS for 15 min on ice, aliquoted into Falcon 2054 
12 X 75 mm round bottom polystyrene tubes (Becton Dickinson, 
Lincoln Park, NJ) (1-1.5x106 cells/tube), and pelleted (500 
X g for 5 min at 4°C). The supernatant was removed and the 
inside walls of the tubes were thoroughly dried with a Kimwipe 
(Kimberly-Clark Corporation, Atlanta, GA) . The cells were 
resuspended in 40 µl of TDT solution (200 mM potassium cacodylate, 
25 mM Tris, 0.25 mg/ml BSA, 1 mM CoC12 , 25 µM biotin-16-dUTP 
(Boehringer Mannheim) , and 25 U of terminal transferase 
(Boehringer Mannheim)) and incubated at 37°C for 30 min. The 
cells were then washed 3X with 2 ml of cold PBS + 2% BCS, 
resuspended in 50 µl of staining buffer (4X SSC, 0.1% Triton 
X-100, 5% Carnation nonfat dry milk, and O. 75 µg/ml fluorescein 
isothiocyanate-conjugated avidin (Sigma)) and incubated at room 
temperature for 30 min in the dark. The cells were washed 3X 
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in 2 ml of cold PBS + 2% BCS, resuspended in 1 ml of PBS + 2% 
BCS and stored in the dark on ice until subjected to FACS 
analysis. Ten thousand events were recorded using a Becton 
Dickinson FACStarPtus (San Jose, CA) and analyzed using LYSIS 
II software. A 5 W argon ion laser tuned to 488 nm and emitting 
at 200 mW, was used for fluorescein excitation and emissions 
were measured using a 530/30 band pass filter. Each sample 
was split into 2 tubes, one with terminal transferase and one 
without terminal transferase, therefore, each sample was run 
with its own negative control. 
Morphological Analysis of Apoptotic Nuclei 
The percentage of apoptotic and necrotic cells occurring 
in a nitrogen mustard treated population was quantitated by 
the morphological analysis of propidium iodide stained nuclei. 
Briefly, 1-2 X 106 cells were isolated at various times following 
exposure to HN2, washed lX with ice cold PBS (pH 7. 4) and fixed 
in 1% formaldehyde (in PBS) for 15 min on ice. The cells were 
washed lX with ice cold PBS, permeabilized with 0.1% Triton 
X-100 for 3 'min on ice and then treated with RNase A (1 mg/ml) 
for 30 min at 37°C. RNase was removed and the cells incubated 
with propidium iodide (50 µg/ml in PBS) (Sigma) for at least 
1 h at 4°C in the dark. The cells were then analyzed by 
fluorescence microscopy on a Nikon DIAPHOT-TMD inverted microscope 
(Nippon Kogaku K.K, Tokyo, Japan) with a Nikon mercury lamp 
power supply (HBO-lOOW/2). Photomicrographs were taken using 
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a Nikon N6006 35 mm SLR camera and Tmax 100 black and white 
negative film (Kodak) . 
~llular Viability Assay 
Cellular viability was assessed based upon membrane integrity 
and cellular enzyme function using a propidium iodide/fluorescein 
diacetate (Sigma) based flow cytometric assay. The nucleic 
acid intercalating dye propidium iodide is impermeable to the 
intact cellular membrane of viable cells but stains the nuclei 
of non viable cells because the cell membrane of non viable 
cells becomes leaky as integrity is lost. Fluorescein diacetate 
is membrane permeable and once inside the cell is cleaved by 
general cellular esterases, generating a non-permeable 
fluorochrome, fluorescein, which becomes trapped inside viable 
cells. 
Viability of cells was determined as follows: 1-2 X 106 
cells were aliquoted into 12 X 75 mm Falcon round bottom 
polystyrene tubes and washed 2X in ice cold HBSS (pH 7. 4) (Gibco 
BRL) . The cells were resuspended in 1 ml of HBSS containing 
fluorescein diacetate (0 .1 ng/ml) and propidium iodide (50 µg/ml), 
incubated at room temperature for 10 min in the dark, and washed 
lX with HBSS. The cells were then resuspended in 1 ml of HBSS 
and stored in the dark on ice, until analyzed on a Becton 
Dickinson FACStarptus. Ten thousand events were recorded for 
each sample. Fluorochromes were excited at 488 nm and emissions 
measured using a 530/30 band pass filter (fluorescein) and a 
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575/26 band pass filter (propidium iodide) . 
,Antisense ODN Studies 
Gene specific antisense ODNs were used in an attempt to 
modulate the expression of different genes. Two methods of 
ODN delivery were utilized. The first method involved the 
delivery of antisense ODNs to membrane permeabilized cells. 
Briefly, 1 X 106 cells were washed lX in HBSS (pH 7. 4) , 
resuspended in 1 ml of permeabilization buffer (137 mM NaCl, 
100 mM PIPES (pH 7.4), 5.6 mM glucose, 2.7 mM KCl, 2.7 mM EGTA, 
1 mM Na-ATP, O .1% BSA, and 1. 5 U/ml of Streptolysin O (Sigma)) 
containing a specified concentration of either sense or antisense 
ODNs, and incubated for 5-10 min at room temperature. Following 
incubation with ODNs, the permeabilization of cells was reversed 
by pelleting the cells, decanting the buffer and washing the 
cells lX in 5 ml of culture media. The cells were resuspended 
in culture media, incubated at 37°C, and whole cell proteins 
isolated at various time points for western blot analysis of 
specific proteins. This method exposed cells to ODNs for a 
very short time (5-10 min) . 
The second method of antisense delivery involved the 
continuous exposure of cells to ODNs in the culture medium. 
Approximately 1 X 106 cells were resuspended in 3-5 ml of culture 
media containing 5% or 10% DNase inactivated BCS (heated at 
65°C for at least 30 min) and then treated with the appropriate 
concentration of either sense or antisense ODNs. Cells were 
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incubated with ODNs for various times and then whole cell proteins 
were isolated for western blot analysis. In the longer time 
course studies, ODNs were reapplied every 12 or 24 h. 
Three different antisense ODNs targeted against human c-myc 
were utilized in antisense studies. The first anti-c-myc ODN 
was the anti-gene, triplex forming, unmodified ODN, 5' 
TGGGGAGGGTGGGGAGGGTGGGGAAGG 3' , which was targeted against the 
Pl promoter of the c-myc gene (448). The control sense ODN 
was 5' CCTTCCCCACCCTCCCCACCCTCCCCA 3' . The two antisense c-myc 
ODNs were previously characterized by Bacon and Wickstrom ( 44 9) . 
The first of these anti sense ODNs was targeted against the AUG 
initiation codon of the human c-myc mRNA (designated 559-573 
O) . The sequence of the 559-573 0, unmodified antisense ODN 
was 5' AACGTTGAGGGGCAT 3'. The second antisense c-myc ODN (1-14 
F) was targeted against the 5' cap sequence of the human c-myc 
mRNA and was synthesized as either an unmodified or 
phosphorothioated ODN. The 1-14 F antisense and sense sequences 
were 5' GCACAGCTCGGGGGT 3 ' and 5 ' ACCCCCGAGCTGTGC 3 ' , 
respectively. 
The antisense p53 ODN, 5' CTGCGGCTCCTCCATGGCAGT 3', was 
targeted to a flanking region of the translation intitiation 
site of the human p53 mRNA (450). This antisense ODN was 
unmodified for these studies. 
All unmodified ODNs were synthesized on an Applied Biosystems 
391 PCR-MATE EP DNA Synthesizer (Foster City, CA), using standard 
phosphoroamidite chemistry. Oligos were cleaved from the 
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substrate, phosphate deprotected, and base deprotected in 
concentrated ammonium hydroxide for 8 h at 55°C. Deprotected 
oligos were desalted and purified on Oligo Purification Cartridges 
(OPC, Applied Biosystems) following the manufacturer's directions. 
phosphorothioated antisense c-myc ODNs (1-14 F) were purchased 
from Oligos Etc., Inc. 
CHAPTER 3 
RESULTS 
The involvement of c-myc in cellular proliferation, 
differentiation, transformation, and apoptosis has been 
extensively documented (343, 344) . Deregulated overexpression 
of c-myc occurs in a majority of human tumors and is involved 
in the progression of the tumorigenic state (344,351). 
studies utilizing antisense ODNs targeted against c-myc mRNA 
have shown that the clonogenicity of human tumor cell lines 
can be inhibited by the specific reduction in c-myc 
expression (451-454). Bifunctional alkylating agents such as 
nitrogen mustard inhibit the clonogenicity of human tumor 
cells. Our laboratory has previously shown that various 
mustard analogs inhibit c-myc transcription in vitro (29) and 
down-regulate the expression of c-myc mRNA in the human colon 
carcinoma cell line, Colo320HSR, in a concentration and time-
dependent manner (31) . Based upon these observations, the 
following hypothesis was investigated: Bifunctional 
alkylating agents, such as HN2, inhibit the clonogenicity of 
human tumor cells by down-regulating the expression of 
critical cellular oncogenes, such as c-myc. 
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coMPARISON OF C-MYC GENE COPY NUMBER AND EXPRESSION IN THE 
coL0320HSR, HT-29, AND BE HUMAN COLON CARCINOMA CELL LINES 
The three human colon carcinoma cell lines, Colo320HSR, 
HT-29, and BE, were chosen to address this question because 
of their varying levels of c-myc mRNA expression. These cell 
lines were characterized with respect to c-myc gene copy 
number and expression. Southern blot analysis revealed that 
the c-myc gene was highly rearranged and amplified in the 
colo320HSR cell line while no gross alterations were observed 
in the HT-29 or BE cell lines (Figure lA) . The Colo320HSR 
cell line was shown by slot blot analysis to possess 26-30 
copies of the c-myc gene when compared to the BE cell line, 
while the HT-29 cell line contained approximately twice the 
number of c-myc alleles relative to BE cells (Figure lB) . BE 
cells were shown to be single copy for the c-myc gene (i.e. 
possess two alleles) by Southern blot comparison with a panel 
of cell lines containing a single copy of the c-myc gene 
(data not shown) . 
The steady state expression of c-myc mRNA was determined 
in asynchronous log phase cells by Sl nuclease protection 
analysis. These studies showed that c-myc mRNA levels in 
Colo320HSR and HT-29 cells were 10-12 and 1.5-2 fold higher, 
respectively, relative to BE cells (Figure 2A) . Similar 
results were obtained by northern blot analysis (data not 
shown) . BE and HT-29 cells expressed similar levels of c-myc 
protein. However, p64 c-myc protein levels were 
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Figure 1. c-Myc gene analysis of the Colo320HSR, HT-29, and 
BE human colon carcinoma cell lines. 
(A) Southern blot analysis. EcoRI restriction 
endonuclease digested genomic DNA from Colo320HSR cells (5 or 
10 µg), or HT-29 and BE cells (5 µg, in duplicate) was 
fractionated on a 0.5% agarose gel, Southern blotted, and 
hybridized with a 32P-labeled, 420 bp human c-myc exon 2 
probe. The membrane was stripped and rehybridized with a 
human GAPDH probe to assess sample loading (data not shown) . 
(B) Slot blot analysis of c-myc gene copy number. EcoRI 
digested genomic DNA (1 or 5 µg) from each cell line was 
spotted onto a nylon membrane and hybridized with a 32P-
labeled human c-myc exon 2 probe to determine the relative 
gene copy number. The membrane was stripped and rehybridized 
with a human GAPDH probe (a single copy gene) to normalize 
for sample loading. A representative blot of two independent 
isolations, each repeated four times, is shown. Bands were 
quantitated on a Betagen Betascope 603 blot analyzer. 
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Figure 2. Comparison of the relative c-myc mRNA and protein 
levels in the human colon carcinoma cell lines Colo320HSR, 
HT-29, and BE. 
(A) Sl nuclease protection analysis of c-myc mRNA 
levels in the 3 human colon carcinoma cell lines. A 32P-5' 
end labeled c-myc exon 2 probe was hybridized to 20 µg of 
total RNA from each cell line and resulted in a 186 bp 
protection. Samples were done in triplicate and quantitated 
on a Betascope 603 blot analyzer. (B) Western blot analysis 
of p64 c-myc protein levels. Whole cell protein extracts 
from 4 X 105 cells were fractionated on a 10% SDS-
polyacrylamide gel, transferred to nitrocellulose with a 
semiphor semi-dry transfer unit, and immunoblotted with a 
rabbit polyclonal anti-human myc Ab (5 µg/ml) . c-myc protein 
was visualized on autoradiographic film by enhanced 
chemiluminescence detection. c-myc protein levels were 
quantitated by densitometric analysis of autoradiographs. 
The gel shown is representative of at least five independent 
experiments. (C) Immunoprecipitation analysis of p64 c-myc 
protein levels. c-myc protein was immunoprecipitated from 5 
X 106 cells with 1 µg each of a rabbit polyclonal anti-human 
myc Ab and a mouse monoclonal anti-human c-myc Ab. 
Immunoprecipitates were electrophoresed on a 10% SDS-
polyacrylamide gel and immunoblotted with a pan-myc rabbit 
polyclonal Ab. c-myc protein was detected by enhanced 
chemiluminescence and quantitated by densitometric analysis 
of autoradiographs. The gel shown is representative of 4 
independent experiments. Specific bands were sized by 
comparison to protein molecular weight standards which were 
co-electrophoresed and transferred with the samples, cut from 
the rest of the membrane and stained with amido black. 
Unknown molecular weights were determined by Rr values. The 
large band below the specific c-myc band in the IP analysis 
is the heavy chain of the rabbit IgG Ab used in the 
immunoprecipitation. The heavy chain is detected because of 
the subsequent immunoblotting step used to detect the 
specific protein. Since a rabbit primary Ab was used in the 
immunoblotting procedure to detect c-myc protein, the 
secondary Ab is an anti-rabbit IgG Ab and will bind to both 
the rabbit polyclonal Ab which is bound specifically to c-myc 
protein, and also the rabbit IgG heavy chain which is present 
on the membrane. Thus both are visualized following enhanced 
chemiluminescence detection. 
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7 fold higher in Colo320HSR cells relative to 
cells, as determined by either western blot 
analysis (Figure 2B) or immunoprecipitation analysis (Figure 
2C) · 
NITROGEN MUSTARD CAUSES A CONCENTRATION AND TIME-DEPENDENT 
DECREASE IN C-MYC mRNA LEVELS IN HUMAN COLON CARCINOMA CELL 
LINES 
Experiments were designed to determine whether exposure 
to HN2 would reduce the expression levels of c-myc mRNA in 
Colo320HSR, HT-29, and BE cells. If the working hypothesis 
is viable then c-myc mRNA levels should be decreased in all 
three cell lines following drug treatment. Cells were 
treated with concentrations of HN2 that inhibited their 
clonogenicity by either 90% (1 log) or 99.9% (3 logs). These 
concentrations were 2 µM and 6 µM, 4 µM and 10 µM, and 10 µM 
and 30 µM for Colo320HSR, HT-29, and BE cell lines, 
respectively (31,455). Sl nuclease analysis showed that c-
myc mRNA levels in all three cell lines were reduced in a 
concentration and time-dependent manner over a 24 h time 
course following exposure to HN2 (Figure 3A, B, and C) . The 
patterns of c-myc mRNA reductions were similar in all three 
cell lines, with the nadir occurring at 12 h (Figure 4A and 
B) . c-Myc message levels at the 24 h time point showed no 
substantial recovery except in HT-29 cells treated with 4 µM 
HN2, in which mRNA levels began to return to control levels 
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(Figure 4A). Maximum reductions (% of control, mean ± SEM) 
in c-myc mRNA levels in cells treated with HN2 were 60% ± 2, 
66% ± 3, and 26% ± 1 for the Colo320HSR, HT-29, and BE cell 
lines, respectively (Figure 4B). These studies were repeated 
by northern blot analysis with similar results (data not 
shown) . 
Cell lines were treated with an equi-molar concentration 
of HN2 to further confirm the relationship between the 
decrease in c-myc mRNA and the inhibition of clonogenicity. 
Colo320HSR, HT-29, and BE cells were exposed to a 6 µM 
concentration of HN2 which inhibited clonogenicity in these 
cell lines by 3 logs, 1. 5-2 logs, and less than 1 log, 
respectively. If the inhibition of cell growth after HN2 
exposure was linked to the effect on c-myc mRNA levels, then 
Colo320HSR cells should have the greatest reduction in c-myc 
message, followed by HT-29 cells. BE cells should be 
essentially unaffected at a 6 µM concentration. The results 
from this study showed that c-myc mRNA levels were reduced in 
Colo320HSR cells by 60% ± 2 and 52% ± 6 (mean ± SEM) at 12 
and 24 h post HN2 treatment, respectively. c-Myc message 
levels were reduced in HT-29 cells by only 42% ± 2 and 26% ± 
2 at 12 and 24 h, respectively, while BE cells were 
essentially unaffected, showing reductions of 4% ± 4 and 14% 
± 4 at 12 and 24 h post HN2 treatment, respectively (Figure 
5) . These results showed that c-myc mRNA levels were reduced 
in human tumor cell lines following exposure to HN2 and were 
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Figure 4. Graphical representation of the previous figure 
showing the effect of HN2 on c-myc mRNA expression in human 
colon carcinoma cell lines. 
The concentration of HN2 used in these studies produced 
either a 1 log (90%) (A) or 3 log (99. 9%) (B) inhibition of 
cellular clonagenicity. c-myc mRNA expression levels in 
treated cells were presented as the percent change relative 
to each time point control. The data from three independent 
experiments were plotted as the mean ± standard error of the 
mean (SEM) . The points without error bars were those points 
in which the error bars fell within the symbol. 
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decrease in mRNA levels at the 12 and 24 h time points. c-
Myc protein levels were reduced (mean ± SEM) by 52% ± 6 and 
69% ± 2 at 48 and 72 h, respectively (Figure 7) . Contrary 
to the decline in c-myc mRNA, the level of c-myc protein in 
both HT-29 and BE cells increased after nitrogen mustard 
treatment. Levels of c-myc protein began to increase in HT-
29 cells 24 h following drug exposure and were maximally 
induced by approximately 2.5 fold at 48 h post treatment. c-
Myc protein levels in BE cells were induced immediately by 
HN2 and showed a maximal 4 fold induction by 72 h post 
treatment. Protein levels of c-myc in HT-29 and BE cells 
exposed to HN2 remained above control values through 96 h 
(Figure 7) . The data on c-myc protein levels were contrary 
to those expected and do not support a role for the down-
regulation of c-myc in the inhibition of clonogenicity by 
HN2. 
NITROGEN MUSTARD INHIBITS THE Clonogenicity OF HUMAN COLON 
CARCINOMA CELL LINES BY REDUCING VIABILITY 
The third prediction of the working hypothesis was that 
the inhibition of clonogenicity by HN2 would be via a 
mechanism involving growth arrest, not cell death. The 
rationale for this prediction was based upon the known role 
for c-myc in cellular proliferation and differentiation. 
Proliferating cells contain high levels of c-myc, while 
quiescent cells have undetectable levels of c-myc, remain 
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Figure 6. Changes in c-myc protein levels in human colon 
carcinoma cell lines following exposure to equi-cytotoxic 
concentrations of nitrogen mustard. 
Cells were exposed for 1 h to a concentration of HN2 
that inhibited clonagenicity by 99.9%. Whole cell protein 
extracts were isolated at various times following drug 
removal, subjected to SDS-PAGE (10% gel) and western blot 
analysis using a rabbit polyclonal pan myc primary Ab (5 
µg/ml) . p64 c-myc was sized by comparison to protein 
molecular weight standards. Controls (C) were run at each 
time point to reduce variability resulting from uneven 
protein transfer across the membrane. The transfer 
efficiency was monitored by coomassie staining of post-
transferred gels. (A) The effect of 6 µM HN2 on c-myc 
protein levels in Colo320HSR cells. 5 X 105 cell equivalents 
were used for western analysis. (B) The effect of 10 µM HN2 
on c-myc protein levels in HT-29 human colon carcinoma cells. 
Unattached cells in drug treated flasks at the later time 
points were decanted, pelleted, and added back to the 
population of attached cells for analysis. 2. 5 X 105 cell 
equivalents were used for western analysis. (C) Chan~es in 
c-myc protein levels in the BE cell line (2. 5 X 10 cell 
equivalents) following exposure to 30 µM HN2. Unattached 
cells in drug treated flasks at the later time points were 
decanted, pelleted, and added back to the population of 
attached cells for analysis. 
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Figure 7. Time course analysis of the changes in c-myc 
protein levels in human colon carcinoma cell lines following 
exposure to nitrogen mustard. 
A graphic representation of the previous figure showing 
the time course changes in c-myc protein in the Colo320HSR, 
HT-29, and BE cell lines following exposure to equi-cytotoxic 
concentrations of HN2 (6, 10, and 30 µM, respectively). 
Protein levels were quantitated by densitometric analysis of 
autoradiographs and presented as the percent change relative 
to time point controls. Data points represented the mean ± 
SEM of at least three independent experiments. Error bars 
fell within the symbol on some data points. 
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viable, and are capable of reentry into the cell cycle upon 
c-myc induction ( 3 51) . Most differentiated cells contain 
undetectable levels of c-myc and also retain viability (351) . 
Therefore, if the loss of clonogenicity induced by mustard 
treatment were related to the reductions in c-myc, then the 
cells should remain viable, since there is no evidence 
suggesting that the down-regulation of c-myc expression is 
incompatible with cellular viability. 
Cellular viability of nitrogen mustard treated cells 
was determined using a flow cytometric assay that assessed 
both membrane integrity and cellular esterase activity 
(Figure BA). Colo320HSR, HT-29, and BE cells were treated 
with 6, 10, or 30 µM HN2, respectively, and viability was 
measured every 24 h for seven days following drug removal. 
All three cell lines lost viability over the seven day time 
course. Colo320HSR cells rapidly lost viability (50% by 
approximately 3B h) while the loss of viability in both HT-29 
and BE cells was substantially slower (50% by approximately 
96 h) (Figure BB) Colo320HSR and HT-29 cells were 1% and 5% 
viable, respectively, by the seventh day. The pattern of 
viability of BE cells following mustard treatment was 
identical to HT-29 cells out to 96 h, at which time no 
further loss of viability was detected in BE cells out to the 
seventh day (Figure BB) . 
The loss of cellular viability, along with the effects 
observed at the protein level in all three cell lines forced 
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Figure 8. Time course assessment of the cellular viability 
of human colon carcinoma cell lines following treatment with 
nitrogen mustard. 
Cellular viability was assessed in the Colo320HSR, HT-
29, and BE cell lines at various times following a 1 h 
exposure to concentrations of HN2 that inhibited 
clonagenicity by 99.9%. Viability was determined using a 
flow cytometric assay that differentiated viable cells from 
nonviable cells based upon membrane integrity and cellular 
esterase function using the fluorescent dyes propidium iodide 
and f luorescein diacetate, respectively. (A) A scatter plot 
[log fluorescein (FDA) fluorescence versus log propidium 
iodide (PI) fluorescence] of a representative sample with 
each dot being equivalent to one cell. The population of 
viable cells was located in the lower right quadrant while 
the nonviable cells were located in the three other quadrants 
with the major portion of the nonviable cell population being 
located in the upper left quadrant. (B) Time course 
analysis of viability in the Colo320HSR, HT-29, and BE cell 
lines following exposure to 6, 10, and 30 µM HN2, 
respectively. Viability was expressed as the percent of 
control. Control populations of Colo320HSR, HT-29, and BE 
cells were 86.2%, 81.5%, and 87.3% viable. Ten thousand 
cells were analyzed per sample and the data expressed as the 
mean ± standard deviation (SD) of three independent 
experiments. Data points were present where the error bars 
fell within the symbol. For the attached cell lines HT-29 
and BE, unattached drug treated cells at the later time 
points were decanted, pelleted, and added back to the 
population of attached cells for analysis. 
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the rejection of the original hypothesis. These studies did 
not conclusively rule out the partial involvement of cellular 
growth arrest in the inhibition of clonogenicity in the BE 
cell line following HN2 exposure since cellular viability was 
not measured out past 7 days. Therefore, based upon these 
results, I conclude that the inhibition of clonogenicity by 
HN2 in the Colo320HSR, HT-29, and BE (to a major extent) 
human colon carcinoma cell lines resulted from the loss of 
cellular viability and was not mediated by a decrease in c-
myc protein expression. 
Two distinct mechanisms of death are utilized by cells 
exposed to chemotherapeutic agents, necrosis and apoptosis. 
In general, cells that undergo an apoptotic cell death in 
response to anti-neoplastic agents are more sensitive to 
these drugs ( 88) . Several gene products involved in the 
transformation of cells have also been shown to directly or 
indirectly regulate the induction of apoptosis in either a 
positive or negative fashion (85) . The c-myc oncogene is 
such a gene. The constitutive ectopic expression of c-myc 
protein in rodent fibroblasts or murine IL-3-dependent 
myeloid cells has been shown to enhance the induction of 
apoptosis in a dose-dependent manner in cells that have been 
presented with a replication block (growth/survival factor 
deprivation, DNA damage induced by chemotherapeutic agents, 
etc.), thus demonstrating a role for the deregulated 
overexpression of c-myc in the regulation of apoptosis 

necrosis observed. 
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At the time of these studies, the 
presence of oligonucleosomal-sized DNA ladders was thought to 
be a universal biochemical hallmark of apoptosis (101). 
Therefore, initial experiments were performed to determine if 
these DNA ladders were present in Colo320HSR, HT-29, and BE 
cells after HN2 treatment. A time course analysis of HN2 
treated cells showed that DNA ladders were present in 
Colo320HSR cells as early as 48 h post treatment. DNA 
ladders were not observed in HN2 treated HT-29 or BE cells at 
any of the time points (BE seven day time point not shown) 
(Figure 9). 
Further investigation revealed that the appearance of 
DNA ladders in Colo320HSR cells following nitrogen mustard 
exposure was both time and concentration-dependent. Twenty-
five and 50 µM concentrations of HN2 induced the formation of 
DNA ladders in Colo320HSR cells at 24 h (the earliest time 
point measured) while 0. 5 µM (to some extent) and 1 µM 
concentrations of HN2 induced the formation of DNA ladders as 
early as 72 h post drug removal (Figure 10). A preliminary 
concentration-response study (10 to 100 µM HN2) in BE cells 
confirmed the absence of observable DNA ladders at the 96 h 
time point (Figure 11) . These data verified the presence of 
apoptotic Colo320HSR cells and suggested that apoptosis was 
involved in the mediation of HN2-induced cell death in this 
cell line. These experiments were not designed to rule out 
the occurrence of apoptosis and should not be interpreted as 
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Figure 9. Nucleosome DNA laddering gels assessing the 
presence and time course of apoptosis in human colon 
carcinoma cell lines following treatment with equi-cytotoxic 
concentrations of HN2. 
Colo320HSR, HT-29, and BE cells were treated with 6, 10, 
and 30 µM HN2, respectively, for 1 h. Low molecular weight 
genomic DNA was isolated at various times following drug 
removal and electrophoresed as described in the methods. 
Unattached cells were decanted, pelleted, and added back to 
the attached cells for analysis. The appearance of 
nucleosome-sized DNA ladders (=180 bp multimers), a classical 
biochemical hallmark of apoptosis, indicated the presence of 
apoptotic cells in drug treated populations. Actinomycin D 
(5 µg/ml) treated Colo320HSR cells were used as a positive 
control for the presence of nucleosome DNA ladders. A 1 kb 
DNA ladder (left most lane) was included to size nucleosome 
DNA fragments. Gels shown were representative of three 
independent experiments. 
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Figure 10. Concentration-response analysis of the time 
course of nitrogen mustard-induced apoptosis in Colo320HSR 
cells as assessed by nucleosome DNA laddering. 
Colo320HSR cells were treated with various 
concentrations (µM) of HN2 for 1 h and low molecular weight 
DNA was isolated at various times following drug removal and 
electrophoresed through agarose gels as described in the 
methods. Actinomycin D (5 µg/ml) was used as a positive 
control for the presence of nucleosome ladders in Colo320HSR 
cells. The gels shown were representative of three 
independent experiments. 
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Figure 13. Concentration-response analysis of the time 
course of nitrogen mustard-induced DNA fragmentation in the 
HT-29 human colon carcinoma cell line. 
A quantitative in situ TDT assay was used to determine 
the number of cells in a drug treated population possessing 
the fragmented DNA characteristic of apoptosis. HT-29 cells 
were exposed to various µM concentrations of HN2 for 1 h and 
then cells were fixed at various times following drug removal 
and subjected to TDT analysis as described in the methods. 
Unattached cells at the later time points were combined with 
attached cells for analysis. Data are presented as the log 
fluorescence of TDT staining versus the number of cells. Ten 
thousand cells were analyzed for each sample. 
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Figure 14. Concentration-response analysis of the time 
course of nitrogen mustard-induced DNA fragmentation in the 
BE human colon carcinoma cell line. 
A quantitative in situ TDT assay was used to determine 
the number of cells in a drug treated population possessing 
the fragmented DNA characteristic of apoptosis. BE cells 
were exposed to various µM concentrations of HN2 for 1 h and 
then cells were fixed at various times following drug removal 
and subjected to TDT analysis as described in the methods. 
Unattached cells from the later time points were combined 
with the attached cells for analysis. Data are presented as 
the log fluorescence of TDT staining versus the number of 
cells. Ten thousand cells were analyzed for each sample. 
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oligonucleosome-sized DNA fragments (107) . 
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Therefore, the 
absence of DNA ladders is not sufficient evidence to rule out 
apoptosis as a mechanism of cell death. On closer 
examination, the TDT data for both HT-29 and BE cells showed 
a broadening of the peaks due to an increase in fluorescence 
at the later time points. This broadening was more prominent 
in HT-29 cells (Figure 13) than in BE cells (Figure 14) . 
Although none of these peaks showed the clear separation and 
increase in fluorescence as observed in Colo320HSR cells, 
which possessed oligonucleosomal DNA fragments, their 
appearance was consistent with the possibility that DNA 
fragmentation in HT-29 and BE cells occurred at a higher 
order of chromatin organization (300 and 50 kbp) . These 
results suggested that some apoptotic cells were present in 
populations of HT-29 and BE cells treated with HN2. 
COL0320HSR, HT-29, AND BE CELLS UTILIZE APOPTOTIC AND 
NECROTIC MODES OF CELL DEATH TO VARYING DEGREES FOLLOWING 
EXPOSURE TO HN2 
The morphological analysis of Colo320HSR, HT-29, and BE 
cells following HN2 exposure confirmed the presence of 
apoptotic cells in all three cell lines (Figure 16A, B, and 
C). Quantitation of viable, apoptotic, and necrotic cells 
showed that the induction of cell death in Colo320HSR cells 
was a rapid event and occurred exclusively via the apoptotic 
mechanism of cell death (Figure 17). These results 
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Figure 16. Photomicrographs of the morphological analysis of 
the time course of nitrogen mustard-induced cell death in 
human colon carcinoma cell lines. 
Colo320HSR (A) , HT-29 (B) , and BE (C) cells were exposed 
to 6, 10, and 30 µM HN2, respectively, for 1 hand at various 
times following drug removal, cells were fixed, 
permeabilized, and stained with propidium iodide as described 
in the methods. Unattached HT-29 and BE cells from the later 
time points were added back to the population of attached 
cells for analysis. Nuclei were visualized by fluorescence 
microscopy (200X magnification) . Nuclei from viable cells 
were small and evenly stained (control A, B, and C) while 
apoptotic nuclei showed the presence of condensed and 
fragmented chromatin (A, 96 h) . Nuclei from necrotic cells 
were large and evenly stained (C, 96 h) . 
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Figure 17. Quantitative time course of the morphological 
analysis of cell death in human colon carcinoma cell lines 
following exposure to equi-cytotoxic concentrations of 
nitrogen mustard. 
Colo320HSR, HT-29, and BE cells were treated with 6, 10, 
and 30 µM HN2, respectively, for 1 h and then were fixed, 
permeabilized and stained with propidium iodide at various 
times following drug removal (see methods for details) . 
Nuclear morphology was assessed by fluorescence microscopy at 
a magnification of 200X. The number of viable, apoptotic, 
and necrotic cells was determined by projecting the image of 
a photographic negative onto a grid and recording the number 
of cells in each category. Viable cells had a nuclear 
morphology characterized by a small size and evenly stained 
chromatin. A range of nuclear size was determined for 
control cells of each cell type to account for cell cycle 
phase-dependent changes in the size of the nucleus (generally 
2-5 mm) . Cells with evenly stained chromatin whose nuclei 
fell within this size range were considered to be viable 
cells. Cells with evenly stained nuclei that were larger 
than this size range were considered to be necrotic cells. 
Apoptotic cells were characterized by having nuclei that had 
condensed and fragmented chromatin. Any evenly stained 
material under 1 mm was considered to be an apoptotic body 
and was not scored as a cell. The data were expressed as the 
percentage of viable, apoptotic, and necrotic cells. 
Generally, 1200-3500 cells were scored for each time point. 
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c-myc in human tumor cell lines did not appear to be 
predictive for the enhanced onset of apoptosis following 
treatment with the DNA damaging agent, HN2. Therefore, I 
conclude that factors other than high levels of c-myc protein 
appeared to exist which could influence the enhancement of 
apoptosis in human tumor cell lines. 
The fact that c-myc-enhanced apoptosis did not appear to 
occur in HT-29 and BE cells, despite the increase in c-myc 
protein levels, raised the question of whether the c-myc 
enhancement of apoptosis was being modulated by other gene 
products in these cell lines. Several gene products are 
known to regulate the c-myc enhancement of apoptosis and 
include the oncogenes c-abl, c-raf, ras, and bcl-2, and the 
tumor suppressor p53 (154,169,190,250,328). The Colo320HSR, 
HT-29, and BE cell lines did not express detectable mRNA for 
either c-abl, c-raf, rel, H-ras or K-ras, however, all three 
cell lines expressed mRNA for N-ras, with Colo320HSR cells 
showing the greatest level of expression followed by BE and 
HT-29 cells (Q. Dong, unpublished observations, 456). The 
regulation of both apoptosis and the c-myc enhancement of 
apoptosis by bcl-2 and p53 has been extensively studied. 
Therefore, studies were performed to rule out the involvement 
of these two gene products in the regulation of apoptosis in 
these cell lines following exposure to HN2. 
The p53 tumor suppressor gene is mutated in 90% of human 
colon tumors (257) . In some cell types, wild-type p53 
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protein is required for the utilization of the apoptotic 
pathway following exposure to various chemotherapeutic agents 
(l73,316). In murine systems, studies have shown the 
following: an increase in wild-type p53 protein is sufficient 
for the induction of apoptosis (172); a post-translational 
increase in wild-type p53 protein mediates the c-myc 
enhancement of apoptosis (327); and the presence of mutant 
p53 can abrogate the enhancement of apoptosis by c-myc (328) . 
The following hypothesis was tested: p53 protein regulates 
the c-myc enhancement of apoptosis in the Colo320HSR, HT-29, 
and BE human colon carcinoma cell lines. 
CHARACTERIZATION OF THE PS3 GENE AND ITS EXPRESSION IN THE 
COL0320HSR, HT-29, AND BE CELL LINES 
The p53 tumor suppressor phenotype was characterized in 
the Colo320HSR, HT-29, and BE cell lines to rule out its 
involvement in the regulation of apoptosis following HN2 
treatment. Based upon the previous conclusions and the 
information regarding p53, if p53 were involved in the 
regulation of apoptosis in these cell lines, then Colo320HSR 
cells would be predicted to express wild-type p53 protein, 
while HT-29 and BE cells would express the mutant form of the 
protein. The levels of p53 protein in Colo320HSR cells would 
also be expected to increase following exposure to HN2 while 
the levels of protein in HT-29 and BE cells should not 
change. 
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Figure 18. Southern, northern, and western blot analysis of 
p53 in the Colo320HSR, HT-29, and BE cell lines. 
(A) Southern blot analysis of EcoRI and HindIII 
restriction endonuclease digested genomic DNA from human 
carcinoma cell lines. Ten µg of cut genomic DNA from each 
cell line was fractionated on a 0.5% agarose gel, Southern 
blotted and hybridized with a 32P-labeled 790 bp p53 cDNA 
probe. The size of each DNA fragment was shown on the left 
and was determined by comparison to a 1 kb DNA ladder which 
was included on the gel. (B) Northern blot analysis of p53 
mRNA levels in human carcinoma cell lines. Total RNA (35 µg) 
from each cell line was fractionated on a 1% agarose gel, 
northern blotted, and hybridized with a 32P-labeled 790 bp p53 
cDNA probe. The membrane was stripped and rehybridized with 
a histone 3.3 probe to assess RNA loading. Bands were sized 
based upon the relative positions of the 18S and 28S 
ribosomal RNA bands and quantitated on a Betagen Betascope 
603 blot analyzer. (C) Western blot analysis of p53 protein 
levels in human cell lines. Whole cell protein extracts (3 
X 105 cell equivalents) were fractionated on a 10% 
polyacrylamide gel, transferred to nitrocellulose and 
immunoblotted with an anti-p53 antibody as described in the 
methods. p53 protein levels were quantitated by 
densitometric analysis of autoradiographs. 
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Southern blot analysis of Colo320HSR, HT-29, and BE 
cells revealed no gross differences in p53 gene structure 
when compared to the HeLa cell line which is known to contain 
a wild-type p53 gene (325 and references within) (Figure 18A) . 
No major differences in the expression of p53 mRNA in the 
three cell lines were detected when compared to HeLa cells by 
northern blot analysis (Figure 18B) . Western blot analysis 
showed that p53 protein was grossly overexpressed in the 
Colo320HSR, HT-29, and BE cell lines when compared to the 
IMR-90 and HeLa cell lines, both of which contain wild-type 
p53 protein (Figure 18C) . HL-60 cells were included in the 
analysis as the negative western blot control since this cell 
line is null for the p53 gene and does not express p53 
protein. The wild-type p53 protein has a very short half 
life (approximately 15 min) (269) and is present in 
proliferating cells at low levels. The mutant forms of p53 
protein tend to have longer half lives than the wild-type 
protein (several hours), and therefore, are overexpressed 
(287,288). These results suggested that the Colo320HSR, HT-
29, and BE cell lines all expressed a mutant p53 protein. 
THE COL0320HSR, HT-29, AND BE CELL LINES EXPRESS A MUTANT 
FORM OF THE P53 PROTEIN 
The existence of mutant p53 protein in the three cell 
lines was confirmed by immunoprecipitation analysis. 
Immunoprecipitation with an antibody that recognized both the 
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Figure 19. Immunoprecipitation analysis of p53 protein 
status (wild-type versus mutant) in the Colo320HSR, HT-29, 
and BE human colon carcinoma cell lines. 
p53 protein was immunoprecipitated from 1 X 106 cells as 
described in the methods using either the Ab-6 or Ab-3 
monoclonal antibody. The Ab-6 antibody recognized both the 
wild-type and mutant forms of the p53 protein (top panel) 
while the Ab-3 antibody recognized only the mutant form of 
the p53 protein (bottom panel) . Extracts from each cell line 
were immunoprecipitated with a specific Ab (Ab-6 or Ab-3) and 
an isotype control Ab ( IgG2a (UPClO) for Ab-6 and IgG1 (MOPC21) for Ab-3). The HL-60 cell line had a deleted p53 
gene and served as a negative control for the presence of p53 
protein. The HeLa cell line had a wild-type p53 gene and 
served as the positive control for the presence of wild-type 
p53 protein. The data shown were representative of three 
independent experiments. 
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Figure 20. Changes in p53 protein levels in human colon 
carcinoma cell lines following exposure to equi-cytotoxic 
concentrations of HN2. 
Colo320HSR (A) , HT-29 (B) , and BE (C) cells were exposed 
to 6, 10, and 30 µM HN2, respectively, for 1 hand whole cell 
protein extracts were isolated at various times following 
drug removal. Unattached HT-29 and BE cells were added back 
to the attached population of cells for analysis. Extracts 
from 5 X 105 cell equivalents (Colo320HSR) or 2.5 X 105 cell 
equivalents (HT-29 and BE) were subjected to SDS-PAGE 
followed by western blot analysis. p53 protein was sized by 
comparison to protein molecular weight standards. Controls 
(C) were run at each time point to reduce the variability 
resulting from uneven protein transfer across the membrane. 
The transfer efficiency was monitored by coomassie staining 
of post-transferred gels. The membranes used for this study 
were the same membranes used in the c-myc study (Figure 6) . 
After detection of c-myc protein, the membranes were stripped 
of Ab as described in the methods and re-immunoblotted with 
the Ab-6 anti-human p53 Ab (2 µg/ml) . 
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Figure 21. Time course analysis of the effect of equi-
cytotoxic concentrations of nitrogen mustard on p53 protein 
levels in human colon carcinoma cell lines. 
A graphic representation of the previous figure showing 
the time course changes in p53 protein levels in the 
Colo320HSR, HT-29, and BE cell lines following exposure to 6, 
10, and 30 µM HN2, respectively. Protein levels were 
quantitated by densitometric analysis of autoradiographs and 
presented as the percent change relative to time point 
controls. Data points represented the mean± SEM of at least 
three independent experiments. 
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wild-type and mutant form of the human p53 protein showed 
that the Colo320HSR, HT-29, BE, and HeLa cell lines all 
contained p53 protein, however, levels in the three colon 
carcinoma cell lines were greatly overexpressed relative to 
the HeLa cell line. Immunoprecipitation with an antibody 
that recognized only the mutant form of the human p53 protein 
showed that mutant p53 was present in the three colon 
carcinoma cell lines but not in the HeLa cell line (Figure 
19) . The HL-60 cell line is null for the p53 gene and 
therefore expressed no p53 protein. These results confirmed 
the presence of the mutant form of the p53 protein in the 
Colo320HSR, HT-29, and BE cell lines. 
NITROGEN MUSTARD DOES NOT AFFECT P53 PROTEIN EXPRESSION IN 
THE COL0320HSR, HT-29, AND BE CELL LINES 
The effect of HN2 on p53 protein expression was 
determined by western blot analysis. These studies showed 
that p53 protein levels were essentially unchanged in 
Colo320HSR, HT-29, or BE cells treated with HN2 (Figure 20A, 
B, and C) . Quantitation of these data showed that p53 
protein levels in treated cells were no different than 
controls, even at the 72 and 96 h time points (Figure 21). 
The mutant status and the lack of induction of the p53 
protein following HN2 treatment in the Colo320HSR cell line 
were inconsistent with the outcomes predicted by the working 
hyPothesis. The fact that an enhanced induction of apoptosis 
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occurred in Colo320HSR cells and that apoptosis still 
occurred in HT-29 and BE cells, despite the presence of a 
mutant p53 protein in all three cell lines, suggested that 
the induction of apoptosis in the Colo320HSR, and possibly 
the HT-29 and BE cell lines, following HN2 exposure was 
regulated in a wild-type p53-independent manner. 
Ectopic overexpression of bcl-2 protein in many cell 
types has been shown to block or delay the onset of apoptosis 
induced by a variety of physiological stimuli and 
chemotherapeutic agents (164,165,234-238). Bcl-2 has also 
been shown to be capable of blocking the c-myc enhancement of 
apoptosis and can cooperate with c-myc in tumorigenesis 
(190,192). Therefore, the following hypothesis was tested: 
bcl-2 regulates the c-myc enhancement of apoptosis in a 
subset of human colon carcinoma cell lines following HN2 
exposure. 
BCL-2 PROTEIN IS NOT OVEREXPRESSED IN THE COL0320HSR, HT-29, 
OR BE CELL LINES 
If bcl-2 were involved in the regulation of apoptosis in 
these cell lines, the simplest explanation would be that bcl-
2 protein is overexpressed in those cell lines which are 
refractory to the c-myc enhancement of apoptosis. Based upon 
this logic, the HT-29 and BE cell lines would be predicted to 
have high levels of bcl-2 protein. 
tested by characterizing bcl-2 
This prediction was 
gene structure, mRNA 
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Figure 22. Analysis of the bcl-2 oncogene and bcl-2 mRNA and 
protein levels in the Colo320HSR, HT-29, and BE human colon 
carcinoma cell lines. 
(A) Southern blot analysis of EcoRI and BamHI 
restriction endonuclease digested genomic DNA from the 
colo320HSR, HT-29, and BE cell lines. Ten µg of cut genomic 
DNA from each cell line was fractionated on a 0.5% agarose 
gel, Southern blotted, and hybridized with a 32P-labeled 447 
bp bcl-2 cDNA probe. DNA fragments were sized by comparison 
to a 1 kb DNA ladder as indicated to the left of the 
photograph. (B) Reverse transcription-PCR analysis of bcl-2 
mRNA expression in human colon carcinoma cell lines. One µg 
of total RNA from each cell line was reverse transcribed as 
described in the methods. One fourth of the RT reaction was 
used for PCR amplification of 0 6 methyl guanine DNA methyl 
transferase (MGMT) cDNA (730 bp) which served as a positive 
control for the reverse transcription reaction. The 
Colo320HSR and BE cells were classical Mer- (Methylation 
Repair deficient) cell lines and did not express detectable 
levels of MGMT mRNA, while the HT-29 cells were classically 
Mer+ and showed a high level of MGMT mRNA expression. The 
lanes marked + or - under the MGMT section were PCR reactions 
using the MGMT primer pair with or without a MGMT 730 bp 
template added, respectively. These reactions were the 
negative and positive PCR controls. Three fourths of the RT 
product was used in a PCR amplification reaction using a bcl-
2 primer pair (see methods) which amplified a 447 bp exon 
1/exon 2 cDNA fragment. The lane marked - under the bcl-2 
section was the negative PCR control using the bcl-2 primer 
pair with no template added. The HL-60 cell line was 
included as a positive control for the presence of bcl-2 
mRNA. A 123 bp DNA ladder was included in the left most lane 
to size the PCR amplification products after they were 
electrophoresed through a 1. 5% agarose gel. (C) Western 
blot analysis of bcl-2 protein levels in the Colo320HSR, HT-
29, and BE cell lines. Whole cell protein extracts from the 
Colo320HSR, HT-29, BE (5 X 105 cell equivalents) and LM-EBV 
(3 X 105 cell equivalents) cell lines were fractionated on a 
12.5% SDS-polyacrylamide gel, transferred to nitrocellulose 
and immunoblotted with an anti-bcl-2 Ab (5 µg/ml) as 
described in the methods. The 26 kDa bcl-2 protein was sized 
by comparison to protein molecular weight markers and 
quantitated by densitometric analysis of autoradiographs. 
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expression, and protein expression in the Colo320HSR, HT-29, 
and BE cell lines. Southern blot analysis showed no gross 
differences in gene structure between the three cell lines. 
Two restriction fragment length polymorphisms existed for the 
bcl-2 gene when digested with the restriction endonuclease, 
EcoRI. Colo320HSR cells were homozygous for one polymorphism 
while the HT-29 and BE cells were homozygous for the other 
polymorphism. The HL-60 cell line was heterozygous for these 
two polymorphisms (Figure 22A) . Reverse transcription-PCR 
analysis revealed the presence of bcl-2 mRNA in the HL-60 
(positive control cell line), Colo320HSR, and BE cell lines. 
Bcl-2 mRNA was present in HT-29 cells, but was barely 
detectable (Figure 22B) . Immunoblot analysis showed that 
none of the three cell lines grossly overexpressed bcl-2 
protein (Figure 22C) . The LM-EBV cell line was included in 
this analysis because it overexpressed bcl-2 protein. Bcl-2 
protein was present in both Colo320HSR and BE cells but was 
undetectable in HT-29 cells. These results showed that bcl-2 
protein was not constitutively overexpressed in any of these 
three colon carcinoma cell lines. 
BCL-2 PROTEIN LEVELS ARE ELEVATED IN THE COL0320HSR AND BE 
CELL LINES FOLLOWING EXPOSURE TO HN2 
The lack of any constitutive overexpression of bcl-2 
protein in these colon carcinoma cell lines prompted the 
search for a more complex explanation of how bcl-2 was 
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Figure 23. Time course analysis of the effect of nitrogen 
mustard on bcl-2 protein levels in the Colo320HSR and BE 
human colon carcinoma cell lines. 
Colo320HSR (A) and BE (B) cells were exposed to 6 and 30 
µM HN2, respectively, for 1 hand whole cell protein extracts 
were isolated at various times following drug removal. Both 
unattached and attached BE cells were combined for analysis. 
Extracts from Colo320HSR (4 X 105 cell equivalents) and BE 
(2.5 X 105 cell equivalents) cells were fractionated on 12.5% 
SDS-polyacrylamide gels, transferred to nitrocellulose and 
immunoblotted with an anti-bcl-2 Ab as described in the 
methods. Controls (C) were run at each time point to reduce 
the variability resulting from uneven protein transfer across 
the membrane. Transfer efficiency was monitored by coomassie 
staining of post-transferred gels. LM-EBV cell extracts were 
included in the left most lane to serve as a positive control 
for the presence of bcl-2 protein. {C) Quantitative 
analysis of changes in bcl-2 protein levels in Colo320HSR and 
BE cells following HN2 treatment. Bcl-2 protein levels were 
quantitated by densitometric analysis of autoradiographs and 
expressed as the percent change relative to controls. The 
data were presented as the mean ± SEM of at least three 
independent experiments. Data points existed where the error 
bars fell within the symbol. 
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possibly regulating apoptosis. A plausible explanation could 
be that HN2 induced the expression of bcl-2 protein, 
therefore, bcl-2 protein levels would be predicted to 
increase in HT-29 and BE cells after HN2 treatment. This 
hypothesis was tested by analyzing bcl-2 protein levels in 
Colo320HSR, HT-29, and BE cells at various times following 
HN2 exposure. 
The results from these studies showed no apparent 
increase in bcl-2 protein levels in HT-29 cells (data not 
shown) . Treatment of both Colo320HSR and BE cells with HN2 
resulted in an increase in the level of bcl-2 protein at 
various times following drug removal (Figure 23A and B, 
respectively) . Bcl-2 protein levels were increased 
approximately 3-4 fold in Colo320HSR cells from 12 to 72 h 
following drug treatment (Figure 23C) . BE cells treated with 
HN2 showed an initial decrease (approximately 50%) in bcl-2 
protein levels through 24 h. The decrease in bcl-2 protein 
was followed by a large induction from 48-96 h, with a 
maximum increase of 12-16 fold at 72 h (Figure 23C) . 
Endogenous bcl-2 did not appear to regulate the 
induction of apoptosis in the Colo320HSR and HT-29 cell lines 
following HN2 exposure since bcl-2 was not greatly induced 
and both cell lines underwent apoptosis. The large induction 
of bcl-2 protein in BE cells occurred from 48-96 h and 
previous results showed that the viability of BE cells 
following HN2 exposure was maintained at 50% from 96 h out to 
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seven days and that the level of apoptotic events were low in 
this cell line. Taken together, the results for BE cells 
were consistent with the possibility that bcl-2 was delaying 
the death of these cells. Other factors known to be involved 
in the bcl-2 system (bcl-x, bax, bad, and bag-1) were not 
examined in these studies. Further studies need to be 
performed to clarify the role of bcl-2 in BE cells. 
The results from studies on p53 and bcl-2 were 
inconsistent with the involvement of these gene products in 
the abrogation of c-myc-enhanced apoptosis and suggested that 
other abrogating mechanisms existed in these cell lines. 
Therefore, members of the myc transcription factor network 
were investigated to determine their involvement, if any, in 
the regulation of c-myc-enhanced apoptosis. c-Myc belongs to 
a transcription factor network which includes its only known 
binding partner, max (414) c-Myc and max form heterodimers 
via their complimentary helix-loop-helix/leucine zipper 
(HLH/LZ) regions (414). Dimerization with max is required 
for the dose-dependent regulation of apoptosis which is 
thought to involve the specific binding of DNA and 
transactivation of genes (426,432). The level of c-myc/max 
heterodimers formed in a cell is determined by the ratio of 
c-myc and mad proteins and in normal cells is thought not to 
be limited by max protein (415) . Mad heterodimerizes with 
max and antagonizes the transcriptional activation abilities 
of c-myc/max dimers by competitively binding to the same 
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consensus E-box motif (415) . 
current serum starvation models of c-myc-enhanced 
apoptosis suggest that constitutive expression of c-myc leads 
to high levels of c-myc/max dimers which transactivate genes 
involved in the regulation of apoptosis ( 432) . The apoptotic 
regulatory machinery set into place by c-myc expression is 
thought to be present prior to the block to replication 
imparted by serum starvation, but its activation is inhibited 
(432). However, data from the same and other studies have 
shown that the activation of a chimeric c-myc/ER protein in 
serum starved, growth arrested cells resulted in the rapid 
induction of apoptosis suggesting that the apoptotic 
regulatory system affected by c-myc expression can be 
functionally induced after the replication block is in place 
(327,432). The following working hypothesis was proposed to 
address the role of myc transcription factor network proteins 
in the regulation of c-myc-enhanced apoptosis: Genes, other 
than c-myc, which belong to the myc transcription factor 
network are capable of modulating c-myc-enhanced apoptosis in 
human tumor cell lines which overexpress c-myc protein. 
Initial studies were based upon the assumption that the 
apoptotic regulatory machinery was already in place at the 
time of HN2 exposure as a result of c-myc overexpression. 
The c-myc enhancement of apoptosis has been shown to occur in 
a manner that is dependent upon the dose of c-myc (431,432). 
Therefore, c-myc-enhanced apoptosis would be predicted to 
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Figure 24. Comparison of the levels of p21/22 max protein, 
c-myc/max protein heterodimers, and p35 mad protein in the 
colo320HSR, HT-29, and BE human colon carcinoma cell lines. 
(A) Coprecipitation of c-myc and max proteins from 5 X 
106 Colo320HSR, HT-29, and BE cells using an anti-max rabbit 
polyclonal Ab as described in the Methods. 
rmmunoprecipitated proteins were fractionated by SDS-PAGE and 
transferred to nitrocellulose. The membrane was cut in half 
and the top portion (~ 45 kDa) was immunoblotted with an 
anti-myc polyclonal Ab while the bottom half (s 45 kDa) was 
immunoblotted with an anti-max polyclonal Ab. The p21/22 max 
bands were indicative of the total amount of 
immunoprecipitable max protein in each cell line. The p64 c-
myc band did not reflect the total cellular level of c-myc 
protein but rather was indicative of the amount of c-myc 
which was coprecipitable with max and thus represented the 
level of c-myc/max heterodimers in each cell line. The 
figure shown is representative of three independent 
experiments. Two to four independent cell isolations of each 
cell line were immunoprecipitated in each experiment. (B) 
Immunoblot analysis of p35 mad protein levels in the 
Colo320HSR, HT-29, and BE cell lines. Whole cell lysates 
from 3 X 105 cell equivalents were fractionated on a 12.5% 
SDS-polyacrylamide gel, transferred to nitrocellulose, and 
immunoblotted with an anti-mad rabbit polyclonal Ab as 
described in the methods. The mad protein was previously 
characterized and shown to migrate as a 35 kDa doublet. The 
relative positions of protein molecular weight size markers 
were shown to the left of the gel. Two independent protein 
isolations of each cell line were shown and were 
representative of at least four separate experiments. 
Antigen peptide blocking of the anti-mad Ab revealed the 
presence of several specific protein bands which included the 
35 kDa doublet and other bands at 24 kDa, 44 kDa and 55 kDa. 
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occur more readily in cells that have a higher ratio of c-
myc/max to mad/max heterodimers and max/max homodimers. 
previous results suggest that apoptosis is enhanced in the 
colo320HSR cell line which expresses high levels of c-myc 
protein, but not in the HT-29 or BE cell lines. Therefore, 
colo320HSR cells would be expected to have the highest ratio 
of c-myc/max to mad/max heterodimers and max/max homodimers 
compared to HT-29 and BE cells. 
CHARACTERIZATION OF THE MYC TRANSCRIPTION FACTOR NETWORK IN 
COL0320HSR, HT-29, AND BE HUMAN COLON CARCINOMA CELLS 
To test this prediction, the levels of c-myc, max, mad, 
and c-myc/max heterodimers were compared between the 
Colo320HSR, HT-29, and BE cell lines. c-Myc protein levels 
were approximately 7 fold higher in Colo320HSR cells compared 
to both HT-29 and BE cells (Figure 2B and C) . Max protein 
levels were 2-3 fold and 5-7 fold greater in BE cells 
relative to Colo320HSR and HT-29 cells, respectively (Figure 
24A) . The levels of mad protein in the HT-29 and BE cell 
lines were similar and approximately 3 fold greater relative 
to Colo320HSR cells (Figure 24B) . The levels of c-myc/max 
dimers were 2 and 4 fold higher in Colo320HSR cells relative 
to BE and HT-29 cells, respectively (Figure 24A) . The level 
of mad/max dimers were not determined in these studies. 
These results and others (data not shown, and Figure 
25A) provided indirect evidence that max levels were limiting 
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in the formation of c-myc/max dimers in the Colo320HSR cell 
line and perhaps HT-29 cells, not c-myc, as was the case in 
BE cells. Therefore, the difference in c-myc/max dimer 
levels between the cell lines was less than would have been 
predicted based upon c-myc protein levels alone. The 
question arises about whether a 2 fold difference in c-
myc/max dimer levels is sufficient to account for the 
differences observed in the 
apoptosis in these cell lines. 
outcome of c-myc-enhanced 
The observation that all 
available max protein was dimerized with c-myc, and that mad 
levels were low, was consistent with the possibility that 
mad/max and max/max dimers were not present in Colo320HSR 
cells. Max protein was in slight excess over c-myc in HT-29 
cells, and in large excess over c-myc in BE cells. Mad 
protein levels were relatively high in both HT-29 and BE 
cells. These results were consistent with the possibility 
that mad/max dimers existed in HT-29 cells, and that both 
mad/max and max/max dimers existed in BE cells, and were 
antagonistic to the function of c-myc/max dimers. Therefore, 
in comparison to BE and HT-29 cells, the transcriptional 
activation abilities of c-myc/max dimers in Colo320HSR cells 
would actually be greater than the 2 or 4 fold difference 
predicted by dimer levels. These results were consistent 
with the possibility that the apoptotic machinery was in 
place prior to HN2 exposure and the occurrence of c-myc-
enhanced apoptosis in these cell lines was determined by the 
166 
differences in the transcriptional activation abilities of c-
myc/max dimers. However, the lack of direct evidence for the 
presence of mad/max dimers in these cell lines leaves these 
results open to alternative interpretations. 
If the differences in the levels of functional c-myc/max 
dimers was not sufficient to explain why apoptosis was 
enhanced in Colo320HSR cells but not HT-29 or BE cells, then 
another possibility was that the myc network was being 
modulated in response to HN2 treatment. This assumption 
predicts that HN2 would induce changes in the expression of 
genes belonging to the myc network and alter the levels of c-
myc/max (and possibly mad/max) dimers. Therefore, cells 
which undergo enhanced apoptosis would have increased levels 
of c-myc/max dimers following HN2 treatment, while cells 
which failed to enhance the induction of apoptosis would show 
either a decrease in c-myc/max dimers and/or an increase in 
mad/max (max/max) dimers. Experiments were performed to rule 
out the possibility that the myc network was being altered 
following HN2 exposure. 
THE INCREASE IN C-MYC/MAX HETERODIMER LEVELS IN COL0320HSR 
CELLS FOLLOWING HN2 EXPOSURE OCCURS PRIOR TO THE ONSET OF 
APOPTOSIS AND CORRELATES WITH THE INDUCTION OF P21/22 MAX 
Coimmunoprecipitation time course studies using an anti-
human p21/22 max Ab showed that max protein was induced by 
HN2 (Figure 25A) . The initial induction of p21/22 max was 
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Figure 25. Changes in myc transcription factor network 
protein levels (c-myc, max, and c-myc/max heterodimers) in 
colo320HSR human colon carcinoma cells following exposure to 
nitrogen mustard. 
(A) Coimmunoprecipitation analysis of the effect of 
nitrogen mustard on max protein and coprecipitable c-myc 
protein (c-myc/max heterodimers) levels in Colo320HSR cells. 
Cells were treated with 6 µM HN2 for 1 h. Whole cell protein 
extracts were isolated from 5 X 106 cells at various times 
following drug removal using a low stringency 
immunoprecipitation lysis buffer. An anti-max rabbit 
polyclonal Ab was used to coimmunoprecipitate c-myc and max 
proteins as described in the methods. Immunoprecipi tated 
proteins were then fractionated on a 10% SDS-polyacrylamide 
gel and transferred to nitrocellulose. The membrane was cut 
in half and the top part (~ 45 kDa) was immunoblotted with an 
anti-myc polyclonal Ab while the bottom half (s 45 kDa) was 
immunoblotted with the anti-max polyclonal Ab. Proteins on 
both halves of the membrane were detected by enhanced 
chemiluminescence, after which the membrane halves were 
realigned and exposed to autoradiographic film. The p64 c-
myc protein was coprecipitated along with the p21/22 human 
max protein. The band below the p64 c-myc band was the 
rabbit IgG heavy chain from the immunoprecipitation step 
which was recognized by the anti-rabbit IgG secondary Ab used 
in the immunoblotting procedure. The specificity of the myc 
and max bands was ascertained by immunoprecipitating a sample 
with a peptide antigen-blocked anti-max Ab. Briefly, 0.1 µg 
of anti-max Ab was incubated with 1 µg of max peptide antigen 
for 1 h at room temperature and then used to 
coimmunoprecipitate c-myc and max as previously described. 
(B) Time course analysis of the changes in c-myc, p21/22 
max, and c-myc/max heterodimer levels in Colo320HSR cells 
following exposure to HN2. A graphical representation of the 
data from figure 6A (c-myc protein levels) and from the 
coimmunoprecipitation studies presented above. Protein 
levels were quantitated by densitometric analysis of 
autoradiographs and presented as the percent change relative 
to the control. Data points for coimmunoprecipitation 
studies represented the mean ± SEM of four independent 
experiments. Error bars fell within the symbol on some data 
points. 
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approximately 7 fold by 12 h following drug removal and 
remained above control levels through 48 h. A maximal 22 
fold induction of max protein was observed at the 24 h time 
point (Figure 25B) . Coprecipitable levels of c-myc protein 
(indicative of c-myc/max dimers) also increased following 
nitrogen mustard treatment (Figure 25A) . The levels of c-
myc/max dimers (coprecipitable c-myc) increased approximately 
3 fold at 18 h following drug removal and were maximally 
induced by approximately 5 fold at 24 h (Figure 25B) . 
Following HN2 exposure, c-myc protein levels did not change 
through 24 h and then were reduced by 52% and 69% at 48 and 
72 h, respectively (Figure 25B) . 
These results provided indirect evidence that max 
protein was limiting in Colo320HSR cells, not c-myc. These 
results also showed that the myc network was modulated by 
nitrogen mustard prior to the induction of apoptosis in a 
manner that was consistent with the possibility that the 
increase in c-myc/max dimers was involved in the enhancement 
of apoptosis in the Colo320HSR cell line. 
THE DECREASES IN C-MYC/MAX HETERODIMER LEVELS IN HT-29 AND BE 
CELLS FOLLOWING HN2 EXPOSURE ARE CONSISTENT WITH THE LACK OF 
AN ENHANCED INDUCTION OF APOPTOSIS AND OCCURS DESPITE AN 
INCREASE IN BOTH C-MYC AND MAX PROTEINS 
Initial studies in HT-29 cells showed that c-myc 
protein levels increased over a 96 h time course following 
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Figure 26. Changes in myc transcription factor network 
protein levels (c-myc, max, and c-myc/max heterodimers) in 
HT-29 human colon carcinoma cells following exposure to 
nitrogen mustard. 
(A) Coimmunoprecipitation analysis of the effect of 
nitrogen mustard on max protein and coprecipitable c-myc 
protein (c-myc/max heterodimers) levels in HT-29 cells. 
cells were treated with 10 µM HN2 for 1 h. Whole cell 
protein extracts were isolated from 5 X 106 cells at various 
times following drug removal using a low stringency 
immunoprecipitation lysis buffer. Unattached cells from the 
later times points were included in the analysis. An anti-
max rabbit polyclonal Ab was used to coimmunoprecipitate c-
myc and max proteins as described in the methods. 
rmmunoprecipitated proteins were then fractionated on a 10% 
SDS-polyacrylamide gel and transferred to nitrocellulose. 
The membrane was cut in half and the top part (~ 45 kDa) was 
immunoblotted with an anti-myc polyclonal Ab while the bottom 
half (s 45 kDa) was immunoblotted with the anti-max 
polyclonal Ab. Proteins on both halves of the membrane were 
detected by enhanced chemiluminescence, after which the 
membrane halves were realigned and exposed to 
autoradiographic film. The p64 c-myc protein was 
coprecipitated along with the p21/22 human max protein. The 
band below the p64 c-myc band was the rabbit IgG heavy chain 
from the immunoprecipitation step which was recognized by the 
anti-rabbit IgG secondary Ab used in the immunoblotting 
procedure. The specificity of the c-myc and max bands was 
ascertained by immunoprecipitating a sample with a peptide 
antigen-blocked anti-max Ab. Briefly, 0.1 µg of anti-max Ab 
was incubated with 1 µg of max peptide antigen for 1 h at 
room temperature and then used to coimmunoprecipitate c-myc 
and max as previously described. (B) Time course analysis 
of the changes in c-myc, p21/22 max, and c-myc/max 
heterodimer levels in HT-29 cells following exposure to HN2. 
A graphical representation of the data from figure 6B (c-myc 
protein levels) and from the coimmunoprecipitation studies 
presented above. Protein levels were quantitated by 
densitometric analysis of autoradiographs and presented as 
the percent change relative to the control. Data points for 
coimmunoprecipitation studies represented the mean ± SEM of 
four independent experiments. Error bars fell within the 
symbol on some data points. 
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in myc transcription factor network 
max, and c-myc/max heterodimers) in BE 
cells following exposure to nitrogen 
(A} Coimmunoprecipitation analysis of the effect of 
nitrogen mustard on max protein and coprecipitable c-myc 
protein (c-myc/max heterodimers) levels in BE cells. Cells 
were treated with 30 µM HN2 for 1 h. Whole cell protein 
extracts were isolated from 5 X 106 cells at various times 
following drug removal using a low stringency 
immunoprecipitation lysis buffer. Unattached cells from the 
later time points were included in the analysis. An anti-max 
rabbit polyclonal Ab was used to coimmunoprecipitate c-myc 
and max proteins as described in the methods. 
Immunoprecipitated proteins were then fractionated on a 10% 
SDS-polyacrylamide gel and transferred to nitrocellulose. 
The membrane was cut in half and the top part (~ 45 kDa) was 
immunoblotted with an anti-myc polyclonal Ab while the bottom 
half (s 45 kDa) was immunoblotted with the anti-max 
polyclonal Ab. Proteins on both halves of the membrane were 
detected by enhanced chemiluminescence, after which the 
membrane halves were realigned and exposed to 
autoradiographic film. The p64 c-myc protein was 
coprecipitated along with the p21/22 human max protein. The 
band below the p64 c-myc band was the rabbit IgG heavy chain 
from the immunoprecipitation step which was recognized by the 
anti-rabbit IgG secondary Ab used in the immunoblotting 
procedure. The specificity of the c-myc and max bands was 
ascertained by immunoprecipitating a sample with a peptide 
antigen-blocked anti-max Ab. Briefly, 0.1 µg of anti-max Ab 
was incubated with 1 µg of max peptide antigen for 1 h at 
room temperature and then used to coimmunoprecipitate c-myc 
and max as previously described. (B) A shorter exposure of 
the p21/22 max band emphasizing the subtle changes in max 
levels. (C) Time course analysis of the changes in c-myc, 
p21/22 max, and c-myc/max heterodimer levels in BE cells 
following exposure to HN2. A graphical representation of the 
data from figure 6C (c-myc protein levels) and from the 
coimmunoprecipitation studies presented above. Protein 
levels were quantitated by densitometric analysis of 
autoradiographs and presented as the percent change relative 
to the control. Data points for coimmunoprecipitation 
studies represented the mean ± SEM of four independent 
experiments. Error bars fell within the symbol on some data 
points. 
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BN2 exposure (Figure 26B) . Coimmunoprecipitation studies in 
BT-29 cells showed that p21/22 max was also induced by HN2 
(Figure 26A) Max protein levels were induced as early as 15 
h following drug removal and remained above control levels 
through 72 h, returning to control values by 96 h. Peak 
induction of max protein occurred at 24 and 48 h (almost 3 
fold) (Figure 26B) . c-Myc/max dimer levels never increased 
above control levels following HN2 exposure, despite the 
increase in both c-myc and max protein levels (Figure 26A) . 
Dimer levels were decreased by approximately 44% at the 15 h 
time point, returned to control levels by 24 h, and then 
progressively declined through 96 h (Figure 26B) . The 
decreases in c-myc/max dimer levels at the 48, 72, and 96 h 
time points were 
respectively. 
approximately 40%, 54%, and 75%, 
c-Myc protein levels were also increased in BE cells 
over a 96 h time course following exposure to HN2 (Figure 
27C). Max protein levels showed only a small induction (< 2 
fold) in BE cells following HN2 exposure (Figure 27B and C) , 
however max protein was previously shown to be in vast excess 
over c-myc protein. The level of c-myc/max dimers in HN2-
treated BE cells never increased above control values (Figure 
27A and C) . Dimer levels were reduced approximately 21% at 
the 15 h time point, returned to control levels by 24 h, and 
then progressively declined over the remaining time course. 
Dimer levels were reduced by approximately 31%, 60%, and 83% 
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at the 48, 72, and 96 h time points, respectively (Figure 
27C) · 
The results from the studies of HT-29 and BE cells 
showed that the formation of c-myc/max dimers was a complex 
process that was regulated by more than just the mere 
presence of c-myc and max proteins. The c-myc/max dimer 
levels in both of these cell lines were never increased above 
control levels despite conditions in both cell types that 
would have predicted an increase in dimers. The decrease in 
c-myc/max dimer levels in both HT-29 and BE cells occurred 
before the loss of viability and appearance of apoptotic 
events in either cell line. These results were consistent 
with the possibility that the decrease in c-myc/max dimers 
following HN2 exposure was involved in preventing the 
enhancement of apoptosis in the HT-29 and BE cell lines. 
The results from the myc network studies provided 
support for the possibility that the pretreatment status of 
the myc network in Colo320HSR, HT-29, and BE cells was 
sufficient to account for the differences observed in the c-
myc enhancement of apoptosis after HN2 treatment. These 
results indicated that enhanced apoptosis may not be 
accurately predicted by the simple comparison of c-myc 
protein levels. The results from these studies also showed 
that the myc transcription factor network was modulated by 
exposure to nitrogen mustard, and were consistent with the 
possibility that the c-myc enhancement of apoptosis in human 
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Figure 28. The relative changes in c-myc/max heterodimer 
levels in the Colo320HSR, HT-29, and BE human colon carcinoma 
cell lines following exposure to nitrogen mustard. 
A time course analysis of the relative changes in c-
myc/max heterodimer levels in three human colon carcinoma 
cell lines following treatment with equi-cytotoxic 
concentrations of HN2. The data were taken from Figures 25-
27 and were expressed as the percent change of control 
relative to HT-29 cells. The relative control levels of 
heterodimers in the three cell lines were determined from the 
results presented in Figure 24A. The data were presented as 
the mean ± SEM of four independent experiments. Error bars 
fell within the symbol on some data points. Note the break 
in the y-axis. 
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tumor cells was determined, in part, by the response of the 
royc transcription factor network to chemotherapeutic agent 
exposure. This possibility was difficult to refute when the 
changes in c-myc/max dimer levels in Colo320HSR, HT-29, and 
BE cells following HN2 exposure were graphed relative to the 
pretreatment dimer levels in HT-29 cells. These results 
demonstrated that, although pretreatment levels of c-myc/max 
dimers in Colo320HSR cells were 4 fold higher than in HT-29 
cells, this relative difference was approximately 19-20 fold 
higher in Colo320HSR cells by 24 h after treatment with HN2 
(Figure 28) . The possibility that these HN2-induced changes 
in the myc transcription factor network were positively and 
negatively influencing the c-myc enhancement of apoptosis in 
these cell lines was strongly supported by the dose-dependent 
nature of c-myc-enhanced apoptosis. Evidence supporting both 
assumptions was presented, and the c-myc enhancement of 
apoptosis may be influenced by both factors. These results 
showed that max was induced in response to HN2 in a cell 
type-dependent manner. Taken together, these studies 
provided evidence supporting the hypothesis that genes, other 
than c-myc, which belong to the myc transcription factor 
network, were capable of regulating the c-myc enhancement of 
apoptosis in human tumor cell lines. 
ANTISENSE C-MYC STUDIES 
The modulation of c-myc protein by antisense ODNs 
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directed against c-myc mRNA was attempted in Colo320HSR cells 
to directly address the role of c-myc/max dimer increases in 
the enhancement of apoptosis following HN2 treatment. The 
goal of these studies was to prevent the HN2-induced increase 
in c-myc/max dimers by treatment of cells with antisense ODNs 
targeted against c-myc. The prevention of dimer increases 
would be expected to inhibit or delay the onset of apoptosis 
in Colo320HSR cells following HN2 exposure if these newly 
formed dimers were involved in the enhancement of apoptosis. 
Antisense molecules were delivered to Colo320HSR cells 
by various methods. However, consistent reductions in c-myc 
protein could not be achieved. One antigene and 2 antisense 
ODNs (unmodified) targeted to different regions of the c-myc 
gene or mRNA, respectively, were used in these preliminary 
studies along with a phosphorothioated antisense ODN. The 
ODN' s were delivered to either untreated cells or cells whose 
membranes were made permeable. ODNs delivered to non-
permiabilized cells were added directly to culture media 
which contained serum (5%, 10%, or 15%) that was either DNase 
inactivated or not. Concentration-response, along with both 
short and long term time course studies were done with the 
ODNs using the various conditions previously described. Long 
term time course studies were done in which antisense 
molecules were added to the culture media every 12 or 24 h. 
None of these attempts at antisense modulation consistently 
reduced c-myc protein levels in Colo320HSR cells. Studies 
179 
involving the antisense modulation of c-myc were therefore 
dropped, because of the potential difficulties in 
interpreting the data obtained from such experiments. 
CHAPTER 4 
DISCUSSION 
This dissertation attempts to clarify the involvement of 
the c-myc oncogene in bifunctional alkylating agent-induced 
cytotoxicity in human colon carcinoma cell lines. The 
initial investigations were performed prior to the discovery 
of the role of c-myc in the enhancement of apoptosis and were 
based upon the known role of c-myc in the regulation of 
cellular proliferation. The remaining studies dealt with the 
apoptotic functions of c-myc and genes which were thought to 
be capable of regulating this function. The studies in this 
dissertation were not intended to "close the book" on this 
area of research, an accomplishment that literally hundreds 
of studies have yet to achieve. The purpose of this document 
is simply to make a small, yet hopefully meaningful, 
contribution to the field and to provide further insight into 
how human tumor cells respond to chemotherapeutic agent 
exposure and ultimately survive or die. 
To this end, these data show that the cytotoxic effects 
of the bifunctional alkylating agent, nitrogen mustard, were 
not mediated by specific reductions in c-myc expression in 
three human colon carcinoma cell lines. Therefore, these 
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data do not support the hypothesis that chemotherapeutic 
agents exert their anti-neoplastic activities by inhibiting 
cellular proliferation via the specific down-regulation of 
critical cellular oncogene expression. The results from the 
remaining studies are consistent with a role for c-myc in the 
enhancement of apoptosis in human tumor cells exposed to 
chemotherapeutic agents and describes a novel mechanism by 
which c-myc-enhanced apoptosis may be regulated in human 
colon carcinoma cell lines exposed to HN2. 
ANTI-NEOPLASTIC ACTIVITY OF NITROGEN MUSTARD AND EFFECTS ON 
C-MYC EXPRESSION 
The alkylating agents are clinically effective and are 
incorporated into many of the combination-chemotherapeutic 
regimens used in the fight against human cancers (1, 2). 
Al though the cross linking of DNA appears to be important, the 
mechanism by which these drugs exert their anti-neoplastic 
activity remains to be fully elucidated (15,20). One 
hypothesis suggests that these drugs can interact with the 
DNA of activated oncogenes and inhibit their expression, 
thus, reversing the tumorigenic potential of the cell (12). 
One aim of this dissertation was to investigate this 
hypothesis, that nitrogen mustard exerts its anti-neoplastic 
activity in human tumor cell lines by inhibiting the 
expression of the critical cellular oncogene, c-myc. 
Three human colon carcinoma cell lines were used 
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throughout these studies and were initially characterized 
with respect to c-myc gene structure and expression. The 
colo320HSR cell line contains 16-33 copies of the c-myc gene, 
which is both amplified and translocated (457). The results 
from these studies confirmed the presence of a highly 
amplified (approximately 26-30 fold) and rearranged c-myc 
gene in Colo320HSR cells while HT-29 and BE cells possessed 
a non-amplified, non-rearranged c-myc gene (Figure lA and B) . 
The expression level of c-myc mRNA did not exactly correlate 
with the number of gene copies, nor did c-myc protein levels 
exactly correlate with mRNA levels when compared between cell 
lines. The slight discrepancy between mRNA and protein 
expression may be explained by the fact that protein levels 
were compared on a cell equivalent basis, while mRNA 
expression was compared based upon µg of total RNA isolated. 
c-Myc protein was overexpressed in all three cell lines when 
compared to the normal human fibroblast cell line, IMR-90 
(data not shown) . The overexpression of c-myc in human 
tumors is common and frequently occurs without the presence 
of an amplified or rearranged c-myc locus (458,459). 
Nitrogen mustard down-regulated the expression of c-myc 
mRNA in all three cell lines in a concentration and time-
dependent manner following drug exposure (Figure 4A and B) . 
Studies utilizing an equi-molar concentration of HN2 showed 
that the level of c-myc mRNA inhibition was correlated with 
the degree of growth inhibition produced by the drug (Figure 
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5) . Despite the effects seen at the mRNA level, c-myc 
protein expression was either unchanged through 24 h 
(Colo320HSR) or induced 2.5 and 4 fold in HT-29 and BE cells, 
respectively, over a 96 h time course (Figure 7). Finally, 
the anti-clonogenic effects of HN2 on these human tumor cell 
lines were shown to be mediated by a loss of cellular 
viability (Figure 8) which would not have been expected to 
occur if the down-regulation of c-myc expression was 
mediating the growth inhibition, since the reduction of c-myc 
expression is not cytotoxic to cells. 
Several studies have shown that c-myc mRNA expression is 
down-regulated following exposure to various anti-cancer 
agents, including bifunctional alkylating agents (31,460), 
fluorodeoxyuridine (461), amsacrine (m-AMSA) (462), and the 
topoisomerase inhibitor, VM-26 (463). The mechanism by which 
c-myc message is down-regulated by most of these agents is 
unknown. However, VM-26 was shown to down-regulate c-myc via 
a transcriptional mechanism (463) and therefore, the other 
agents may affect c-myc expression by a similar mechanism. 
The majority of these studies have tried to link the down-
regulation of c-myc to the anti-clonogenic effect of these 
drugs on tumor cells (31,461-463). However, all but one 
(461) failed to look at the drug effects at the protein 
level. This appears to be a critical flaw based on studies 
performed in this dissertation. All of these studies failed 
to investigate the possibility that the cells were undergoing 
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apoptosis following drug exposure and were not simply 
arrested in growth (31,461-463). Therefore, one possible 
explanation for the results observed in some of these studies 
is that the down-regulation of c-myc mRNA expression is a 
consequence of cell death within the population. 
The effects of HN2 on c-myc mRNA expression in the 
Colo320HSR, HT-29, and BE cell lines appeared to be a true 
consequence of drug exposure since down-regulation of c-myc 
mRNA was maximal by 12 h post treatment, a time at which all 
cells were shown to be viable (Figures 4 and 8). The 
mechanism by which HN2 down-regulated c-myc mRNA expression 
is unknown. DNA-DNA interstrand crosslinks were formed in 
the c-myc gene of all three cell lines following exposure to 
HN2 (data not shown). However, no concrete evidence exists 
to suggest that the down-regulation of c-myc mRNA expression 
is a direct consequence of DNA crosslinks formed in the c-myc 
gene, and therefore, it is as likely to be an indirect 
consequence of drug exposure. 
The studies on protein expression showed that c-myc 
protein was induced in human colon carcinoma cells following 
exposure to HN2. These results were unexpected in light of 
the effects of HN2 on c-myc mRNA expression and the short 
half-life of both c-myc mRNA and protein (362,365), but are 
not unprecedented. Sullivan and Willis showed that the mono-
and bifunctional alkylating agents, dimethylsulphate (DMS), 
ethylmethane sulphonate (EMS), mitomycin C (MMC), bleomycin, 
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and gamma irradiation all induced the expression of c-myc 
protein in a dose and time-dependent manner in a human 
lymphoblastoid cell line, GM1953 (464) . The bifunctional 
alkylating agent, MMC caused a 7 fold induction of c-myc 
protein 24 h following drug exposure and these levels 
remained elevated out to 72 h, the latest time point recorded 
(464) . These results were similar to those produced by HN2 
in the HT-29 and BE cell lines (Figure 7). Taken together, 
the data from these studies did not support the original 
hypothesis and prompted further investigations into the 
mechanisms by which HN2 exerted its cytotoxic effects on the 
Colo320HSR, HT-29, and BE human colon carcinoma cell lines. 
HN2, CELL DEATH, AND C-MYC 
The initial studies in this dissertation showed that the 
anti-neoplastic effects of HN2 on human colon carcinoma cell 
lines were mediated by the loss of cellular viability, and 
that this process did not involve the proliferative activity 
of c-myc. Given that HN2 caused cell death and that c-myc 
was overexpressed in all three of these colon tumor cell 
lines, and in light of the recent discoveries showing that c-
myc was involved in the regulation of apoptosis (431,432), 
the following hypothesis was investigated: Human tumor cell 
lines which overexpress c-myc will undergo an enhanced 
apoptotic cell death following exposure to chemotherapeutic 
agents that cause DNA damage. 
Studies were 
apoptotic cells 
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performed to detect the presence of 
using conventional agarose gel 
electrophoresis and a quantitative, in situ TDT assay. These 
studies showed that Colo320HSR cells underwent an apoptotic 
cell death following HN2 exposure. Oligonucleosomal DNA 
fragmentation was clearly detectable in this cell line 
following exposure to HN2 (Figures 9, 10, and 12). Other 
studies have shown that Colo320HSR cells fragment their DNA 
following exposure to the topoisomerase II inhibitor, VM-26 
and the authors suggested that the overexpression of c-myc in 
this cell line was involved in the induction of apoptosis 
(465). HT-29 and BE cells did not exhibit oligonucleosomal 
DNA ladders. However, the induction of apoptosis in these 
cell lines following exposure to HN2 could not be ruled out 
(Figures 9,11,13, and 14). Studies have shown that HT-29 
cells do not produce nucleosomal DNA ladders following 
exposure to VM-26, at least out to the 48 h time point that 
was investigated, and the authors suggested that the lack of 
apoptosis seen in this cell line might be related to the 
lower levels of c-myc as compared to Colo320HSR cells (465) . 
However, the results from studies in this dissertation showed 
that HT-29 cells did not start to lose viability until 72 h 
following HN2 exposure. Therefore, it is possible that 
fragmentation was not detected following VM-26 exposure 
simply because the cells were still viable. 
Recent studies have demonstrated that cells exposed to 
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chemotherapeutic agents can undergo apoptosis without the 
appearance of nucleosomal DNA ladders (107,108), suggesting 
that the lack of this biochemical hallmark does not correlate 
with the absence of apoptotic cell death. Cells undergoing 
apoptosis have been shown to initially fragment their DNA 
into 300 kbp rosettes and 50 kbp chromatin loops which are 
thought to represent fragmentation at higher orders of 
chromatin structure (107,108). HT-29 cells exposed to 5-
fluorodeoxyuridine (5-FdUrd) have been shown to lack 
oligonucleosomal DNA ladders, but possessed DNA fragments in 
the low megabase to 50 kbp range which could have represented 
the higher order chromatin fragmentation seen in apoptotic 
cells. However, the presence of apoptotic cells was not 
morphologically assessed in these studies (466) . Studies 
from this dissertation provided no direct evidence that these 
large DNA fragments existed in HT-29 and BE cells treated 
with HN2. However, the results from the TDT analyses were 
consistent with the possibility that these cells were 
fragmenting their DNA at a higher order of chromatin 
structure, as evidenced by the broadening of the peaks at the 
later time points (Figures 13 and 14). 
Morphological analysis of HN2-treated cells provided 
direct evidence that both HT-29 and BE cells underwent 
apoptosis following exposure to HN2 to some degree (Figure 
16B and C) . These studies also confirmed that Colo320HSR 
cells underwent an apoptotic cell death after HN2 treatment 
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(Figure 16A) . The morphological analyses of the three cell 
lines quantitated the occurrence of both apoptotic and 
necrotic cell deaths at various time points following 
exposure to HN2. This approach was unique, compared to most 
studies of this type, which simply document the loss of 
cellular viability with the assumption that all cell deaths 
are by apoptosis. 
The results from the morphology studies showed that 
colo320HSR cells died exclusively by apoptosis. The results 
from the viability studies (Figure 8) were consistent with 
the results from the TDT analysis (Figure 15) which showed 
that, in Colo320HSR cells, cell death began as early as 24 h 
post HN2 exposure. DNA fragmentation was also detectable at 
this time point. Fragmentation and loss of viability were 
fairly well correlated in this cell line. The morphological 
analysis of Colo320HSR cells (Figure 17) corroborated both 
the viability and fragmentation studies. However, few 
apoptotic cells were morphologically detectable at the 24 h 
time point, and the levels detected at 48 h were less than 
those predicted by the viability studies. This apparent 
discrepancy may have been due to the differences in 
sensitivity between techniques. 
assays were performed by 
Both the viability and TDT 
FACS analysis while the 
morphological analysis relied on human analysis and, 
therefore, was subject to error. Another possibility was 
that apoptotic cells, which have a higher buoyant density 
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than normal cells, may have been mechanically restricted to 
various areas under the cover slip when in the presence of 
large numbers of viable cells and, therefore, this 
discrepancy may simply have been an artifact of cell 
spreading. Regardless, the results from these studies 
clearly showed that Colo320HSR cells underwent a rapid 
induction of apoptotic cell death following exposure to HN2 
with no necrosis observed. 
The morphology results corroborated the viability 
studies for HT-29 cells and showed that these cells utilize 
apoptotic and necrotic modes of cell death to similar extents 
(Figures 8 and 17) . The results for BE cells were also 
consistent between the viability and morphology studies 
(Figures 8 and 17). The only discrepancy for BE cells was at 
the 96 h time point in which viability was slightly 
overestimated by morphological analysis. This discrepancy 
was probably caused by the underestimation of necrotic cells 
at this time point. Although G2 phase cells were clearly 
distinguishable from most necrotic cells, those which have 
just begun to lose membrane permeability may not have been 
swollen enough to be distinguished as necrotic by 
morphological criteria and, therefore, were counted as 
viable. The viability assay was clearly a more accurate 
method of determining the number of viable cells remaining 
since the subjectivity was removed. Also, the apoptotic 
events may have been underestimated at this time point for 
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the reasons described previously. Clearly, necrosis was the 
major mode of cell death in BE cells, although apoptotic 
events were detected to a small degree at the time points 
investigated. 
The role of c-myc in the regulation of apoptosis is 
important in carcinogenesis and tumor response to 
chemotherapy (154,434). Many studies have shown that c-myc 
overexpression in a variety of cell types is capable of 
enhancing the induction of apoptosis induced by a variety of 
physiological stimuli (431,435,437,467-469) and 
chemotherapeutic agents (154,432,433,470,471). Malde and 
Collins suggested that the levels of c-myc in tumor cells may 
be predictive of their sensitivity to cancer therapy (471). 
This notion is somewhat short-sighted, however, since many 
oncogenes have been shown to cooperate with c-myc in the 
transformation of cells by inhibiting its apoptotic functions 
(153,154,166,169,250,251). Therefore, high levels of c-myc 
would not always be predictive of chemotherapeutic agent 
sensitivity. The studies presented in this dissertation 
cleary demonstrate the difficulty in trying to use c-myc 
protein levels alone as a predictive measure for the 
induction of apoptosis of human tumor cells exposed to 
chemotherapeutic agents. 
Taken together, the results for HT-29 and BE cells 
suggested that c-myc was not enhancing the induction of 
apoptosis in these cell lines following exposure to HN2. 
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These results were interesting since c-myc protein levels in 
both of these cell lines were high compared to normal human 
fibroblasts and were actually induced following exposure to 
HN2. This observation suggested that factors other than high 
levels of c-myc could influence the c-myc enhancement of 
apoptosis in human colon carcinoma cell lines. Colo320HSR 
cells exposed to HN2 were shown to die in a manner that was 
consistent with a role for c-myc in the enhancement of 
apoptosis. 
THE INVOLVEMENT OF P53 AND BCL-2 IN THE REGULATION OF C-MYC 
INDUCED APOPTOSIS 
Many oncogenes have been shown to negatively regulate c-
myc-induced apoptosis and these include c-abl, c-raf, ras, 
bcl-2 and p53 (153,154,166,169,250,251,328). The Colo320HSR, 
HT-29, and BE cell lines have been shown not to express mRNA 
for c-abl, c-raf, or k-ras. However, all three cell lines 
express mRNA for N-ras (Q. Dong, unpublished observations). 
These findings suggested that these oncogenes were not 
involved in the regulation of c-myc-induced apoptosis in 
these cell lines. Therefore, studies were performed to rule 
out the possible involvement of either p53 or bcl-2 in the 
regulation of c-myc-induced apoptosis in the three colon 
tumor cell lines. 
Preliminary studies showed that p53 gene structure and 
mRNA expression were similar in all three cell lines when 
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compared to HeLa cells, which contained a wild-type p53 gene 
(Figure 18A and B) . The expression of p53 protein was high 
in all three colon tumor cell lines compared to HeLa and IMR-
90 cells (Figure 18C) and suggested the presence of mutant 
p53 protein in these cells, since mutant forms of p53 protein 
have substantially longer half-lives than their wild-type 
counterpart, resulting in their overexpression (287,288). 
The presence of mutant p53 protein in Colo320HSR, HT-29, and 
BE cells was confirmed by immunoprecipitation analysis with 
conformation-specific antibodies (Figure 19). Other studies 
have since confirmed that Colo320HSR cells have lost the 
wild-type allele and possess a single mutant p53 allele 
(arginine 248 to tryptophan) (472) HT-29 cells have also 
been shown to possess a mutant p53 gene containing an 
arginine to histidine replacement at codon 273 (473). 
The p53 tumor suppressor gene has been shown to be a 
direct inducer of apoptosis (172) and its involvement in the 
suppression of tumor formation is strongly associated with 
its apoptosis-inducing functions (310). Studies in murine 
systems have shown that wild-type p53 is required for the 
induction of apoptosis by chemotherapeutic agents in many but 
not all cell types (173,175,316,317,320). Mutant p53 protein 
has been shown to confer resistance to cells exposed to many 
types of chemotherapeutic agents and has been shown to 
abrogate c-myc-induced apoptosis (175,328,332). However, the 
situation is much more confusing in human systems where some 
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studies have shown that p53 status is an important 
determinant of the outcome of chemotherapy (333,334) while 
others have shown that it is not (335-338) . 
All three colon tumor cell lines expressed mutant forms 
of p53 protein and all could undergo apoptosis to varying 
degrees following exposure to HN2 suggesting that p53 status 
may not be an important determinant in the cytotoxic response 
to drug exposure. Nitrogen mustard had no effect on mutant 
p53 protein expression in any of the three cell lines out to 
96 h post treatment (Figure 21) . These data were consistent 
with other studies which showed that the expression of mutant 
p53 protein was not affected in several Burkitt's lymphoma 
cell lines following gamma-irradiation ( 4 74) . Colo32 OHSR 
cells, which appeared to undergo a c-myc-enhanced apoptosis 
following exposure to HN2, did not show an induction of p53 
protein following drug treatment and expressed only a mutant 
p53 protein. These findings were contrary to those in murine 
systems which showed that the induction of wild-type p53 was 
involved in the c-myc enhancement of apoptosis and that 
mutant p53 protein abrogated this process (327,328). The 
studies on p53 showed that HN2-induced apoptosis in human 
colon carcinoma cell lines occurred in a wild-type p53-
independent manner and suggested that p53 was not a regulator 
of c-myc-enhanced apoptosis in these cell lines. 
Bcl-2 has been shown to cooperate with c-myc in the 
transformation of cells both in vitro and in vivo by 
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abrogating the apoptotic effects of c-myc overexpression 
(163,190-192). The ectopic overexpression of bcl-2 has been 
shown to increase the resistance of many tumor cell types to 
a variety of anti-neoplastic agents (164,165,234-238). 
Therefore, studies were performed to rule out the involvement 
of bcl-2 in the abrogation of c-myc-induced apoptosis in the 
HT-29 and BE cell lines. The Colo320HSR and BE cell lines 
expressed mRNA and protein for bcl-2, while the expression of 
bcl-2 mRNA was low and bcl-2 protein was undetectable in HT-
29 cells (Figure 22B and C) . The lack of bcl-2 protein 
expression in HT-29 cells has been previously reported (475) . 
Bcl-2 protein did not appear to be overexpressed in 
Colo320HSR and BE cells since bcl-2 protein levels were well 
below those seen in the LM-EBV cell line (Figure 22C) . This 
cell line overexpressed bcl-2 protein as a result of the 
presence of the latent membrane protein 1 (LMP-1) of the 
Epstein-Barr virus, which up-regulates bcl-2 expression and 
prevents virally infected cells from undergoing apoptosis 
(476) . 
Bcl-2 expression can be either up- or down-regulated in 
response to various physiological stimuli including estrogen, 
TGFBl, and wild-type p53 protein (322,323,477). Studies on 
the modulation of bcl-2 protein expression by HN2 in this 
dissertation demonstrated that bcl-2 protein expression was 
induced in a cell type specific and time-dependent manner 
following HN2 exposure (Figure 23) . Based upon the many 
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studies involving the forced, ectopic overexpression of bcl-2 
(234-238), the data from this dissertation suggested that 
colo320HSR and BE cells would have been protected from the 
apoptosis-inducing effects of HN2 exposure. However, we now 
know that the regulation of cell death by bcl-2 is extremely 
complex and probably cell type specific. Therefore, the 
status of bcl-2 expression alone may be insufficient to 
predict a protective effect (218,222,223,226-230). 
Colo320HSR cells died rapidly and exclusively by apoptosis 
despite the presence of bcl-2 and its induction following HN2 
exposure. The induction of bcl-2 in BE cells was a robust 
and late event following drug exposure. However, the peak 
induction preceded the point in time at which further cell 
death in these cells was inhibited (Figure 8) and, therefore, 
was consistent with the possibility that bcl-2 was delaying 
the death of BE cells following HN2 exposure. Ectopic 
overexpression of bcl-2 has been shown to delay the death of 
murine FLS .12 prolymphoid progenitor cells following exposure 
to either HN2 or the topoisomerase I inhibitor, camptothecin 
(242) . 
Few studies 
chemotherapeutic 
have 
agents 
investigated the effects of 
on the modulation of bcl-2 
expression. Most, if not all, of the studies involving the 
effects of bcl-2 on chemotherapeutic agent responses have 
been performed on cells engineered to ectopically overexpress 
bcl-2. If the results from the studies in this dissertation 
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are confirmed to be a real and consistent effect of anti-
neoplastic agent exposure on human tumor cells, then the 
modulation of bcl-2 and other death repressor family genes 
such as bcl-x, mcl-1, Al, bax, bag-1, and bad by 
chemotherapeutic agents may be playing an important, as yet 
unexplored role in the modulation of drug resistance in human 
tumor cells. In the cell lines studied in this dissertation, 
bcl-2 did not appear to be involved in the abrogation of c-
myc-enhanced apoptosis following HN2 treatment. The 
induction of bcl-2 at the later time points appeared to be 
associated with a delay in the death of BE cells. However, 
the low levels of constitutive expression, along with the 
decline in bcl-2 levels through 24 h post HN2 treatment and 
lack of induction until 48 h post treatment suggested that 
bcl-2 was not overexpressed through 48 h following drug 
exposure. Therefore, the involvement of bcl-2 in the 
abrogation of c-myc-induced apoptosis did not appear to be 
warranted in this cell line. This conclusion is not 
contradictory, since the death repressor activity of bcl-2 
occurs in a manner that is independent of c-myc functions. 
INVOLVEMENT OF THE MYC TRANSCRIPTION FACTOR NETWORK IN THE C-
MYC ENHANCEMENT OF APOPTOSIS INDUCED BY HN2 
The previous studies in this dissertation suggested that 
c-myc-enhanced apoptosis in HT-29 and BE cells was not 
abrogated by the various oncogenes known to regulate the 
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enhancement of apoptosis by c-myc. Therefore, the 
involvement of the myc transcription factor network in this 
process was investigated. 
It has been suggested that the apoptosis-inducing 
functions of c-myc require its dimerization with max and 
occur in a manner that is dependent upon the dose of c-myc 
(426,432). However, this is a simplistic view of the system. 
In fact, the level of c-myc/max dimers is what determines the 
outcome, since this is the functional transactivating unit of 
this system (426) . The amount of c-myc/max dimers is thought 
to be determined by the relative levels of c-myc and mad 
proteins, which, unlike max, are thought to be the limiting 
factors in this system (415) . The mad/max, mxil/max, and 
max/max dimers all antagonize the transcriptional activity of 
the c-myc/max dimer (415,416). Therefore, a true assessment 
of the transcriptional capabilities of this system would 
require knowledge of the levels of all four of these dimer 
types at any point in time. 
In these studies, the levels of c-myc, max, and mad 
protein, and c-myc/max dimers were measured in an attempt to 
characterize this system and determine its status prior to 
and following exposure to HN2. Mad/max dimers were not 
measured in these studies. The involvement of mxil in these 
systems was not determined. When this system was 
characterized, several important observations were noted. 
The levels of max protein varied greatly between the three 
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colon tumor cell lines, suggesting that tumor cells may show 
a wide range of max expression which could have important 
implications on tumor cell studies involving c-myc (Figure 
24A) . Indeed, c-myc/max dimer levels did not correlate with 
c-myc protein expression in either Colo320HSR or HT-29 cells 
(Figure 29, control panel). In Colo320HSR cells max protein 
levels were clearly limiting the formation of c-myc/max 
dimers which was contrary to the results from previous 
studies which suggested that all of the c-myc protein in 
cells was dimerized with max, and that max was not the 
limiting factor of this system in cells (426,478). 
Three lines of indirect evidence all suggested that max 
protein levels were limiting the formation of c-myc/max 
dimers in Colo320HSR cells. First, the amount of 
immunoprecipitable max protein was never greater than the 
amount of co-precipitable c-myc in Colo320HSR cells as was 
clearly the case in both HT-29 and BE cells, showing that 
excess max protein was present in these two cell lines 
(Figure 24A) Second, the levels of immunoprecipitable c-myc 
were greater than the levels of max-co-precipitable c-myc 
implying that not all of the c-myc present in Colo320HSR 
cells was dimerized with max (data not shown). Finally, and 
most convincingly, the increase in c-myc/max dimers in 
Colo320HSR cells exposed to HN2 was shown to be mediated by 
the induction of max protein, which could have occurred only 
if max levels were limiting the formation of c-myc/max dimers 
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Figure 29. The relative pre-treatment status and post-
treatment changes in the major components of the myc 
transcription factor network in Colo320HSR, HT-29, and BE 
cell lines following exposure to HN2. 
The figures in this diagram were based upon the previous 
data presented on the myc transcription factor network and 
data not shown. The relative protein and dimer levels were 
expressed as arbitrary units and were comparable within each 
cell line and between cell lines. The c-myc/max dimers for 
BE cells were arbitrarily set as 1 unit, and were the basis 
upon which everything else was compared. The 0, 12/15, 72, 
and 96 h time points were not shown. 
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(Figure 25) . These results clearly underscore the 
limitations of studies in tumor cells that only measure 
effects on c-myc protein. 
If the pretreatment status of the myc transcription 
factor network was involved in determining the outcome of c-
myc-enhanced apoptosis in the three colon tumor cell lines, 
then the transactivating capabilities of this system would 
have been predicted to be the highest in Colo320HSR cells. 
Although c-myc protein levels were 7 fold higher in 
Colo320HSR cells, the levels of c-myc/max dimers were only 2 
or 4 fold greater relative to BE and HT-29 cells, 
respectively. Therefore, the question arises, was a 2 fold 
difference in c-myc/max dimers enough to account for the lack 
of enhanced apoptosis in BE cells? The answer to this 
question is, probably not. However, if the whole system is 
taken into account, then perhaps this difference was enough. 
In Colo320HSR cells, all available max protein appeared to be 
dimerized with c-myc (Figure 29), and it appeared that mad 
levels, although detectable in these cells, were not high 
enough to compete with c-myc for max binding. Therefore, in 
Colo320HSR cells, it was possible that only c-myc/max dimers 
existed and little or no max/max or mad/max dimers were 
present to antagonize the activity of these dimers. In HT-29 
cells, mad levels were higher and c-myc levels were lower 
than in Colo320HSR cells. The fact that c-myc/max dimer 
levels were lower than the levels of c-myc protein even 
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though max protein levels were equivalent to c-myc levels 
suggested that mad/max or max/max dimers may have existed in 
these cells (Figure 29). The existence of these antagonistic 
dimers would have effectively lowered the transactivating 
activity of c-myc/max dimers in these cells. Therefore, the 
difference in c-myc/max dimer transactivating activity 
between Colo320HSR and HT-29 cells would have been much 
greater than the 4 fold difference predicted by c-myc/max 
dimer levels alone. The same logic held true for BE cells, 
which expressed high levels of mad, low levels of c-myc 
(relative to Colo320HSR cells) and an almost 5 fold excess of 
max protein. However, a direct demonstration of the 
existence of mad/max or max/max dimers in these cell lines, 
along with an index of the in vivo transactivation capacity 
of the myc network is required to validate these statements. 
The final set of studies described in this dissertation 
were designed to investigate the effects of HN2 on the myc 
transcription factor network in human colon carcinoma cell 
lines to determine if post-treatment effects could explain 
the apparent lack of c-myc-enhanced apoptosis in HT-29 and BE 
cells. These studies were novel in that no other studies 
have been found describing the effect of a chemotherapeutic 
agent on the members of the myc transcription factor network, 
including c-myc/max dimers. 
In the Colo320HSR cell line, HN2 induced the expression 
of both p21 and p22 max, which led to the approximately 5 
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fold induction of c-myc/max dimers by 24 h post treatment 
(Figure 25). The increase in c-myc/max dimers occurred 
without any changes in c-myc protein expression (through 24 
h) and prior to the onset of apoptosis in these cells. This 
large increase in the "dose" of c-myc/max dimers prior to the 
onset of apoptosis induced by HN2 was consistent with the 
possibility that these newly formed dimers were contributing 
to the c-myc enhancement of apoptosis in Colo320HSR cells. 
The decrease in c-myc/max dimers at the 48 h time point was 
due, in part, to the decrease in c-myc protein at this time 
which was most likely a consequence of cell death (Figure 
25B) 
The ef feet of HN2 on the myc transcription factor 
network in both HT-29 and BE cells was consistent with the 
possibility that decreases in c-myc/max dimers were involved 
in the abrogation of c-myc-enhanced apoptosis in these cell 
lines. In HT-29 cells, both c-myc and p21/p22 max proteins 
were induced following exposure to HN2. 
dimer levels never increased above 
declined over the post-treatment time 
However, c-myc/max 
control levels and 
course despite the 
continued elevation of both c-myc and max protein levels 
(Figure 26). An almost identical situation was observed in 
BE cells exposed to HN2, except that the induction of max was 
minimal. However, max levels in this cell line were already 
very high relative to HT-29 cells (Figure 27) . 
The finding that c-myc/max dimer levels did not increase 
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despite an increase in both c-myc and max protein levels in 
both HT-29 and BE cells was quite unexpected given that 
current thinking suggests that all c-myc in the cell is 
associated with max (426,478). These results suggested that 
the c-myc and max proteins were prevented from interacting 
and forming dimers by alterations in their cellular 
localization since no known posttranslational modifications 
in c-myc or max proteins are known to prevent or antagonize 
their association (479) These findings merit further 
investigation. 
The studies on the myc transcription factor network were 
consistent with a role for this system in the regulation of 
c-myc-enhanced apoptosis in human tumor cell lines, and 
showed the problems involved in trying to predict the 
occurrence of c-myc-induced apoptosis based upon the levels 
of c-myc protein alone. These studies were consistent with 
the dose-response relationship between c-myc/max dimers and 
the induction of apoptosis (432). However, these studies did 
not conclusively determine whether the pre-treatment status 
or post-treatment responses were responsible for determining 
whether apoptosis was enhanced in these cell lines. 
Convincing arguments can be made for either scenario. The 
argument for the pre-treatment status has already been 
discussed. The post-treatment changes in the myc 
transcription factor network following HN2 exposure strongly 
suggested that these changes were involved in regulating 
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apoptosis. However, these results, as presented, were only 
correlative and not causative. Regardless, the dose-response 
relationship between c-myc/max dimer levels and the 
enhancement of apoptosis was quite impressive when compared 
between cell lines, relative to HT-29 cells (Figure 28). 
These results were certainly consistent with the possibility 
that post-treatment changes in the myc transcription factor 
network were involved in the regulation of c-myc-induced 
apoptosis in these cell lines. 
Experiments were designed to address the relative 
importance of pre-treatment status versus post-treatment 
changes in the myc transcription factor network in the 
regulation of c-myc-enhanced apoptosis in Colo320HSR cells 
exposed to HN2. These experiments relied upon the specific 
reductions in c-myc protein by antisense ODNs targeted 
against c-myc mRNA (449,454). Numerous attempts were made to 
modulate this system in a consistent manner, with antisense 
technology, but were unsuccessful. These studies were not 
continued since they were deemed unlikely to produce 
interpretable results. Therefore, the investigations into 
the myc transcription factor network remain correlative at 
best. 
The involvement of deregulated c-myc expression in the 
regulation of apoptosis has been demonstrated in Burkitt's 
lymphoma cells, Epstein-Barr virus-immortalized B cells, rat 
fibroblasts, murine myeloid cells, and T cells 
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(431,432,435,480,481) However, the participation of c-myc 
is not a requirement in all apoptotic pathways in all cell 
types (431,435,482,483). The regulation of apoptosis by c-
myc has been shown to require dimerization with max and is 
thought to involve the transactivation of genes (426,432). 
several genes have been described as possible mediators of c-
myc-induced apoptosis (327,408,444), the most convincing of 
which seems to be the ODC gene (444). The ODC gene is a 
direct transcriptional target of c-myc/max dimers (404) and 
the enforced overexpression of ODC has been shown to induce 
apoptosis upon factor withdrawal (444). To this end, it 
would be interesting to look at the expression of ODC and 
cyclin A, two known mediators of c-myc-induced apoptosis, in 
Colo320HSR cells following exposure to HN2, to determine 
whether their expression correlates with changes in c-myc/max 
dimer levels. Also, the bax gene has recently been shown to 
contain 4 E-box motifs (321) suggesting that c-myc may be 
capable of inducing the expression of bax. Since bax is 
known to be directly involved in the cell death pathway 
(218), it would be interesting to determine whether bax 
expression is induced in Colo320HSR cells following HN2 
treatment. 
The current thinking of how anti-neoplastic agents exert 
their cytotoxic effects on tumor cells has begun to change. 
The impetus behind this change in thinking has come from the 
growing body of evidence which has shown that the induction 
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of apoptosis is the end result of drug exposure in most, if 
not all, tumor cell types regardless of the chemotherapeutic 
agent used (156,157; 85,86 and references within). The cell 
can no longer be thought of as simply a dart board in which 
drugs are interacting with specific cellular targets, killing 
cells as a direct result of this drug/target interaction 
(90,156,161). The cell is a complex structure and the fact 
that drugs with so many varied mechanisms of action all evoke 
a similar, genetically programmed response, suggests that 
these drugs produce cellular responses downstream of the 
drug/target interaction that impinge at various nodes upon a 
common cell death pathway. This "stimulus-response coupling" 
theory suggests that the drug/target interaction is only the 
initial event; the stimulus, and the cellular context in 
which this stimulus is received is probably more important 
than the actual type of drug/target interaction (90,156). 
The probability that the apoptotic program is engaged 
following drug/target interaction is thought to be determined 
by the cellular response to the stimulus which is cell type-
specif ic (90) . This theory suggests that cells can become 
resistant to chemotherapeutic agents by either not receiving 
the stimulus (classical drug resistance) or more importantly, 
by not responding to it. Cells that do not respond to the 
stimulus have effectively uncoupled the response from the 
stimulus and are effectively protected from cell death. 
However, these cells can still undergo apoptosis in response 
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to other stimuli that utilize a different signal transduction 
pathway to impinge upon the final, common cell death pathway 
(173,316). Many studies support such a "stimulus-response" 
type of model (39,90,162,173,243,316,323,456), including the 
studies from this dissertation. 
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